text stringlengths 65 123k | url stringlengths 25 420 | crawl_date timestamp[us, tz=UTC]date 2022-04-01 01:00:57 2022-09-19 04:34:04 |
|---|---|---|
Security for election workers, officials, and ballots has been a major concern in many Texas communities as supporters of former President Trump continue to push his false claim that the 2020 election was stolen. And Dallas County Commissioners on Tuesday may approve money to review election security ahead of a high-stakes election.
Early voting begins in less than two months in races to choose Texas governor, lieutenant governor, attorney general, and control of Congress.
“With high concerns and fear regarding security both physical and cyber, the Dallas County Elections Department (DCED) is preparing for the upcoming elections to include safety before and during the voting process,” according to an agenda item for Tuesday’s meeting of the Dallas County Commissioners Court.
The document proposes $50,000 for an assessment that “identifies, assesses and implements key security controls for protection of voters, as well as election workers.”
The assessment would also focus on “preventing security vulnerabilities.” The request said the county’s emergency management department recently did a review of the elections campus and found “concerns,” prompting the request to bring in a vendor.
Dallas County Judge Clay Jenkins, who runs emergency management for the county, declined an interview request.
“Due to the sensitive nature of the topic, and as standard with security assessments and emergency plans, we won’t be providing any comments at this time,” a Jenkins spokesperson said in an email.
The physical safety of election workers in Texas and the rest of the country has taken on new urgency since the 2020 vote.
Last month, all three members of the elections staff in Gillespie County in Central Texas resigned after years of intimidation and aggressive behavior from activists.
In her resignation letter, Gillespie County Elections Administrator Annisa Herrera said “threats against election officials and my election staff, dangerous misinformation, lack of full-time personnel for the elections office, unpaid compensation, and absurd legislation have completely changed the job I initially accepted.”
Earlier this year, an investigation into election misinformation by Democrats on a U.S. House committee described threats to election officials, including a Texas official who was repeatedly harassed and even told in a Facebook message, “I think we should end your bloodline.”
That official, Tarrant County Elections Administrator Heider Garcia, asked the Senate Judiciary Committee to pass legislation protecting elections officials’ addresses, make doxing an offense, and requiring organizations to disclose their finances if they raise money to prove election fraud.
He also urged them to consider allowing law enforcement to treat violent online threats as real threats.
“There is a difference between saying ‘Heider should be fired’ and someone telling me ‘I think we should end your bloodline,’” he wrote.
Got a tip? Email Bret Jaspers at bjaspers@kera.org. You can follow Bret on Twitter @bretjaspers.
KERA News is made possible through the generosity of our members. If you find this reporting valuable, consider making a tax-deductible gift today. Thank you. | https://www.keranews.org/news/2022-09-06/dallas-county-officials-may-fund-election-security-review-ahead-of-high-stakes-midterm-election | 2022-09-06T10:48:30Z |
Britain's Conservative Party announced that Foreign Minister Liz Truss will serve as the nation's next prime minister. She has a lot of work to do in these troubling political and economic times.
Copyright 2022 NPR
Britain's Conservative Party announced that Foreign Minister Liz Truss will serve as the nation's next prime minister. She has a lot of work to do in these troubling political and economic times.
Copyright 2022 NPR | https://www.wyomingpublicmedia.org/2022-09-06/liz-truss-is-great-britains-new-prime-minister-replacing-boris-johnson | 2022-09-06T10:48:31Z |
Judge grants Trump's special master request to review search materials. Uvalde students return to school for the first time since May's shooting. Britain's prime minister will be formally appointed.
Copyright 2022 NPR
Judge grants Trump's special master request to review search materials. Uvalde students return to school for the first time since May's shooting. Britain's prime minister will be formally appointed.
Copyright 2022 NPR | https://www.wyomingpublicmedia.org/2022-09-06/news-brief-special-master-request-granted-uvalde-students-britains-liz-truss | 2022-09-06T10:48:37Z |
While many universities have raised tuition in the last decade, Purdue University has frozen those costs. NPR's Steve Inskeep talks to outgoing Purdue President Mitch Daniels about the strategy.
Copyright 2022 NPR
While many universities have raised tuition in the last decade, Purdue University has frozen those costs. NPR's Steve Inskeep talks to outgoing Purdue President Mitch Daniels about the strategy.
Copyright 2022 NPR | https://www.wyomingpublicmedia.org/2022-09-06/purdues-reputation-for-affordability-results-in-substantial-growth-for-the-school | 2022-09-06T10:48:38Z |
Violinist Randall Goosby has arrived – and not just at the Tiny Desk. The young Juilliard graduate is racking up debuts with the world's most important orchestras, he just pocketed the $25,000 Avery Fisher Career Grant and he can boast none other than violin legend Itzhak Perlman as his mentor. Not bad for 26 years old.
We know Goosby's star is on the rise, but the way his career got off the ground is worth mentioning. Goosby is an alum of the Detroit-based Sphinx Organization, which, for 25 years, has helped launch many prominent musicians of color, including composers Jessie Montgomery and Carlos Simon, pianist Lara Downes and opera stars Davóne Tines and Will Liverman. Goosby, at age 13, was the youngest to win the Sphinx Concerto Competition.
Sphinx was also where he first performed neglected music by Black composers. "With each passing day," Goosby told NPR last year, "you can almost see this wave of reckoning, and people starting to realize the magnitude of the body of work that we've not paid attention to."
Joined by the discerning pianist Zhu Wang, Goosby begins with the Black British composer Samuel Coleridge-Taylor's "Deep River," the bittersweet spiritual whose melody floats with uncommon beauty in this performance. Listen for the perfectly placed high note at the end. Goosby then tips his hat to Antonin Dvorak, the composer who suggested that American composers look to the music of African Americans for pure inspiration. The two young musicians close with "Estrellita," a bon-bon of unrequited love from Mexican composer Manuel Ponce.
With his secure technique, natural phrasing, gorgeous tone and smart programming, Randall Goosby has everything it takes to craft a major career.
SET LIST
MUSICIANS
TINY DESK TEAM
Copyright 2022 NPR. To see more, visit https://www.npr.org. | https://www.wyomingpublicmedia.org/2022-09-06/randall-goosby-tiny-desk-concert | 2022-09-06T10:48:45Z |
Former President Donald Trump has remained a constant presence in this year's statewide primaries, endorsing more than 200 Republican candidates running for U.S. Senate, U.S. House and top state executive offices across the country.
So with the end of the primary calendar nearing, how have his endorsees fared?
An NPR tally of Trump's endorsements finds the vast majority won their GOP primaries, but about three-fourths of his picks are incumbents who were already expected to win, with many running unopposed in their primary contests.
In fact, only one Trump-endorsed incumbent — North Carolina Rep. Madison Cawthorn — was ousted in a primary.
The former president's endorsees performed somewhat worse in open races, without an incumbent, or when he backed a challenger to a Republican incumbent.
Overall, 91% of Trump's candidates won their open primaries, and 4 of 10 challengers topped incumbents. His picks fared particularly poorly in Georgia, as he sought to oust sitting GOP officials from state executive offices.
Loading...
Looking at who Trump endorsed, most candidates said they support his false claims that the 2020 election was fraudulent. And among just Trump-endorsed House incumbents, the vast majority objected to certifying the 2020 election.
Up and down the ballot, Trump made a concerted effort to endorse and actively campaign for Republicans challenging GOP incumbents who disagreed with his election lies.
Notably, of the 10 House Republicans who voted to impeach him following the Jan. 6 insurrection, five of six who ran for reelection faced Trump-backed primary challengers, and just two of those incumbents prevailed.
Many Republicans endorsed by Trump face competitive general election matchups against Democratic candidates, so it's unclear how they'll fare in November.
The full list is below. Did we miss something? Email nprpolitics@npr.org.
Copyright 2022 NPR. To see more, visit https://www.npr.org.
Loading... | https://www.wyomingpublicmedia.org/2022-09-06/tracking-trumps-endorsements-heres-how-his-picks-have-fared-in-primaries | 2022-09-06T10:48:51Z |
The temperatures in the Ukrainian capital have been in the 70s lately. But as summer wanes, residents are already preparing for a harsh winter ahead.
Copyright 2022 NPR
The temperatures in the Ukrainian capital have been in the 70s lately. But as summer wanes, residents are already preparing for a harsh winter ahead.
Copyright 2022 NPR | https://www.wyomingpublicmedia.org/2022-09-06/ukrainians-prep-for-winter-if-russia-hits-heating-systems-cities-will-freeze | 2022-09-06T10:48:57Z |
Brendan Fraser is officially on a comeback.
The Whale, a new Darren Aronofsky film in which Fraser stars, premiered at the Venice Film Festival Sunday night to a six-minute standing ovation.
Actors and longtime fans alike took to social media to share their own happiness at the recognition Fraser received with this latest role. As the applause continued for Fraser on Sunday, the actor and some audience members appeared to get choked up.
This comes years after Fraser was at the height of his career. So, why has this moment has brought so many people joy at the same time that others lament the fact that this film is Fraser's return to stardom?
Fraser was once a major star with hits such as George of the Jungle and The Mummy franchise. But after a sustained run as one of Hollywood's leading men, Fraser receded to the sidelines of TV and film in recent years.
Seeing Fraser who was so "universally loved" by the public for so long receive praise resonated with fans, according to film and media historian Chris Yogerst.
"It's almost like the public was just waiting for this moment," said Yogerst. "Everyone has missed him. Seeing him back on the screen, it was like an old friend was back."
Nostalgia certainly plays into the joy this moment brings to some people, Yogerst said.
"I mean, I'm still nostalgic about the silly remake of Bedazzled," a Fraser movie with Elizabeth Hurley that came out in 2000, Yogerst said.
Part of this collective happiness also stems from knowledge of Fraser's recent struggles, according to Nicholas Baer, an assistant professor of film studies at the University of Groningen in the Netherlands.
After Fraser was absent from any big Hollywood movie for several years, GQ published a profile in 2018 of the actor titled, "What ever happened to Brendan Fraser?"
In it, Fraser discussed years of suffering from injuries (sustained from performing stunts during filming of The Mummy franchise), subsequent surgeries, personal loss and a divorce. Most startling were details Fraser shared of being allegedly groped by Philip Berk, a former president of the Hollywood Foreign Press Association. Berk told GQ that Fraser's account was "a total fabrication."
Fraser in the GQ article openly questioned whether he was actually blacklisted from Hollywood because he came forward about his experience.
"[The Whale] is offering us an opportunity to kind of recognize the virtue and the kind of fundamental decency of Brendan Fraser, who has been really wronged by the industry and has long suffered," Baer said.
A comeback with controversy
The Whale is about a reclusive English teacher (Fraser) who weighs 600 pounds, and as he struggles with his health, tries to reconnect with his estranged daughter. A combination of prosthetics and CGI help Fraser as he portrays this character.
Fraser's return will likely be controversial for some, Baer noted.
"I think it's definitely going to be a point of contention in the discourse. I think it's a practice [the use of prosthetics or so-called fat suits] that has been relatively commonplace among major Hollywood actors for a long time and that's been increasingly criticized for being fat phobic and offensive," Baer said.
Indeed, critics have turned to social media to say that the movie's premise is inherently dehumanizing. There's a question of whether it should have been made at all.
Aubrey Gordon, an author and co-host of the Maintenance Phase, a podcast focused on debunking health fads, took to Twitter to call out the movie's aim.
"It's so telling that so many only see fat people as 'humanized' in media that shows us doing exactly what they expect: living short, small lives; 'eating ourselves to death'; feeling sad & regretful. All reminders of how tragic it is to be fat, and how superior it is to be thin," she wrote.
This kind of media just "reinforces viewers' anti-fat bias," she wrote.
Pia Glenn, a Broadway actress, also criticized the movie, lamenting the fact that this film is Fraser's comeback.
"Mr. Fraser's 'comeback' and personal journey as an actor and human are significant and I hate that I feel so negatively about the project that brought them about. I know I won't see it, so I've been reading reviews," she wrote on Twitter. "References to rolls and hanging flesh and Jabba the Hut (!) NO."
Copyright 2022 NPR. To see more, visit https://www.npr.org. | https://www.wyomingpublicmedia.org/2022-09-06/why-brendan-frasers-hollywood-comeback-story-is-both-warming-hearts-and-raising-ire | 2022-09-06T10:48:58Z |
California facing chance of blackouts amid brutal heat wave
LOS ANGELES (AP) — California will face its highest chance of blackouts this year as a brutal heat wave continues to blanket the state with triple-digit temperatures, officials warned Monday.
As people crank up their air conditioners, the state forecasted record levels of energy use that could exceed supply Monday evening, said Elliot Mainzer, president of California Independent System Operators, which runs the state’s electrical grid.
The state could fall 2,000 to 4,000 megawatts of electricity short of its power supply, which represents as much as 10% of normal demand, he said.
State energy officials said the electrical load on Tuesday potentially could hit 51,000 megawatts, the highest demand ever seen in California.
The scorching heat and low humidity were further drying out brush and adding to the challenges of battling wildfires, said Anale Burlew, a deputy chief with the California Department of Forestry and Fire Protection.
Some 4,400 firefighters were battling 14 large fires around the state, and there were 45 new blazes on Sunday alone, she said.
In Southern California, two people were killed and one injured by the Fairview Fire, which started Monday near the city of Hemet, the Riverside County Fire Department said. Roughly 50 miles (80 kilometers) southeast of Los Angeles, the fire had quickly spread to more than 2,000 acres by 11 p.m., prompting evacuations, and was only 5% contained. Multiple residential structures burned.
CAISO on Monday evening requested the activation of temporary emergency power generators deployed by the Department of Water Resources in Roseville and Yuba City. The four generators, which were activated for the first time since they were installed last year, can provide up to 120 megawatts of electricity, enough to power up to 120,000 homes.
Earlier in the day, CAISO issued a Flex Alert call for voluntary conservation between 4 p.m. and 10 p.m. on Monday and for 4 p.m. to 10 p.m. Tuesday, making seven alerts in as many days. Consumers were urged to keep air conditioners at 78 degrees (25.5 degrees C) or higher during the period and avoiding using major appliances such as ovens and dishwashers.
The efforts have worked to keep the lights on “but we have now entered the most intense phase of this heat wave” that could last into the week, and two to three times the level of conservation will be needed from people and businesses, Mainzer said.
During the day, California’s energy grid runs on a mix of mostly solar and natural gas, as well as some imports of power from other states. But solar power begins to fall off during the late afternoon and into the evening, which is the hottest time of day in some parts of the state.
Meanwhile, some of the aging natural gas plants that California relies on for backup power aren’t as reliable in hot weather.
CAISO also issued a Stage 2 Energy Emergency Alert from 6:30 p.m. to 8 p.m. Monday. The second of three emergency alert stages means taking emergency energy-saving measures “such as tapping backup generators, buying more power from other states and using so-called demand response programs,” according to a CAISO website. Stage 3 would be rolling blackouts.
Southern California Edison urged its customers to conserve energy through 10 p.m. tonight, the company said.
The state has additional energy capacity for protection at the moment “but blackouts, rolling, rotating outages are a possibility today,” Mainzer said, calling additional conservation “absolutely essential.”
Several hundred thousand Californians lost power in rolling blackouts in August 2020 amid hot weather. The state avoided a similar scenario last summer. Gov. Gavin Newsom on Friday signed legislation potentially allowing the state’s last remaining nuclear plant to stay open beyond its planned 2025 closure in order to ensure more power for the energy grid.
The National Weather Service predicted highs between 100 and 115 degrees across inland areas of the state with 80s to 90s closer to the coast. Nighttime won’t bring much relief, with many places seeing lows in the 80s or even 90s.
Ironically, unsettled weather also brought the chance of thunderstorms over Southern California and into the Sierra Nevada, with a few isolated areas of rain but nothing widespread. The storms also could produce lightning, forecasters said, which can spark wildfires.
South of the Oregon state line, the Mill Fire was 40% contained on Monday after killing two people, injuring others and destroying at least 88 homes and other buildings since it erupted last week, Burlew said.
The fire killed two women, ages 66 and 73, who were found inside the city limits of Weed on Friday after the fire broke out, the Siskyou County Sheriff’s Office announced Monday. Their names and details of their deaths weren’t immediately released.
Last week, seven firefighters were sent to the hospital for heat-related problems, but Burlew said the extreme weather wasn’t likely to disrupt current firefighting efforts.
The fire had burned 6.6 square miles of grass, brush and timber, but it wasn’t expected to grow. Many evacuations had been lifted.
However a few miles away, the Mountain Fire was 16.6 square miles, only 10% contained and winds could renew its growth east in steep terrain, fire officials said at a Monday morning briefing. No buildings had burned.
Scientists say climate change has made the West warmer and drier over the last three decades and will continue to make weather more extreme and wildfires more frequent and destructive.
Copyright 2022 The Associated Press. All rights reserved. | https://www.whsv.com/2022/09/06/california-facing-chance-blackouts-amid-brutal-heat-wave/ | 2022-09-06T11:22:51Z |
Fears grow for Ukraine nuke plant ahead of inspector report
KYIV, Ukraine (AP) — Fears grew Tuesday for Europe’s largest nuclear power plant as shelling around it continued, a day after the facility was again knocked off Ukraine’s electricity grid and put in the precarious position of relying on its own power to run safety systems.
Repeated warnings from world leaders that fighting around the Zaporizhzhia plant has put it in an untenable situation that could lead to a nuclear catastrophe have done little to stem the hostilities. Russian-installed officials accused the Ukrainian forces of shelling the city where the plant is located on Tuesday, hours after the Ukrainians said Kremlin forces attacked a city across the river.
Both sides have traded such accusations since Russian troops seized the plant early in the war. With the danger rising, an International Atomic Energy Agency team finally traveled to the plant last week, and inspectors are expected to report what they found to the U.N. Security Council later in the day.
Two inspectors remain at the plant, which is run by Ukrainians workers, and Ukrainian presidential adviser Mykhailo Podolyak applauded that decision.
“There are Russian troops now who don’t understand what’s happening, don’t assess the risks correctly,” Podolyak said. “There is a number of our workers there, who need some kind of protection, people from the international community standing by their side and telling (Russian troops): ‘Don’t touch these people, let them work.’”
But that appears to have done little to lessen the risks. On Monday, the IAEA said Ukrainian authorities reported that the plant’s last transmission line was disconnected to allow workers to put out a fire caused by shelling.
“The line itself is not damaged, and it will be reconnected once the fire is extinguished,” the IAEA said.
In the meantime, the plant’s only remaining operational reactor would “generate the power the plant needs for its safety and other functions,” the agency said.
Mycle Schneider, an independent analyst in Canada on nuclear energy, said that means the plant was likely functioning in “island mode,” producing electricity just for its own operations.
“Island mode is a very shaky, unstable, and unreliable way to provide continuous power supply to a nuclear plant,” Schneider said.
It was just the latest incident that fueled fears of a potential nuclear disaster in a country still haunted by the world’s worst nuclear accident at Chernobyl. Experts say the reactors at Zaporizhzhia are designed to withstand natural disasters and even aircraft crashes, but the unpredictable fighting around the plant had repeatedly threatened to disrupt critical cooling systems, raising the risk of a meltdown.
Russian-installed officials in the Zaporizhzhia region on Tuesday accused the Ukrainian forces of shelling Enerhodar, the city where the plant is located, and damaging a power line close to the plant.
Russian state news agency RIA Novosti reported, citing its correspondent on the ground, that the power was off in Enerhodar on Tuesday and sounds of explosions could be heard.
Meanwhile, Ukraine’s presidential office said that Russian forces shelled residential buildings in Nikopol, a city across the Dnieper river from the Zaporizhzhia plant. Two people were wounded and a school, a kindergarten and some 30 buildings were damaged, the office said.
Russian shelling elsewhere killed at least three civilians, the statement said.
In the southern Kherson region, occupied by the Russians since early on in the war, the Ukrainian army continued its counteroffensive, destroying Russia’s logistical centers. A pontoon bridge was blown up overnight and a command center was hit, as well as two checkpoints.
In the eastern city of Sloviansk, workers with the Ukrainian Red Cross Society swept up debris Monday from a second rocket attack on its premises in a week. Nobody was hurt in either attack, said Taras Logginov, head of the agency’s rapid response unit. He blamed Russian forces and called the attacks war crimes.
In a row of apartment buildings across the road, the few residents who haven’t evacuated sawed sheets of plywood to board up their shattered windows.
Henadii Sydorenko sat on the porch of his apartment building for a break. He said he’s not sure whether to stay or leave, torn between his responsibility of taking care of three apartments whose owners have already evacuated and the increasing fear of the now frequent shelling.
“It’s frightening,” the 57-year-old said of the shelling. “I’m losing my mind, little by little.”
___
Follow the AP’s coverage of the war at https://apnews.com/hub/russia-ukraine
Copyright 2022 The Associated Press. All rights reserved. | https://www.whsv.com/2022/09/06/fears-grow-ukraine-nuke-plant-ahead-inspector-report/ | 2022-09-06T11:22:57Z |
Police: ‘Fat Leonard’ from Navy bribery scandal escapes house arrest in San Diego
SAN DIEGO (AP) — The military contractor who pleaded guilty to orchestrating the “Fat Leonard” corruption scandal and was under house arrest in San Diego is now on the run after cutting off his GPS monitoring ankle bracelet over the weekend, federal authorities said.
Supervisory Deputy U.S. Marshal Omar Castillo said Leonard Glenn Francis removed the tracker Sunday, the San Diego Union-Tribune reported.
After police officers found Francis’ home empty, the San Diego Regional Fugitive Task Force and the Naval Criminal Investigative Service began a high-profile search, the newspaper reported.
Castillo said neighbors witnessed U-Haul moving trucks coming to and from Francis’ home in the days before his escape.
Francis was arrested in San Diego in 2013 and pleaded guilty in 2015 to offering $500,000 in bribes to Navy officers. In exchange, the officers passed him classified information and even went so far as redirecting military vessels to ports that were lucrative for his Singapore-based ship servicing company.
Prosecutors say Francis and his company overcharged the U.S. military by more than $35 million for its services.
Francis has been on house arrest since at least 2018 and under the supervision of a federal agency that monitors defendants who are out of custody until sentencing. He was set to be sentenced at the end of month.
Francis’ defense attorney, Devin Burstein, declined to comment to the Union-Tribune on Monday.
Copyright 2022 The Associated Press. All rights reserved. | https://www.whsv.com/2022/09/06/police-fat-leonard-navy-bribery-scandal-escapes-house-arrest-san-diego/ | 2022-09-06T11:23:04Z |
Uvalde school year starts amid fear and unfinished security
AUSTIN, Texas (AP) - A new and worrisome school year begins Tuesday in Uvalde.
There is new high fencing around the Texas community’s public school campuses that still isn’t finished, a heavy police patrol that many families don’t trust and no classes ever again at Robb Elementary School, three months after a gunman with an AR-15-style rifle killed 19 children and two teachers inside two adjoining fourth-grade classrooms.
Ashley Morales is putting her son, Jeremiah, back in class — because she says she has no other choice as a working single mother. She will drop him off outside Uvalde Elementary on the first day. She says parents won’t be allowed inside.
“I’m just nervous, scared,” said Morales, whose son was a third-grader last year at Robb Elementary and lost three friends in the May 24 massacre. During a recent “Meet the Teacher” night, she felt a rush of anxiety walking down the school hall.
“Oh my gosh, it’s actually going to happen,” she said. “School is going to start.”
Although school already started weeks ago in many parts of Texas, officials pushed back the first day of class in Uvalde after a summer of unfathomable heartache, anger and revelations of widespread failures by law enforcement who allowed an 18-year-old gunman to fire inside the adjoining classrooms for more than 70 minutes.
Despite pushing back the start of the year, Uvalde school officials said several enhanced security measures remain incomplete, including installing additional cameras and new locks.
The Texas Department of Public Safety has committed to putting nearly three dozen state troopers on Uvalde campuses — but that is of no comfort to some families since there were more than 90 state troopers on scene during the attack.
More than 100 families in Uvalde signed up for virtual school, while others pulled their kids out of the district and enrolled them in private schools. One teacher who was shot in the abdomen and survived, Elsa Avila, will not be greetings students for the first time in 30 years because she is still recovering.
A damning report by a Texas House committee found that nearly 400 officers in all rushed to Robb Elementary after the shooting but hesitated for more than hour to confront the shooter. Body camera and surveillance footage showed heavily armed officers, some holding bulletproof shields, stacked in the hallway but not advancing to the classroom.
Steve McCraw, head of the Texas Department of Public Safety, called the response “an abject failure.”
Last month, the Uvalde school board fired district police Chief Pete Arredondo, who McCraw and the House report accused of failing to take control of the scene and wasting time by looking for a key for a classroom door that was likely unlocked. The firing has not quieted demands for others to face punishment. One other officer — Uvalde Lt. Mariano Pargas, the acting police chief that day — has been placed on administrative leave.
___
For more AP coverage of the Uvalde school shooting: https://apnews.com/hub/uvalde-school-shooting.
Copyright 2022 The Associated Press. All rights reserved. | https://www.whsv.com/2022/09/06/uvalde-school-year-starts-amid-fear-unfinished-security/ | 2022-09-06T11:23:11Z |
ST. PAUL, Minn., Sept. 6, 2022 /PRNewswire/ -- 3M (NYSE: MMM) announced today the final proration factor of 7.346065 percent in its split-off exchange offer to 3M stockholders in connection with the separation of 3M's food safety business and merger of Garden SpinCo Corporation ("SpinCo"), the 3M subsidiary holding the food safety business, with a subsidiary of Neogen Corporation.
A total of approximately 203,610,687 shares of 3M common stock were validly tendered and not properly withdrawn in the exchange offer, including approximately 1,114,015 shares tendered by odd-lot stockholders not subject to proration. All tenders by odd-lot shareholders were fully accepted in the offer. The remaining validly tendered shares of 3M common stock were accepted in the exchange on a pro rata basis using the final proration factor of 7.346065 percent. Shares of 3M common stock that were validly tendered but not accepted for exchange are expected to be returned to tendering stockholders on or around September 8, 2022.
Under the terms of the exchange offer, 108,269,946 shares of SpinCo common stock were available in exchange for shares of 3M common stock accepted in the exchange offer. The final exchange ratio for the exchange offer was set at 6.7713 shares of SpinCo common stock for each share of 3M common stock validly tendered and not properly withdrawn. In the merger, each share of SpinCo common stock automatically converted into the right to receive one share of Neogen common stock. Accordingly, 3M stockholders who tendered shares of 3M common stock in the exchange offer will receive approximately 6.7713 shares of Neogen common stock (subject to the receipt of cash in lieu of fractional shares) for each share of 3M common stock tendered and accepted for exchange. 3M accepted approximately 15,989,536 shares of 3M common stock for exchange in the exchange offer.
About 3M
3M (NYSE: MMM) believes science helps create a brighter world for everyone. By unlocking the power of people, ideas and science to reimagine what's possible, our global team uniquely addresses the opportunities and challenges of our customers, communities, and planet. Learn how we're working to improve lives and make what's next at 3M.com/news or on Twitter at @3M or @3MNews.
3M Media Contact:
Jennifer Ehrlich
(651) 592-0132 or 3Mnews@mmm.com
3M Investor Contact:
Bruce Jermeland
(651) 733-1807
Diane Farrow
(612) 202-2449
Cautionary Note on Forward-Looking Statements
This release includes "forward-looking statements" as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995, including statements regarding the transaction between Neogen, 3M and SpinCo. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "forecast," "outlook," "target," "endeavor," "seek," "predict," "intend," "strategy," "plan," "may," "could," "should," "will," "would," "will be," "will continue," "will likely result," or the negative thereof or variations thereon or similar terminology generally intended to identify forward-looking statements. All statements, other than historical facts, including, but not limited to, the expected benefits of the transaction, including future financial and operating results and strategic benefits, the tax consequences of the transaction, and the combined Neogen-SpinCo company's plans, objectives, expectations and intentions, legal, economic and regulatory conditions, and any assumptions underlying any of the foregoing, are forward-looking statements.
These forward-looking statements are based on Neogen and 3M's current expectations and are subject to risks and uncertainties, which may cause actual results to differ materially from Neogen and 3M's current expectations. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. The inclusion of such statements should not be regarded as a representation that such plans, estimates or expectations will be achieved. Important factors that could cause actual results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from the transaction; (2) uncertainty of the expected financial performance of the combined company following completion of the transaction; (3) failure to realize the anticipated benefits of the transaction, including as a result of delay in integrating the business of Neogen and the Food Safety Business, on the expected timeframe or at all; (4) the ability of the combined company to implement its business strategy; (5) difficulties and delays in the combined company achieving revenue and cost synergies; (6) inability of the combined company to retain and hire key personnel; (7) the risk that stockholder litigation in connection with the transaction or other litigation, settlements or investigations may result in significant costs of defense, indemnification and liability; (8) evolving legal, regulatory and tax regimes; (9) changes in general economic and/or industry specific conditions; (10) actions by third parties, including government agencies; and (11) risk factors detailed from time to time in Neogen's and 3M's reports filed with the Securities and Exchange Commission (the "SEC"), including Neogen's and 3M's annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC, including Neogen's registration statement on Form S-4 (Reg. No. 333-263667) that includes a prospectus relating to the shares of Neogen common stock issued in the transaction, as amended and supplemented (the "Neogen Registration Statement"), which was declared effective by the SEC on August 4, 2022, and SpinCo's registration statement on Form S-4 and Form S-1 (Reg. No. 333-263669) in connection with its separation from 3M that contains a prospectus relating to the shares of SpinCo common stock issued in the transaction, as amended and supplemented (the "SpinCo Registration Statement"), which was declared effective by the SEC on August 4, 2022, in each case, filed with the SEC in connection with the transaction. The foregoing list of important factors is not exclusive.
Any forward-looking statements speak only as of the date of this communication. None of Neogen, 3M or SpinCo undertakes, and each party expressly disclaims, any obligation to update any forward-looking statements, whether as a result of new information or development, future events or otherwise, except as required by law. Readers are cautioned not to place undue reliance on any of these forward-looking statements.
View original content to download multimedia:
SOURCE 3M | https://www.whsv.com/prnewswire/2022/09/06/3m-announces-final-proration-factor-7346065-percent-shares-tendered-split-off-exchange-offer/ | 2022-09-06T11:23:17Z |
LUCERNE, Switzerland , Sept. 6, 2022 /PRNewswire/ -- As previously announced, in March 2022 the UK Gambling Commission selected Allwyn Entertainment Ltd, a subsidiary of Allwyn Entertainment AG ("Allwyn"), as its preferred applicant for the fourth license to operate the UK National Lottery. The award of the license has been contested in a legal challenge.
On June 29, 2022, the court ruled to lift the automatic suspension preventing the UK Gambling Commission from entering into agreements with Allwyn Entertainment Ltd to commence the transition process. That ruling was appealed by Camelot UK Lotteries Limited (the incumbent operator of the UK National Lottery) and Camelot Global Lottery Solutions Limited (together, the "Camelot Entities" and the "Camelot Appeal") and International Game Technology plc, resulting in the suspension continuing.
Today, Allwyn announced that the Camelot Entities have decided to withdraw the Camelot Appeal, and Allwyn Entertainment Ltd and Allwyn International A.S. have agreed to waive all claims for costs or damages against the Camelot Entities. Allwyn very much welcomes this decision and looks forward to cooperating with Camelot and the Gambling Commission on the transition process. Allwyn is excited at the prospect of becoming the custodian of Europe's biggest lottery.
About Allwyn
Allwyn is a leading global lottery operator. Allwyn builds lotteries that return more to good causes by focusing on innovation, technology, efficiency and safety across a growing casual gaming entertainment portfolio. The lottery-first approach of focusing on affordable recreational play has earned Allwyn leading market positions with trusted brands across Europe in Austria, Czech Republic, Greece and Cyprus and Italy.
Additional Information about the Business Combination and Where to Find It
Additional information about the Business Combination, including a copy of the Business Combination Agreement and prospectus, are provided in the Registration Statement. The Registration Statement has been mailed to each of Cohn Robbins Holdings Corp.'s (NYSE: CRHC) ("CRHC") shareholders as of August 15, 2022, and can be found for free on the SEC's website at www.sec.gov under the registrant "Allwyn Entertainment AG."
Cautionary Statement Regarding Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 with respect to the Business Combination between, among other parties, CRHC and Allwyn. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believe," "predict," "potential," "continue," "strategy," "future," "opportunity," "would," "seem," "seek," "outlook" and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These statements are based on various assumptions, whether or not identified in this press release. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. These forward-looking statements include, without limitation, Allwyn's and CRHC's expectations with respect to anticipated financial impacts of the Business Combination, the satisfaction of closing conditions to the Business Combination, and the timing of the completion of the Business Combination. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of CRHC's registration statement on Form S-1 (File No. 333-240277), its Annual Report on Form 10-K, as amended from time to time, for the fiscal year ended December 31, 2021 and its subsequent Quarterly Reports on Form 10-Q, and the Registration Statement filed by Allwyn. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Most of these factors are outside Allwyn's and CRHC's control and are difficult to predict. Many factors could cause actual future events to differ from the forward-looking statements in this document, including but not limited to: (1) the outcome of any legal proceedings that may be instituted against CRHC or Allwyn following the announcement of the Business Combination; (2) the inability to complete the Business Combination, including due to the inability to concurrently close the Business Combination and the private placement of common stock or due to failure to obtain approval of CRHC's shareholders; (3) the risk that the Business Combination may not be completed by CRHC's business combination deadline and the potential failure to obtain an extension of such deadline sought by CRHC; (4) the failure to satisfy the conditions to the consummation of the Business Combination, including the approval by CRHC's shareholders and the satisfaction of the minimum trust account amount following any redemptions by CRHC's public shareholders; (5) the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement; (6) the risk that The Business Combination disrupts current plans and operations as a result of the consummation of the Business Combination; (7) the inability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain key employees; (8) costs related to the Business Combination; (9) changes in the applicable laws or regulations; (10) the possibility that the combined company may be adversely affected by other economic, business, and/or competitive factors; (11) the risk of downturns and a changing regulatory landscape in the industry in which Allwyn operates; (12) Allwyn's ability to obtain or maintain rights or licenses to operate in any market in which Allwyn operates or seeks to operate in the future; (13) the potential inability of Allwyn to raise additional capital needed to pursue its business objectives or to achieve efficiencies regarding other costs; (14) the enforceability of Allwyn's intellectual property, including its patents, and the potential infringement on the intellectual property rights of others, cyber security risks or potential breaches of data security; and (15) other risks and uncertainties described in CRHC's registration statement on Form S-1 and Annual Report on Form 10-K, as amended from time to time, for the fiscal year ended December 31, 2020 and its subsequent Quarterly Reports on Form 10-Q, and the Registration Statement. Allwyn and CRHC caution that the foregoing list of factors is not exclusive or exhaustive and not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither Allwyn nor CRHC gives any assurance that Allwyn or CRHC will achieve its expectations. Neither Allwyn nor CRHC undertakes or accepts any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, or should circumstances change, except as otherwise required by securities and other applicable laws.
Contact: Dana Dvorakova, dana.dvorakova@allwynent.com
View original content:
SOURCE Allwyn Entertainment | https://www.whsv.com/prnewswire/2022/09/06/allwyn-entertainment-announces-withdrawal-by-camelot-entities-legal-challenge-allwyns-selection-preferred-applicant-uk-national-lottery-license/ | 2022-09-06T11:23:24Z |
GENEVA, 6th September 2022 /PRNewswire/ -- Alpian SA ("Alpian"), Switzerland's first digital private bank, today announces its partnership with Visa, a world leader in digital payments. With this step Alpian has become a Principal Member of Visa, allowing the company to issue its exclusive metal debit card in Switzerland.
With the partnership made official, Alpian can now issue its premium, intelligent metal debit card offering across Switzerland. The pairing of an exclusive metal debit card with a multi-currency current account (CHF, EUR, GBP and USD) and real-time foreign exchange capabilities with no handling fees gives each Alpian client a unique, elegant, and cost-effective means to facilitate their everyday banking needs both within Switzerland and abroad. As a member of the Visa network, Alpian's debit card is accepted in over 200 countries and regions and at more than 100 million merchant locations[1] worldwide.
The official initiation of the partnership follows the granting of a full Swiss banking license from FINMA and the successful completion of a Series B+ financing round of CHF 19 million. Both milestones have enabled Alpian to launch its services to select members of its waitlist, with a launch to the general public of Switzerland planned before the end of 2022.
Schuyler Weiss, CEO of Alpian, commented:
"At Alpian we are committed to delivering a premium service to each and every one of our clients. The capabilities, sophistication, and stability of the Visa enterprise enables Alpian to deliver just that in its card offering. Visa has been one of Alpian's most long-standing and trusted partners, and we are excited to take our next steps with them by our side."
Santosh Ritter, Country Manager Switzerland & Liechtenstein, Visa, stated:
"The joint journey with Alpian now receiving a full FINMA banking license has been excellent. We are very much looking forward to see the first Alpian-issued Visa debit cards in the Swiss market and to continue the collaboration with this great partner to help them achieve their growth objectives in providing innovative services for all regions of Switzerland."
[1] Includes an estimate of 20 million small businesses that utilize payment facilitators (as of September 2021)
Logo - https://mma.prnewswire.com/media/1859449/Alpian_Logo.jpg
View original content:
SOURCE Alpian SA | https://www.whsv.com/prnewswire/2022/09/06/alpian-partners-with-visa-offer-innovative-digital-smart-payment-solutions-switzerland/ | 2022-09-06T11:23:30Z |
Ark Addresses Demand For Innovation From Private Capital Managers and Fund Administrators
BOSTON, Sept. 6, 2022 /PRNewswire/ -- Ark announced the launch of its next generation fund operations platform. Building on an already widely adopted portal technology connecting LP investors with GP managers, Ark's new capabilities take fund operations and investor reporting automation to a new level. Fund administrators and GP manager teams are able to streamline and launch processes in just a few clicks.
The new Ark platform includes:
- Branded client portals (unlimited users & SPVs)
- Capital call and distribution automation
- Portfolio Management with dynamic Schedule of Investments
- Investor Allocations with Capital Account Statement automation
- General ledger integration
- Multi-manager platform administration
"With Ark as an integral part of our technology stack, we can go live for clients same-day without any need for custom development," said Michael Trinkaus, CEO of 4Pines Fund Services. "Ark's intuitive design and ease of use give investors exactly what they want and helps magnify the power of my team so we can keep our focus on client service."
Many off-the-shelf ledgers remain in wide use today because they handle the basics quite well; however, these tools lack true partnership accounting. They handcuff their user teams to spreadsheets, which requires manual reconciliation and increases the risk of errors. Ark's new platform provides partnership accounting capabilities that can plug right into existing off-the-shelf GL solutions, saving time and reducing errors. With Ark you can continue to use what's working well across your existing tech stack and go much further.
"When it comes to customer adoption and realizing tangible ROI, Ark is truly a game changer," said Rob Stype, CEO of Ark. "With no implementation fees, fast and configurable setup, and multi-manager engagement on a single screen, we are the industry's most dynamic and scalable operating platform. Top fund services firms and GPs are the inspiration for our nimble and thoughtfully designed product."
Ark's clients include top fund administrators, private equity, venture capital, real estate, private credit and fund of funds teams. Today the platform supports over $100B in capital commitments, 70,000 end users, and 425 fund managers.
Ark is a SOC 2 Type 2 certified fit for purpose cloud-based operating system for fund administrators and GP managers that streamlines fund operations and automates investor reporting on a secure, connected, and client-branded platform. The Ark team unifies decades of deep fund operations and financial technology experience across the private capital markets. Ark's clients include top fund administrators, private equity, venture capital, real estate, private credit and fund of funds teams. Ark was founded in Boston in 2017 and has operations nationwide. For more information visit www.arkpes.com.
CONTACT: Chris Gale at chris@galestrategies.com
View original content:
SOURCE Ark PES | https://www.whsv.com/prnewswire/2022/09/06/ark-launches-next-generation-fund-ops-platform/ | 2022-09-06T11:23:36Z |
NORTHBOROUGH, Mass., Sept. 6, 2022 /PRNewswire/ -- Aspen Aerogels, Inc. (NYSE: ASPN) ("Aspen" or the "Company"), a technology leader in sustainability and electrification solutions, today announced that the Company is scheduled to participate in the 15th Annual Cowen Global Transportation & Sustainable Mobility Virtual Conference on Wednesday September 7, 2022. The presentation materials utilized during the conference will be available on the Investor Relations section of Aspen's website at www.aerogel.com.
Donald R. Young, President & CEO, and Ricardo C. Rodriguez, Senior VP, CFO and Treasurer, will be hosting one-on-one meetings with investors during the conference.
In addition, the conference will feature a Fireside Chat with Messrs. Young and Rodriguez, hosted by Cowen's equity research analyst Jeff Osborne, Managing Director Sustainability & Mobility Technology. The Fireside Chat is scheduled for 9:20 a.m. - 9:50 a.m. ET. A live webcast of the Fireside Chat will be available at: https://wsw.com/webcast/cowen123/aspn/2017092. A replay will be available for 90 days.
For those interested in arranging a one-on-one meeting with Aspen management, please contact your Cowen representative.
About Aspen Aerogels, Inc.
Aspen is a technology leader in sustainability and electrification solutions. The Company's aerogel technology enables its customers and partners to achieve their own objectives around the global megatrends of resource efficiency, e-mobility and clean energy. Aspen's PyroThin® products enable solutions to thermal runaway challenges within the electric vehicle ("EV") market. Aspen Battery Materials, the Company's carbon aerogel initiative, seeks to increase the performance of lithium-ion battery cells to enable EV manufacturers to extend the driving range and reduce the cost of EVs. Aspen's Spaceloft® products provide building owners with industry-leading energy efficiency and fire safety. The Company's Cryogel® and Pyrogel® products are valued by the world's largest energy infrastructure companies. Aspen's strategy is to partner with world-class industry leaders to leverage its Aerogel Technology Platform™ into additional high-value markets. Headquartered in Northborough, Mass., Aspen manufactures its products at its East Providence, R.I. facilities. For more information, please visit www.aerogel.com.
View original content:
SOURCE Aspen Aerogels, Inc. | https://www.whsv.com/prnewswire/2022/09/06/aspen-aerogels-participate-15th-annual-cowen-global-transportation-amp-sustainable-mobility-virtual-conference/ | 2022-09-06T11:23:43Z |
MOBILE, Ala., Sept. 6, 2022 /PRNewswire/ -- Teamwork and caring for others. With those thoughts in mind, pharmacy students from the Auburn University Harrison College of Pharmacy's campus in Mobile and health care professions students from the University of South Alabama came together in 2014, founding what has turned into the USA Student Run Free Clinic.
Operated out of the Salvation Army on Dauphin Street in downtown Mobile, students across multiple health and social science disciplines collaborate to empower patients through health education, promotion of health literacy and improving access to community health resources.
Much of health care today is done in a team setting with pharmacists, physicians, nurses and many others working together to provide the best care possible for their patients. The interprofessional nature of the clinic allows Harrison College of Pharmacy, or HCOP, students to get a preview of what lies ahead in a professional setting.
"Interprofessional experience has been a big part of the HCOP curriculum and being able to actually use these skills before entering my fourth year was important to me," said Angelique Holmes, a member of the Class of 2024. "This experience has allowed me to see the roles of other disciplines in a health care team and where my place was as a pharmacy student."
Holmes, a native of Otsego, Michigan, and a graduate of Western Michigan University, currently serves as president of the clinic's student board. Holding a leadership position within the clinic, she understands the value of experiential learning as she prepares for her career.
"This experience is vital to my learning because I was able to work with actual patients in my first year of pharmacy school," said Holmes. "This opportunity has taught me how to critically think about a patient's case and learn in a relaxed, welcoming atmosphere where it is ok to be wrong."
Under the supervision of a faculty advisor and various preceptors, students working in the clinic see a variety of patients, many of whom are experiencing homelessness. While providing an experiential learning opportunity for students to practice clinical and communication skills, the clinic also improves sensitivity to vulnerable populations and promotes a lifelong commitment to service.
"As health care professionals, it is our responsibility to serve humanity, which includes people from all walks of life, backgrounds and socioeconomic statuses," said Sarah Grace Barnes, also a member of the Class of 2024 and the pharmacy liaison on the student board. "Everyone deserves access to care, and the patients we serve at Student Run Free Clinic are extremely grateful that we show up for them and provide care each week."
Barnes, a Fairhope native, was first exposed to the clinic while working on her biology degree at the University of South Alabama. Seeing firsthand the valuable experience and the impact on patients, she knew it was something she wanted to be a part of as soon as she started pharmacy school.
"Experiential learning is an absolute necessity to becoming a pharmacist. The skills we learn in lab and in the classroom need to be practiced to ensure we are practice-ready pharmacists upon entering the workforce after graduation," said Barnes. "The Student Run Free Clinic is the perfect place to practice blood pressure and blood glucose screenings, patient counseling and assessing medication regimens for appropriateness."
From improving health outcomes to building relationships, Auburn and South Alabama students are working together to make a difference in their community.
"Our patients come back to the clinic weekly to get checks on their blood pressure or blood sugar, or just to sit and talk with the volunteers," said Holmes. "You never know how you are going to be able to help someone, whether that be by providing services or a listening ear.
"From the time I started volunteering, that was the most surprising thing: I wasn't just there to practice my skills in the classroom, I was there to build a relationship with the patients."
View original content to download multimedia:
SOURCE Auburn University | https://www.whsv.com/prnewswire/2022/09/06/auburn-university-pharmacy-students-university-south-alabama-health-students-team-up-student-run-free-clinic/ | 2022-09-06T11:23:49Z |
PDUFA Action Date is June 28, 2023
VAUGHAN, Ontario and HEIDELBERG, Germany, Sept. 6, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) filing for investigational treatment NOV03 (perfluorohexyloctane). A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). NOV03 has been assigned a Prescription Drug User Fee Act (PDUFA) action date of June 28, 2023.
"With the FDA commencing review of the NDA filing, we are one step closer to bringing an important new treatment option to the millions of Americans affected by dry eye disease associated with Meibomian gland dysfunction," said Joseph C. Papa, CEO, Bausch + Lomb. "NOV03 is distinct from anti-inflammatory and immunomodulatory agents, and, if approved, would be the first prescription eye drop to address excessive tear evaporation. The approval would also mark a significant milestone for Bausch + Lomb, as the company's first FDA approval for a prescription medicine since becoming a publicly traded company earlier this year."
DED is one of the most common ocular surface disorders, with MGD as a major cause of development and progression, affecting approximately nine out of 10 people with DED.1,2 DED due to MGD is caused by a deficient tear film lipid layer that leads to increased tear evaporation.3 There is currently no approved prescription eye drop in the United States for DED associated with MGD.
"We are thrilled the FDA has accepted our NDA filing for NOV03," said Christian Roesky, Ph.D., CEO, Novaliq. "With only limited treatment options currently available, NOV03 is a promising potential new therapy, specifically designed to alleviate the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction."
The clinical development program for NOV03 includes two Phase 3 studies (GOBI and MOJAVE), both of which demonstrated statistically significant improvement vs. control for both primary and key secondary sign and symptom endpoints as early as day 15 and through day 57. NOV03 was well tolerated in both studies.
About NOV03 (perfluorohexyloctane) Ophthalmic Solution
NOV03 (perfluorohexyloctane) is an investigational, proprietary, water-free, non-steroidal, single-component preservative-free eye drop.4 In 2019, Bausch + Lomb acquired an exclusive license for the commercialization and development of NOV03 in the United States and Canada. Data from the first pivotal Phase 3 trial (GOBI) were presented at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, D.C. on April 24, 2022. Data from the second pivotal Phase 3 trial (MOJAVE) were presented at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Denver on May 2, 2022. Results from the pivotal Phase 2 trial (SEECASE) were published in Cornea in September 2021.5 The clinical program for NOV03 concluded with the completion of a multi-center, open-label, single-arm, 12-month safety extension trial (KALAHARI).
About Novaliq
Novaliq is a biopharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology. Novaliq offers an industry-leading portfolio addressing today's unmet medical needs of millions of patients with eye diseases. Novaliq GmbH is headquartered in Heidelberg, Germany and Novaliq Inc. has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech holding GmbH & Co. KG, an active investor in Life and Health Sciences companies. More on www.novaliq.com.
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with more than 12,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram.
Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb's filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch + Lomb, including but not limited to its project development timelines, launches and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
References
- Leonardi, A., Modugno, R. L., & Salami, E. (2021). Allergy and Dry Eye Disease. Ocular immunology and inflammation, 29(6), 1168–1176. https://doi.org/10.1080/09273948.2020.1841804.
- Lemp, M. A., Crews, L. A., Bron, A. J., Foulks, G. N., & Sullivan, B. D. (2012). Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea, 31(5), 472–478. https://doi.org/10.1097/ICO.0b013e318225415a
- Geerling G, Baudouin C, Aragona P, et al. (2017). Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: Proceedings of the OCEAN group meeting. The Ocular Surface,15(2): 179-192. https://doi.org/10.1016/j.jtos.2017.01.006
- In December 2019, Bausch + Lomb acquired the rights from Novaliq GmbH to pursue development and commercialization of NOV03 for DED and combination products based on NOV03 in additional ophthalmic indications in the United States and Canada.
- Tauber J, Wirta DL, Sall K, Majmudar PA, Willen D, Krösser S; SEECASE study group. (2021). A randomized clinical study (SEECASE) to assess efficacy, safety, and tolerability of NOV03 for treatment of dry eye disease. Cornea;40(9):1132-1140. http://doi.org/10.1097/ICO.0000000000002622.
All product/brand names and/or logos are trademarks of the respective owners.
© 2022 Bausch & Lomb Incorporated or its affiliates.
NOV03.0016.USA.22
View original content to download multimedia:
SOURCE Bausch + Lomb Corporation | https://www.whsv.com/prnewswire/2022/09/06/bausch-lomb-novaliq-announce-us-fda-filing-acceptance-investigational-treatment-nov03-perfluorohexyloctane/ | 2022-09-06T11:23:55Z |
TEMPE, Ariz., Sept. 6, 2022 /PRNewswire/ -- Bierman Autism Centers recently announced that it has appointed Dr. Bryan Davey, BCBA-D, LBA as its new Chief Operating Officer. In this role he will lead the operations team and will closely partner with the clinical leadership of the company.
Dr. Davey has clinical expertise in training personnel in applying behavioral principles and procedures, functional behavior assessments, assessment and treatment of severe and complex behaviors, organizational behavior management and effective teaching practice.
He has held various executive leadership positions at both for profit and non-profit organizations. He has served as an SVP of Operations for a national behavioral health organization that operated a continuum of treatment programs for children, adolescents, adults, and families. Prior to that he served as CEO of a multi-site integrated physical and behavioral health organization, which primarily focused on children served through Medicaid. Most recently, Dr. Davey was the CEO of a telehealth platform that served members in over 40 countries.
In addition, Dr. Davey advocates for behavior analysis by supporting certification, practice standards, monitoring, developing legislation, policy at the state and national levels. Dr. Davey serves on the Arizona Governor's Autism Spectrum Disorder Committee and Telehealth Advisory Committee. He is a past Board Member and Public Policy Chair of CalABA, founding member of AZABA, a past Board Member and Past-President of APBA, and served on the National ABA CPT Code Steering Committee. He continues to serve as a subject matter expert to the BACB, CASP, health plans, and managed care organizations.
When asked about his addition to the team, Dr. Davey said "I am honored to join Bierman Autism Centers and I look forward to working alongside so many amazing clinicians and professionals as we support the families that trust us with their children's care and growth. Our mission is to Create Progress & Possibilities for Children with Autism, and I am thrilled to join a team that sets the standard in services and continues to achieve impactful outcomes for the families and individuals we serve."
By adding Dr. Davey as Chief Operating Officer, Bierman continues to focus on clinical excellence and quality of care.
Bierman Autism Centers is a place where kids up to 9 years of age acquire foundational skills they can build on such as self-advocacy and communication. To date they have graduated over 175 kids from their programs. They recognize that every kid's success is unique, and their one-on-one approach allows them to drive progress and measurable outcomes, ensuring each child is advancing on their own terms. Bierman currently has 14 centers, and is expanding in: Arizona, Indiana, Massachusetts, North Carolina, New Jersey, Rhode Island, and Ohio. For more about Bierman Autism Centers visit www.biermanautism.com or contact marketing@biermanautism.com.
View original content to download multimedia:
SOURCE Bierman Autism Centers | https://www.whsv.com/prnewswire/2022/09/06/bierman-autism-centers-names-dr-bryan-davey-bcba-d-lba-chief-operating-officer/ | 2022-09-06T11:24:02Z |
MINNEAPOLIS, Sept. 6, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022, at 12:50 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022 and has approximately 3,000 employees worldwide.
View original content to download multimedia:
SOURCE Bio-Techne Corporation | https://www.whsv.com/prnewswire/2022/09/06/bio-techne-present-baird-2022-global-healthcare-conference/ | 2022-09-06T11:24:08Z |
KOURTNEY KARDASHIAN BARKER COLLABORATES WITH BOOHOO TO DISCOVER MORE ABOUT SUSTAINABILITY & STYLE. WORKING TO EMPOWER HERSELF AND OTHERS WITH A BETTER UNDERSTANDING OF THE FASHION INDUSTRY'S ENVIRONMENTAL IMPACT
LOS ANGELES, Sept. 6, 2022 /PRNewswire/ -- Global e-retailer boohoo announces collaboration and partnership with Kourtney Kardashian Barker, entertainment personality and the CEO & founder of Poosh. Kardashian Barker is the brand's newest ambassador with a focus on sustainability, delivering two capsule collections that have been created in tandem with a journey of investigation into opportunities for creating a more sustainable fashion future. Launching in September 2022, the year-long project started with design meetings, where Kardashian Barker posed questions about the possibility of using the partnership to discuss the challenges of sustainability in fashion and help people make more informed choices. As the design team worked with Kardashian Barker to develop the first 46-piece capsule collection, discussions with global industry experts began, and Kardashian Barker worked to gain a better understanding of the challenges the fashion industry faces in this space. The entire journey has been captured as part of a social content series and gives a first-hand account of the experts they met on and off camera, the conversations they had, what they discovered and how this continues to inform the project and the boohoo brand into the future.
In the series, Kardashian Barker works to dig under the surface of the industry, speaking with experts who help her and the audience, form a better understanding of the challenges and opportunities. The audience will hear from specialists in worker welfare, human rights, textile waste, upcycling, resale and vintage fashion. Kardashian Barker also called upon the expertise of her long-time friend sustainability influencer Stephanie Shepard, co-founder of Future Earth to identify the difficult questions we need to ask and get the conversation started about whether style and sustainability can really go together.
"When boohoo first approached me with this idea that was all about sustainability and style, I was concerned about the effects of the fast fashion industry on our planet. Boohoo responded with excitement and a desire to incorporate more sustainable practices into our line. It's been an enlightening experience speaking directly with industry experts. I'm grateful for the opportunity to use my platform to drive conversations that lead to ongoing change and use my voice to share actionable tips with consumers on how we can play our own part. There's still lots of work to be done and improvements to be made, but I truly believe that any progress we can make when it comes to sustainability is a step in the right direction and will open up the conversation for future advancements." - KOURTNEY KARDASHIAN BARKER
The conversation starts with the content series and New York Fashion Week will be the backdrop for the launch of the first collection and help to ignite a more in-depth conversation. The fashion industry has challenges ahead, and boohoo are committed to playing their part in delivering more sustainable style choices. This is just the start and as the discovery continues, the second collection, launching in spring will encompass more of what Kourtney and our design team have learned and we will mark the end of the partnership by announcing a series of commitments based on what all of the independent experts have recommended.
The first limited edition 46-piece capsule has been carefully curated, our customers told us that they think more sustainable options are out of their reach, so we've made the prices of these collections extremely attractive to make sure it's accessible to all. We want to get these products into the hands of those who want a more conscious choice, because we know they'll love the quality, design and feel, so we are investing into certain price points and categories so that our customers don't have to pay more.
The collection includes boohoo's first foray into vintage, with two key styles custom sourced exclusively for this range. John Hickling from Glass Onion said, "These biker jackets are your statement vintage piece. It has taken us months to individually source, hand select and curate this huge collection. We have made sure that each piece is authentic, standout and aged to perfection"
Other garments feature materials made from recycled fibers, statement pieces to cherish forever, staple wardrobe silhouettes made with traceable cotton and cleverly designed multiway pieces that give customers a variety of styling options. The brand has also explored ways to extend the life cycle of the collection and have embarked on a partnership with Hirestreet. Our customers love faux leather and sparkle in their wardrobes, and so we have created selected outerwear pieces using recycled polyester backing for the faux leather and three showpieces using recycled sequins. UK customers will be able to hire a selection of garments through the partnership with Hirestreet exclusively. Although these improved fabric options are not the perfect solution, customers are given clear information about how their garments are made, offered options in terms of how they might access these pieces, and also provided with a free Kares document to help them extend the life of their purchases. Boohoo believes customers should be able to buy clothes at an affordable price and that includes more sustainable ranges and so all items in the collection have been priced in line with boohoo's mainline collection.
'We are delighted to be working with Kourtney. We all know there's an environmental and social cost to producing clothes, but there are ways the fashion industry can be smarter. boohoo has taken the bold decision to listen to our customers when they tell us they want to make more sustainable choices, but that the jargon makes it hard to really understand what their options are. When we first met with Kourtney, she said exactly the same thing, and we realized we had an opportunity to use this collaboration to try and help inform our customers and empower them to make more informed choices. When we spoke to the experts from across the industry, everyone said education was the key, and we could all see this was quite a unique opportunity to speak directly to millions of people across the globe and deliver something we don't believe has been done before.' - Carol Kane ' Co-Founder and Executive Director boohoo Group'
Assets
Collection Details
Collection will launch on September 13th, 2022 at 12 ET ahead of the New York Fashion Week show at 8pm ET as see now, buy now from the runway
- 45 pieces with price range - From $6 to $100
- 2 vintage pieces
- 41/45 contain pieces that contain recycled fibres like recycles cotton
- 12 styles made in the UK including our own British Factory
- 5 styles can be worn in multiple ways
- 2 made from cotton connect which has seen 2500 farmers trained in the benefits of more sustainable cotton production and good business practices
The Content Series Cast
- Tim Nelson – Hope for Justice
- John Hickling – Glass Onion
- Christina Dean – Redress
- Steven Bethell – Bank and Vogue/Beyond Retro
- Patrick Duffy – Global Fashion Exchange
- Steph Shep – Future Earth
We launched our UPFRONT sustainability strategy in 2021 and we're focusing our efforts in the areas that stand to deliver the biggest impact on creating more sustainable fashion - materials, design, waste, packaging and finding ways to keep our clothes in use for longer.
Entertainment Personality, executive producer, entrepreneur, and mom Kourtney Kardashian Barker has been a staple in the American media since 2007, when she rose to fame as the witty, monotoned sister alongside her family on the hit E! Entertainment reality series "Keeping Up with the Kardashians." In 2021, after 15 years, 20 seasons, and multiple spin-offs, Kardashian Barker and her family parted ways with E! and began their journey with Hulu, where they produce and star in the successful documentary-style reality show "The Kardashians."
Kourtney, an advocate for clean living, founded Poosh in 2019 as a content-meets-commerce lifestyle platform that promotes living your best life with actionable insights and tips. Poosh remains a trusted destination to inform and inspire across multiple content verticals including sustainable practices, healthy recipes, sex and relationships, clean beauty, and mindfulness hacks.
Kourtney's commitments to both health and the environment have continued as she has advocated for the cleanup of the Santa Susana Field Lab and successfully lobbied congress alongside the Environmental Working Group for the Personal Care Products Safety Act, helping implement cleaner standards for personal care products.
Leading the fashion e-commerce market and founded in Manchester in 2006, the group started life as boohoo.com, an inclusive and innovative brand targeting young, value-orientated customers. For over ten years, boohoo has been pushing boundaries to bring its customers up-to-date and inspirational fashion, 24/7. In early 2017, the group extended its customer offering through the acquisitions of the vibrant fashion brand PrettyLittleThing, and free-thinking brand Nasty Gal. United by a shared customer value proposition, our brand's design, source, market, and sell great quality clothes, shoes and accessories at unbeatable prices. This investment proposition has helped the group grow from a single brand into a major multi-brand online retailer, leading the fashion e-commerce market for 16 to 30-year-olds around the world. The boohoo group has continued to further strengthen its multi-brand platform, in 2019, the group acquired online womenswear retailer Miss Pap and UK brands Karen Millen and Coast. Today the boohoo group sells to over 8 million ever-growing customers globally.
View original content to download multimedia:
SOURCE boohoo | https://www.whsv.com/prnewswire/2022/09/06/boohoo-announces-ambassador-kourtney-kardashian-barker/ | 2022-09-06T11:24:14Z |
WATCHMAN FLX now the only LAAC technology in the United States that allows for either DAPT or OAC immediately following implantation
MARLBOROUGH, Mass., Sept. 6, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use labeling for the current-generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device to include a 45-day dual anti-platelet therapy (DAPT) option as an alternative to 45-day oral anticoagulation (OAC) plus aspirin for post-procedural treatment of patients with non-valvular atrial fibrillation (NVAF).
"This revised labeling provides physicians more flexibility to exercise their clinical judgment based on individual patient characteristics to determine the most appropriate post-procedural antithrombotic medication regimen," said Dr. Ian Meredith, global chief medical officer, Boston Scientific. "This significant step forward is supported by the robust safety and efficacy profile demonstrated by both the legacy WATCHMAN and current-generation WATCHMAN FLX technologies."
Clinical evidence submitted to the FDA to support the labeling update included analyses spanning approximately 8,300 patients from the Left Atrial Appendage Occlusion Registry (LAAO Registry) within the American College of Cardiology Foundation's (ACCF) National Cardiovascular Data Registry (NCDR). The data was submitted to the FDA to support the safety and efficacy of DAPT as a post-procedural antithrombotic regimen in patients with NVAF who may have a reason for seeking an alternative to OAC.
The labeling in Europe has included the choice of either OAC or a DAPT post-procedural drug regimen for WATCHMAN technology since 2017.
Additional Recent Clinical Data Supporting the WATCHMAN FLX Device
Recently announced real-world data for the WATCHMAN FLX device include the results of an analysis of more than 17,000 patients from the NCDR-LAAO Registry that demonstrated no significant difference in rates of major adverse events at 45 days post implant, whether patients were discharged from the hospital on DAPT, a direct OAC and aspirin, or warfarin and aspirin.
Additionally, recently presented data from the SURPASS analysis of more than 16,000 patients from the NCDR-LAAO Registry demonstrated low rates of adverse events and peri-device leak through 45 days post implant, and, in the investigator-led SEAL-FLX study – the first study exclusively comparing the WATCHMAN FLX device vs. the Amplatzer™ Amulet™ device – there was a significantly higher rate of complete occlusion of the left atrial appendage at eight weeks with the WATCHMAN FLX technology compared to the Amulet device (72.6% vs. 30.5%), as evaluated by contrast enhanced cardiac computed tomography (CT) imaging. This single-center retrospective study of 300 patients also demonstrated that the median peri-device leak area (residual flow around the device from the LAA) was significantly smaller with the WATCHMAN FLX device.
Ongoing studies with the WATCHMAN FLX device include the CHAMPION-AF and OPTION clinical trials to evaluate use of the device for broader patient populations with NVAF.
For more information on the WATCHMAN FLX device, visit www.watchman.com/implanter.
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, clinical trials and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
CONTACTS:
Angela Mineo
Media Relations
(763) 955-8325 (office)
Angela.mineo@bsci.com
Lauren Tengler
Investor Relations
(508) 683-4479
BSXInvestorRelations@bsci.com
View original content to download multimedia:
SOURCE Boston Scientific Corporation | https://www.whsv.com/prnewswire/2022/09/06/boston-scientific-receives-fda-approval-expanded-labeling-watchman-flx-laac-device-dual-anti-platelet-therapy-post-procedural-medication-option/ | 2022-09-06T11:24:22Z |
Adds Four New Independent Directors to the Board
Forms New Business Review Committee to Evaluate Portfolio and Operations
DUBLIN, Ohio, Sept. 6, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced initiatives aimed at positioning the Company for long-term success, building on Cardinal Health's previously announced growth plans. These initiatives have benefited from input received from Elliott Investment Management L.P. ("Elliott"). In connection with these initiatives, Elliott has also entered into a cooperation agreement with Cardinal Health, and Elliott's Steven Barg will join the Company's Board of Directors.
As part of Cardinal Health's ongoing commitment to Board refreshment and the initiatives announced today, the Governance and Sustainability Committee of the Board has recommended and the Board has approved the appointment of four new independent directors: Steven Barg, Michelle Brennan, Sujatha Chandrasekaran and Christine Mundkur. With these immediate appointments, Cardinal Health's Board will be made up of 15 Directors, 14 of whom are independent under the Company's director independence standards. Two existing Directors – Dean Scarborough and John Weiland – have announced their intentions to conclude their Board service at the end of their previously elected terms this fall and will not stand for re-election at Cardinal Health's 2022 Annual Meeting, resulting in a 13-member Board. Following the Annual Meeting, Cardinal Health's Board will consist of 54% women and 23% racially or ethnically diverse individuals.
Cardinal Health's Board has also formed a new Board committee, the Business Review Committee, to support a comprehensive review of the Company's strategy, portfolio, capital-allocation framework, and operations with the goal of maximizing Cardinal Health's potential for the benefit of all stakeholders. The Business Review Committee will be chaired by Chief Executive Officer Jason Hollar; Mr. Barg and Akhil Johri will also serve on the Committee. The Committee, with the assistance of the Company's legal and financial advisors, will make recommendations to the full Board. The Company expects to conduct an investor day in the first half of calendar 2023 to share the Board's conclusions and to provide additional guidance.
"We'd like to thank Dean and John for their service to the Board. We're grateful for their leadership and contributions and wish them both the very best," said Gregory Kenny, Independent Chairman of the Board of Cardinal Health. "We're pleased to welcome Steven, Michelle, Sujatha and Christine to the Board and believe the Company and our many stakeholders will benefit from their mix of experience, skills and leadership. We are also pleased with Elliott's confidence in, and commitment to, the go-forward long-term potential of Cardinal Health. Our Board looks forward to receiving the recommendations of the Business Review Committee and updating the market in due course, as Jason and his leadership team chart a path to deliver upon our mission for our customers and employees and drive value creation for our shareholders."
"Cardinal Health's leadership team is focused on creating value for all our stakeholders, and the newly initiated Business Review Committee, as well as the new expertise and experience being added to our Board, are critical steps in this process," said Mr. Hollar, Cardinal Health's Chief Executive Officer. "I look forward to working with the Board, including our four new directors, to optimize our strategy, structure, and operations as we position Cardinal Health for long-term success."
Elliott Senior Portfolio Manager Marc Steinberg said, "Our discussions with Jason and the Board have been positive and productive, and we are pleased to have worked collaboratively to reach this agreement. Cardinal Health plays a mission-critical, market-leading role in the global healthcare system, and we have been encouraged by the Company's openness to taking actions necessary to ensuring that Cardinal Health realizes its full potential. We are confident that the initiatives announced today will drive meaningful shareholder value creation, and we look forward to continuing our collaboration with the Company."
The cooperation agreement that the Company has entered into with Elliott contains customary standstill, voting, confidentiality and other provisions.
Goldman Sachs & Co. LLC is serving as financial advisor to Cardinal Health, and Wachtell, Lipton, Rosen & Katz is serving as legal counsel, both of whom will also support the Business Review Committee and Board's reviews.
New Director Biographies
Steven Barg is Global Head of Engagement at Elliott Management Corporation. Prior to joining Elliott in February of 2020, Mr. Barg spent 30 years in investment banking, most recently as a Participating Managing Director at Goldman Sachs. During his time at Goldman Sachs, Mr. Barg established and led what became the firm's Global Activism and Shareholder Advisory practice; founded and led the M&A Capital Markets practice; and served as Co-Head of Asian Equity Capital Markets in Hong Kong. In addition, Mr. Barg served on both the Asian and Global Equity Commitments Committees and was Global Head of Diversity for the Investment Banking Division. Prior to joining Goldman Sachs, Mr. Barg ran the Asian Equity Capital Markets and later the Integrated Capital Markets business at UBS and served as a managing director in Equity Capital Markets at Credit Suisse in New York and London.
Mr. Barg holds an M.B.A. from the Stanford University Graduate School of Business and a B.A. from Wesleyan University. In addition, Mr. Barg was a Henry Luce Scholar in Hong Kong and a Coro Fellow in Public Affairs in New York.
Michelle Brennan is Chair of Connect Healthcare Council for Pioneering Collective and serves on the Board of Coupa Software. Ms. Brennan spent more than 30 years at Johnson & Johnson, a leader in the field of medical devices, pharmaceutical, and consumer packaged goods, where she focused on driving growth, optimization and business transformation across diverse businesses and geographies. Most recently, Ms. Brennan served as the Global Value Creation Leader for Johnson & Johnson and as a member of the company's Medical Device Executive Leadership Team responsible for the division's value creation through cost management initiatives. Prior to that, Ms. Brennan held a number of positions at Johnson & Johnson, including Company Group Chair, Medical Devices (EMEA); President, Enterprise Standards & Productivity; Worldwide President, Ethicon Energy; as well as a variety of sales and marketing positions for other Johnson & Johnson divisions. Throughout her time at Johnson & Johnson, Ms. Brennan held significant board roles for the company, including Chairman of the Board for Medtech Europe Trading Association. She was previously a member of the UK's Office of Life Sciences Council and Chairman of the Council's Health Technology Partnership Committee.
Ms. Brennan holds a B.S. from the University of Kansas.
Sujatha Chandrasekaran, also known as Suja, is an advisor and independent consultant in the research and technology sectors. She currently serves on the Board of American Eagle Outfitters as well as private companies including Agendia, a molecular diagnostics company, and Blume Global, a digital supply chain platform company. Ms. Chandrasekaran has more than 25 years of experience in technology and leadership roles across the healthcare, consumer packaged goods and retail industries. Most recently, Ms. Chandrasekaran was Senior EVP & Chief Digital and Information Officer at CommonSpirit Health, one of the largest non-profit health systems in the US. Prior to that, she held a number of senior executive roles at several Fortune 500 multinational companies, including Global Chief Information Officer for Kimberly-Clark; SVP, Global Chief Technology and Data Officer for Walmart; as well as a number of C-level roles at The Timberland Company, PepsiCo and Nestlé SA. Ms. Chandrasekaran has a strong track record of delivering significant value to customers and organizations by leading global technology, supply chain and digital transformation initiatives. In 2022, Ms. Chandrasekaran was recognized by Modern Healthcare as one of the Top 25 Women Leaders in Healthcare. She was previously a Director of Symphony Technology Group and a Director of Barry Callebaut AG as well as a Member of Advisory Board at Atmio Inc.
Ms. Chandrasekaran holds an Executive Development Education Certificate from London Business School; a Master of Business Systems/M.B.A. from Monash University in Melbourne, Australia; and a B.Eng. from the University of Madras, India.
Christine Mundkur most recently served as Chief Executive Officer and Non-Voting Chairman of the Board of Directors for Impopharma Inc, a developer of complex formulations focused on inhalation pharmaceutical products. Ms. Mundkur currently serves on the Boards of Lupin Limited and MannKind Corporation. While at Impopharma, she led the transition of the company from a successful clinical research organization into a generic pharmaceutical inhalation development company. She also held leadership positions as President and Chief Executive Officer for North America for Sandoz, Inc. Earlier, she served as Chief Executive Officer of Barr Laboratories, Inc. Ms. Mundkur started her career at Barr as quality and regulatory counsel. In addition, she served as a strategic advisor to clients on generics, 505(b)2, biosimilars and NDA business strategies.
Ms. Mundkur holds a J.D. from the St. Louis University School of Law and a B.S. from St. Louis University.
About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 years in business, operations in more than 30 countries and approximately 44,000 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com.
Contacts
Media: Erich Timmerman, erich.timmerman@cardinalhealth.com and 614.757.8231
Investors: Kevin Moran, kevin.moran@cardinalhealth.com and 614.757.7942
Cautions concerning forward-looking statements
This release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and various accruals and estimates. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include risks arising from ongoing inflationary pressures and supply chain constraints, including the risk that our plans to mitigate such effects may not be as successful as we anticipate and the possibility that costs to source certain personal protective or other equipment, increased costs for transportation, shipping, freight and commodities, reduced price or demand for certain products may result in additional inventory reserves or disruptions and may negatively impact our ability to meet our long-term guidance; the possibility that our Medical unit goodwill could be further impaired, the increase in global interest rates or possible unfavorable changes in the U.S. statutory tax rate; competitive pressures in Cardinal Health's various lines of business; the performance of our generics program, including the amount or rate of generic deflation and our ability to offset generic deflation and maintain other financial and strategic benefits through our generic sourcing venture with CVS Health; ongoing risks associated with the distribution of opioids, including the financial impact associated with the settlements with governmental authorities, the risk that challenges to our plans to take tax deductions for opioid-related losses could adversely impact our financial results, risks arising from the Department of Justice investigation which we believe concerns our anti-diversion program and risks associated with the injunctive relief requirements under the national settlement, including the risk that we may incur higher costs or operational challenges in the implementation and maintenance of the required changes; risks associated with the manufacture and sourcing of certain products, including risks related to our ability and the ability of third-party manufacturers to import or export certain products or component parts and to comply with applicable regulations; risks associated with the competitive labor market and our ability to attract and retain employees in key roles; our ability to manage uncertainties associated with the pricing of branded pharmaceuticals; and risks associated with our cost savings initiatives or other business initiatives, such as the Medical Improvement Plan, including the possibility that they could fail to achieve the intended results. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports. This release reflects management's views as of September 6, 2022. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement. Forward-looking statements are aspirational and not guarantees or promises that goals, targets or projections will be met, and no assurance can be given that any commitment, expectation, initiative or plan in this report can or will be achieved or completed.
View original content to download multimedia:
SOURCE Cardinal Health | https://www.whsv.com/prnewswire/2022/09/06/cardinal-health-announces-governance-enhancements-shareholder-value-creation-initiatives/ | 2022-09-06T11:24:28Z |
ATLANTA, Sept. 6, 2022 /PRNewswire/ -- CatchMark Timber Trust, Inc. (NYSE: CTT) ("CatchMark" or the "Company") announced today that independent proxy advisory firms Glass, Lewis & Co. ("Glass Lewis") and Institutional Shareholder Services Inc. ("ISS") have recommended that the Company's stockholders vote "FOR" the previously announced merger of the Company with PotlatchDeltic Corporation (NASDAQ: PCH) ("PotlatchDeltic") at the Company's upcoming Special Meeting of Stockholders (the "Special Meeting") scheduled for September 13, 2022 at 10:00 a.m., Eastern Time.
As previously announced, the Company, PotlatchDeltic and certain of their respective subsidiaries have entered into a definitive merger agreement (the "Merger Agreement"), pursuant to which CatchMark will merge with and into a wholly owned subsidiary of PotlatchDeltic. Under the terms of the Merger Agreement, among other things, each outstanding share of CatchMark Class A common stock (other than certain shares to be cancelled in accordance with the terms of the Merger Agreement) will be automatically converted into the right to receive 0.230 shares of PotlatchDeltic common stock.
All stockholders of record as of the close of business on August 10, 2022 are entitled to vote at the Special Meeting.
The Company's stockholders are reminded that their vote is extremely important, no matter how many shares they own. To follow the recommendations of Glass Lewis, ISS and our Board of Directors, stockholders should vote "FOR" the proposed merger.
If you have any questions about the Special Meeting or need assistance voting your shares, please contact CatchMark's proxy solicitor, D.F. King & Co., Inc., by email at CTT@dfking.com or by phone at (800) 848-3410.
CatchMark owns prime timberlands located in the nation's leading mill markets, seeking to capture the highest value per acre and to generate sustainable yields through disciplined management and superior stewardship of its exceptional resources. Headquartered in Atlanta and focused exclusively on timberland ownership and management, CatchMark began operations in 2007 and owns interests in approximately 350,000 acres* of timberlands located in the U.S. South. For more information visit www.catchmark.com.
* As of June 30, 2022
This communication is being made in respect of the proposed merger transaction involving PotlatchDeltic and CatchMark. This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. In connection with the proposed transaction, PotlatchDeltic filed with the Securities and Exchange Commission ("SEC") a Registration Statement on Form S-4 that was declared effective on August 10, 2022 that constitutes a prospectus of PotlatchDeltic and a proxy statement of CatchMark. CatchMark filed the proxy statement/prospectus with the SEC on August 10, 2022 and mailed it to its stockholders commencing August 12, 2022. The proxy statement/prospectus related to the proposed merger contains important information about PotlatchDeltic, CatchMark, the proposed transaction and related matters. Investors are urged to carefully read the proxy statement/prospectus and other documents filed or to be filed with the SEC (or incorporated by reference into the proxy statement/prospectus) in connection with the proposed merger. Investors may obtain free copies of the proxy statement/prospectus and other documents through the website maintained by the SEC at www.sec.gov. In addition, investors are able to obtain free copies of the proxy statement/prospectus and other documents filed with the SEC by the parties on PotlatchDeltic's website at www.potlatchdeltic.com (which website is not incorporated herein by reference), for documents filed with the SEC by PotlatchDeltic, or on CatchMark's website at www.catchmark.com (which website is not incorporated herein by reference), for documents filed with the SEC by CatchMark.
PotlatchDeltic and CatchMark and their respective directors and officers and certain other members of management and employees may be deemed to be participants in the solicitation of proxies from stockholders of CatchMark in connection with the merger transaction. Certain information about the directors and executive officers of PotlatchDeltic is set forth in its Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on February 17, 2022, its proxy statement for its 2022 annual meeting of stockholders, which was filed with the SEC on March 29, 2022, and the proxy statement/prospectus filed with the SEC on August 10, 2022. Certain information about the directors and executive officers of CatchMark is set forth in its Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on March 3, 2022, its proxy statement for its 2022 annual meeting of stockholders, which was filed with the SEC on April 15, 2022, and the proxy statement/prospectus filed with the SEC on August 10, 2022. You can obtain free copies of these documents from PotlatchDeltic and CatchMark as described above.
This communication includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, are forward-looking statements that contain our current expectations about future results. These forward-looking statements are based on certain assumptions and expectations made by the Company, which reflect our management's experience, estimates and perception of historical trends, current conditions and anticipated future developments. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or anticipated in the forward-looking statements. When considering these forward-looking statements, you should also keep in mind the risk factors and other cautionary statements found in the Company's respective filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2021, as amended, and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. All forward-looking statements, expressed or implied, included in this communication are expressly qualified in their entirety by this cautionary statement. This cautionary statement should also be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this release. The Company claims the safe harbor protection for forward looking statements contained in the Private Securities Litigation Reform Act of 1995.
View original content to download multimedia:
SOURCE CatchMark Timber Trust, Inc. | https://www.whsv.com/prnewswire/2022/09/06/catchmark-timber-trust-announces-proxy-advisory-firms-glass-lewis-iss-recommend-stockholders-vote-proposed-merger-catchmark-with-potlatchdeltic-corporation/ | 2022-09-06T11:24:34Z |
DALLAS, Sept. 6, 2022 /PRNewswire/ -- CECO Environmental Corp. (Nasdaq: CECE), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment and industrial equipment, today announced that Todd Gleason, Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Sep. 13 in New York. Management will also host one-on-one investor meetings throughout the day.
Additionally, management will present and host one-on-one meetings at the Lake Street 6th Annual Best IDEAS Growth Big 6 Conference on Sep. 14 in New York. The presentation can be accessed on the Lake Street conference portal for registered participants and the Investor Relations section of the Company's website at www.CECOEnviro.com.
ABOUT CECO ENVIRONMENTAL
CECO Environmental is a leading environmentally focused, diversified industrial company, serving a broad landscape of industrial air, industrial water and energy transition markets across the globe through its key business segments: Engineered Systems and Industrial Process Solutions. Providing innovative technology and application expertise, CECO helps companies grow their business with safe, clean, and more efficient solutions that help protect people, the environment and industrial equipment. In regions around the world, CECO works to improve air quality, optimize the energy value chain, and provide custom solutions for applications including power generation, petrochemical processing, general industrial, refining, midstream oil and gas, electric vehicle production, poly silicon fabrication, battery recycling, beverage can, and water/wastewater treatment along with a wide range of other applications. CECO is listed on Nasdaq under the ticker symbol "CECE." Incorporated in 1966, CECO's global headquarters is in Dallas, Texas. For more information, please visit www.cecoenviro.com.
Investor Relations Contact:
Steven Hooser or Gary Guyton
Three Part Advisors
214-872-2710
Investor.Relations@OneCECO.com
888-990-6670
News Media:
Kimberly Plaskett
Corporate Communications Director
kplaskett@OneCECO.com
View original content to download multimedia:
SOURCE CECO Environmental Corp. | https://www.whsv.com/prnewswire/2022/09/06/ceco-environmental-present-upcoming-24th-annual-hc-wainwright-global-investment-conference-lake-street-6th-annual-best-ideas-growth-conference/ | 2022-09-06T11:24:41Z |
- Proposal does not apply to Eurodollar futures and options that expire before June 30, 2023
- Conversion date aligns with OTC market plans
- Market participants invited to provide feedback until September 30
- SOFR options to be added to portfolio margining solution
CHICAGO, Sept. 6, 2022 /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today announced that based on initial client feedback, it is proposing to convert Eurodollar futures and options open interest into corresponding SOFR contracts on April 14, 2023, under the company's previously adopted fallbacks plan. Eurodollar futures and options contracts that expire before June 30, 2023 are excluded from this proposal and will continue to trade until their expiry.
"Our proposed conversion date will help our clients complete their operational work as early as possible in the transition process, while closely aligning with the recently published industry timelines for over-the-counter interest rate swaps," said Agha Mirza, CME Group Global Head of Rates and OTC Products. "SOFR futures and options are now the leading liquidity pool, as open interest has reached 19 million contracts and volume has significantly outpaced Eurodollars. Based on this growth, today's announcement provides a practical timeline by which clients can bring remaining Eurodollar contracts into the SOFR market."
In the month of August, CME Group reported record average daily volume of nearly 2.5 million contracts and record open interest of 19 million contracts for SOFR futures and options contracts. SOFR options had record volume and open interest in August and SOFR futures had record open interest during the same period. Additional highlights include:
Ahead of the final conversion under fallbacks, liquid standard and reduced-tick Inter-Commodity Spread (ICS) instruments are available to facilitate the voluntary conversion of Eurodollar open interest via the SED Spread for futures and the LS Spread for options.
In addition, to further support the deepening of SOFR markets, CME Group plans to add SOFR options to its portfolio margining solution for cleared products in December 2022, subject to regulatory approval. Portfolio margining enables clients to reduce margin requirements by offsetting their exposure on cleared swaps versus interest rate futures and options.
Now among the world's deepest and most consistently liquid markets, SOFR futures and options have broad participation from global banks, hedge funds, asset managers, principal trading firms and other types of traders.
SOFR futures and options are listed with and subject to the rules of CME. For more information, please visit www.cmegroup.com/sofr.
About CME Group
As the world's leading derivatives marketplace, CME Group (www.cmegroup.com) enables clients to trade futures, options, cash and OTC markets, optimize portfolios, and analyze data – empowering market participants worldwide to efficiently manage risk and capture opportunities. CME Group exchanges offer the widest range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange, energy, agricultural products and metals. The company offers futures and options on futures trading through the CME Globex platform, fixed income trading via BrokerTec and foreign exchange trading on the EBS platform. In addition, it operates one of the world's leading central counterparty clearing providers, CME Clearing.
CME Group, the Globe logo, CME, Chicago Mercantile Exchange, Globex, and, E-mini are trademarks of Chicago Mercantile Exchange Inc. CBOT and Chicago Board of Trade are trademarks of Board of Trade of the City of Chicago, Inc. NYMEX, New York Mercantile Exchange and ClearPort are trademarks of New York Mercantile Exchange, Inc. COMEX is a trademark of Commodity Exchange, Inc. BrokerTec and EBS are trademarks of BrokerTec Europe LTD and EBS Group LTD, respectively. Dow Jones, Dow Jones Industrial Average, S&P 500 and S&P are service and/or trademarks of Dow Jones Trademark Holdings LLC, Standard & Poor's Financial Services LLC and S&P/Dow Jones Indices LLC, as the case may be, and have been licensed for use by Chicago Mercantile Exchange Inc. All other trademarks are the property of their respective owners.
CME-G
View original content:
SOURCE CME Group | https://www.whsv.com/prnewswire/2022/09/06/cme-group-proposes-april-14-2023-fallbacks-conversion-eurodollar-futures-options-contracts/ | 2022-09-06T11:24:47Z |
NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Shareholder rights law firm Julie & Holleman is investigating the proposed acquisition of Convey Health Solutions Holdings, Inc. (NYSE: CNVY) by its principal shareholder, TPG Capital.
To learn more about the investigation, click here.
Through its funds, TPG already owns approximately 75% of Convey Health's outstanding shares of common stock. Under the companies' merger agreement, announced on June 21, 2022, TPG will acquire the remaining outstanding shares of Convey Health for $10.50 per share in cash, which represents an enterprise value for the company of approximately $1.1 billion. The acquisition could close as early as September 21, 2022.
Julie & Holleman is investigating potential legal claims available to Convey Health's shareholders regarding the proposed acquisition, including claims relating to TPG's and management's conflicts of interest and the adequacy of the $10.50 per share acquisition price.
If you would like more information about Julie & Holleman's investigation, or about the acquisition in general, please contact W. Scott Holleman by email at scott@julieholleman.com or by telephone at (929) 415-1020. You may also visit the firm's website by clicking here.
Julie & Holleman is a boutique law firm that focuses on shareholder litigation, including derivative actions, mergers and acquisitions cases, securities fraud class actions, and corporate investigations. The firm's attorneys litigate in state and federal courts across the nation. For more information about the firm, please visit www.julieholleman.com. This notice may constitute attorney advertising.
CONTACT INFORMATION
Julie & Holleman LLP
W. Scott Holleman, Esq.
157 East 86th Street
4th Floor
New York, NY 10028
(929) 415-1020
www.julieholleman.com
View original content to download multimedia:
SOURCE Julie & Holleman LLP | https://www.whsv.com/prnewswire/2022/09/06/cnvy-special-alert-julie-amp-holleman-reminds-investors-contact-firm-about-proposed-acquisition-convey-health-solutions-holdings-inc/ | 2022-09-06T11:24:53Z |
REHOVOT, Israel, Sept. 6, 2022 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced that Deputy CEO and CFO Eran Rotem will participate in investor conferences later this month.
- HC Wainwright 24th Annual Global Investment Conference: Participate in investor meetings on Monday and Tuesday, September 12-13.
- Alliance Global Partners MedTech Conference: Virtual investor meetings on Wednesday, September 21.
About CollPlant
CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.
At the beginning of 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. Later in 2021, CollPlant entered a strategic co-development agreement with 3D Systems for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant.
For more information about CollPlant, visit http://www.collplant.com/
Photo - https://mma.prnewswire.com/media/1772558/CollPlant.jpg
Contact at CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@collplant.com
View original content:
SOURCE CollPlant | https://www.whsv.com/prnewswire/2022/09/06/collplant-biotechnologies-participate-september-investor-conferences/ | 2022-09-06T11:25:00Z |
SEDALIA, Colo., Sept. 6, 2022 /PRNewswire/ -- CORE Electric Cooperative (CORE) has asserted its right to withdraw from partial ownership of the Comanche Unit 3 power plant by written notice to Public Service Company of Colorado (PSCo), a subsidiary of Xcel Energy, Inc (Xcel). The notice stipulates that PSCo must purchase the asset from CORE pursuant to project agreements between the two parties. This action is an additional step by CORE to secure its clean and reliable energy future, recover costs and protect its members from future financial burdens due to ongoing mismanagement of the power plant by PSCo.
"Systemic failures by PSCo to prudently operate Comanche 3 since it came online in 2010 have severely impacted our commitment to providing affordable, reliable power to our member-owners," said Jeff Baudier, Chief Executive Officer of CORE. "Despite every effort by CORE to be heard, PSCo has ignored our rights and driven this plant to dysfunction through mismanagement and incompetence. This situation is untenable, and CORE must move on to forge our clean, reliable, and affordable energy future."
CORE currently has 25% non-operating ownership in the Comanche Unit 3 power plant, which has been offline more than 700 days since 2010, including almost all of 2020 and half of 2022 to date. Due to PSCo's failure to operate the plant in accordance with Prudent Utility Practices, CORE has incurred millions of dollars of additional repair and maintenance costs and has deprived its members of entitled power during the numerous, lengthy outages of the unit. Under the project agreements, CORE has the right to withdraw, and PSCo must buy out CORE's interest.
The Colorado Public Utilities Commission's (PUC) investigations into the plant concluded that the operation and maintenance performed by PSCo did not meet basic industry standards of prudence throughout the plant's history. These conclusions mirrored those reached by PSCo's own independent experts.
CORE filed a lawsuit on September 7, 2021, alleging that PSCo breached its contract related to Comanche Unit 3 on several accounts. The trial is scheduled for October 2023.
For more information, visit https://core.coop/xceldispute
ABOUT CORE Electric Cooperative (CORE): CORE is a not-for-profit electric distribution cooperative that provides power to nearly 170,000 members inside a 5,000-square-mile service area along Colorado's Front Range. Its headquarters is in Sedalia, and district offices are in Bennett, Conifer, and Woodland Park.
MEDIA CONTACT:
Cindy Newsome, Strategic Planning and Communications Director
Office- (720) 733-5510, Email - cnewsome@core.coop
View original content to download multimedia:
SOURCE CORE Electric Cooperative | https://www.whsv.com/prnewswire/2022/09/06/core-electric-cooperative-advances-its-energy-future-with-withdrawal-comanche-3-power-plant/ | 2022-09-06T11:25:06Z |
With A Community of Over 390 Million Engaged Followers Across All Platforms, The D'Amelio Family Partners with Serial Entrepreneur and Operator Richard Rosenblatt and Internet Entrepreneur and Business Executive Michael Rubin to Create Their Own Company
LOS ANGELES, Sept. 6, 2022 /PRNewswire/ -- The D'Amelio family, composed of social media phenoms Dixie and Charli and their parents Marc and Heidi, announced their new business venture today – the launch of their namesake company, D'Amelio Brands. Leveraging the D'Amelio family's proven success in brand partnerships and Marc's 30+ years of business experience, D'Amelio Brands was formulated using the family's unparalleled marketing and business knowledge combined with their unique understanding and connection to fans around the globe. The company's goal is to create authentic and accessible products across a variety of industries, from fashion and beauty to CPG and lifestyle, and bring it under one roof, allowing each member of the family to fully immerse themselves in all areas of product development.
"After years of working with other brands on deals and partnerships, we have an innate knowledge of what consumers are looking for as well as the ability to identify voids in the marketplace," says Marc D'Amelio, Co-Founder of D'Amelio Brands. "We are so excited to announce this new venture and launch our own brand, giving us the ability to create products that are true to us and speak directly to our community."
D'Amelio Brands also announced today a $6M seed round from an accomplished group of diverse investors and business advisors, including their Co-Founder, serial entrepreneur and operator Richard Rosenblatt, as well as internet entrepreneur and business executive Michael Rubin, developer and e-commerce entrepreneur Elena Silenok, Apple's Senior Vice President of Services Eddy Cue, Chief Executive Officer of Lions Gate Entertainment Jon Feltheimer, Emmy and Golden Globe Award-winning media entrepreneur and visionary producer Ben Silverman, award-winning entrepreneur and beverage industry veteran Lance Collins, and United Talent Agency (UTA).
"As I spent more and more time with the family, it became clear to me they could build an authentic and successful product business driven by their massive social reach and fashion sensibilities," said Richard Rosenblatt, Co-Founder of D'Amelio Brands. "Not only do they know what voids exist in the market, but they know what consumers are looking for and exactly how to effectively market those products to their audience."
"The D'Amelio's have become some of the most authentic and influential social media personalities globally, and this was the perfect time to elevate their platform and create a new, cutting-edge business model that will reach consumers worldwide who are excited to engage with their brand," adds Michael Rubin, D'Amelio Brands Investor.
D'Amelio Brands launched with the mission to not only create unique, high-quality products that cater to their loyal community, but to build a socially conscious company with a strong ethos that represents the family's core set of values. Being at the center of the cultural zeitgeist, the family understands the importance of working with partners that are socially aware and diverse. Through D'Amelio Brands, they will identify these companies and put an emphasis on empowering small, inclusive, and sustainable businesses. D'Amelio Brands is on track to launch two brands by year's end, with solidified plans for expansion in 2023.
Charli shot to fame as the most followed person on TikTok. Brands immediately took note partnering with the social media superstar to help move products to a captive audience. Her sister Dixie's rise followed with partnerships in music, beauty, and fashion. The family soon launched their own successful docuseries on Hulu which also featured an arc on the formation of their own fashion line, Social Tourist. The show, which has already been picked up for a second season premiering this September, made the family, including parents Marc and Heidi, a household name. Brands continued to seek out the family for their undeniable influence. It is this direct connection with their fanbase that led the family to start D'Amelio Brands.
D'Amelio Brands Image Assets: https://www.dropbox.com/sh/l8icx7j07aigp73/AAB7fCK6uIm7I50-Ti-_j7l4a?dl=0
ABOUT THE D'AMELIO FAMILY
The D'Amelio family, referred to as the "first family of TikTok" by The Guardian, have quickly become digital phenomena. The family of social media megastars have a combined social following of over 390 million and a successful TV show on Hulu, The D'Amelio Show. Season two of the hit series is premiering September 28, 2022. The dynamic sister duo, 21-year-old Dixie and 18-year-old Charli, are the most watched faces of their generation. Charli, the leading female TikTok creator, has catapulted to stardom by captivating the screens of teens and adults worldwide with her bubbly personality combined with her impeccable dance skills and social media sensibility. She recently launched her first ever fragrance venture, Born Dreamer, available in ULTA. Dixie is a music artist who released her first album, A Letter To Me, this year after which she hit the road on tour opening for Big Time Rush. Together, the two are proud voices of their generation. Dixie and Charli are advocates against cyberbullying and have partnered with organizations such as UNICEF to raise awareness on the negative effects cyberbullying can have on young people.
The sister duo continues to make their mark in the fashion industry collaborating with brands like Valentino, Prada, Burberry, PUMA, and Morphe to name a few. In 2021 they launched their own clothing brand, Social Tourist. They have also worked with brands such as Dunkin Donuts, Halo, Lightricks, and Fiton. Their parents, Marc and Heidi, continue to encourage the family to use their platforms for good and to create positive change in the world. Marc leads by example, continuously shining light on causes that are important to the family, while balancing his professional career as an apparel entrepreneur and advisor in the sports industry. Full-time mom, Heidi, who previously pursued a career as a model as well as a personal trainer, continues to pursue her own passions in wellness, fitness, and philanthropy.
Media Contacts: Kacy Shaw, align Public Relations, kacy@align-pr.com, (805) 689-0845.
View original content to download multimedia:
SOURCE D'Amelio Brands | https://www.whsv.com/prnewswire/2022/09/06/damelio-family-announces-formation-damelio-brands/ | 2022-09-06T11:25:13Z |
Customers who order online can take advantage of 20% off all menu-priced items
ANN ARBOR, Mich., Sept. 6, 2022 /PRNewswire/ -- Hold onto your seats! Domino's stores nationwide are offering 20% off all menu-priced items ordered online.
"It's no surprise that prices are up on nearly everything, from milk to eggs, gas and even delivery services," said Joe Jordan, Domino's president of U.S. and global services. "Nobody has been spared from inflation, including restaurants. We want to give customers a break, as they've been emptying their pockets all summer long, but shouldn't have to for delicious pizza."
Domino's 20% off deal is valid on all menu-priced items ordered online, for a limited time. Customers can take advantage of this deal for carryout and delivery.
"We hope customers partake in this great deal and treat themselves to their favorite menu items," Jordan said. "Everything on Domino's menu is 20% off – pizza, Stuffed Cheesy Bread, Chocolate Lava Crunch Cakes – you name it, it's included. Now is a great time to take advantage of this deal, as summer is coming to an end, school is beginning and football is kicking off."
Domino's 20% off deal is available through the following online ordering channels:
- Domino's website (dominos.com)
- Domino's ordering apps for iPad®, iPhone® and Android™
- Domino's AnyWare ordering platforms, including through Google Home, Alexa, Slack and Facebook Messenger
About Domino's Pizza®
Founded in 1960, Domino's Pizza is the largest pizza company in the world, with a significant business in both delivery and carryout pizza. It ranks among the world's top public restaurant brands with a global enterprise of more than 19,200 stores in over 90 markets. Domino's had global retail sales of nearly $17.8 billion in 2021, with over $8.6 billion in the U.S. and over $9.1 billion internationally. In the second quarter of 2022, Domino's had global retail sales of over $4.0 billion, with over $2.0 billion in the U.S. and nearly $2.0 billion internationally. Its system is comprised of independent franchise owners who accounted for 98% of Domino's stores as of the end of the second quarter of 2022. Emphasis on technology innovation helped Domino's achieve more than half of all global retail sales in 2021 from digital channels. In the U.S., Domino's generated more than 75% of U.S. retail sales in 2021 via digital channels and has developed several innovative ordering platforms, including those for Google Home, Facebook Messenger, Apple Watch, Amazon Echo, Twitter and more. In 2019, Domino's announced a partnership with Nuro to further its exploration and testing of autonomous pizza delivery. In mid-2020, Domino's launched a new way to order contactless carryout nationwide – via Domino's Carside Delivery®, which customers can choose when placing a prepaid online order.
Order – dominos.com
Company Info – biz.dominos.com
Media Assets – media.dominos.com
View original content to download multimedia:
SOURCE Domino's Pizza, Inc. | https://www.whsv.com/prnewswire/2022/09/06/did-dominos-just-launch-an-inflation-relief-deal-oh-yes-we-did/ | 2022-09-06T11:25:19Z |
MONTREAL, Sept. 6, 2022 /PRNewswire/ - Paraza Pharma Inc., a fully integrated drug discovery organization passionately committed to contributing to the life sciences sector today announced the appointment of Dr. Sultan Ahmad as Chief Business Officer reporting to Dr. Arshad Siddiqui, founder and CEO of Paraza Pharma.
"We are pleased to announce that Dr. Ahmad is taking on this strategic role in order to support our next phase of growth'' said Dr. Siddiqui. ''His considerable expertise in business development, corporate strategy, and drug discovery research and development, will be very valuable as we continue to further expand our position as a leader in the small molecule integrated drug discovery service space''.
Dr. Ahmad has a successful career in pharmaceutical R&D sector with more than 30 years of experience. He has held positions of increasing responsibilities at Astrazeneca, Neomed Institute and Purdue Pharma, Canada. Dr. Ahmad is uniquely qualified as a drug discovery researcher and business development professional to bring Paraza to the next level of growth. Dr. Ahmad completed his Ph.D. in Biomedical Sciences at McMaster University, Ontario, Canada. He has co-authored over forty (40) peer-reviewed publications and is a co-inventor on seven (7) patents.
''Paraza is a remarkable R&D organization with an exceptionally talented team of scientists and a culture of innovation and high performance,'' said Dr. Ahmad. '' I look forward to starting this new role and excited to work with the Paraza team to outline our business and growth strategy, and work towards establishing innovative partnerships.''
Paraza Pharma is a Montreal, Canada based, fully integrated drug discovery organization passionately committed to contribute to the life sciences sector. As part of the growth strategy, it attracts worldwide best-in-class talent and continues to offer a unique collaborative model to help companies achieve their success milestones and accelerate their business growth. To learn more, visit www.parazapharma.com
Paraza Pharma Inc.:
Arshad Siddiqui, PhD, CEO
arshad.siddiqui@parazapharma.com
www.parazapharma.com
View original content to download multimedia:
SOURCE Paraza Pharma Inc. | https://www.whsv.com/prnewswire/2022/09/06/dr-sultan-ahmad-chief-business-officer-paraza-pharma-inc/ | 2022-09-06T11:25:26Z |
NEW YORK, Sept. 6, 2022 /PRNewswire/ -- ECOGARD, a leading aftermarket brand of filtration and wiper blade products, has launched a new and improved eCatalog on their website - www.ecogard.com. The new ECOGARD eCatalog includes advanced dynamic search functionality and comprehensive data related to fluid capacities and oil grades for all makes and models of vehicles. This innovative new parts lookup functionality is comprehensive, now providing lookup data to support the entire oil change service including all filtration categories, drain plugs, washers, and oil filter housing caps when required. This important eCatalog update will help distributors and professional installers better serve their customers.
"The ECOGARD brand has been an innovator in the traditional and quick service markets since 2011" said John Etheridge, Director of Product Management at Premium Guard Inc. "With this improved eCatalog, we're demonstrating our continued commitment to being ahead of the market by delivering a cutting-edge user experience to support customers in fueling their business growth."
"Being ahead of the market in service and technology is a strategic pillar of the Premium Guard family of brands" said Anan Bishara, CEO of Premium Guard Inc. "Bringing this important user experience to the ECOGARD brand is just another example of how we deliver on innovation in service and technology for our customers."
The improved eCatalog is available now at www.ecogard.com.
ECOGARD is a brand of filtration and wiper blade products owned by Premium Guard Inc. (PGI). Premium Guard Inc. specializes in designing, manufacturing, and distributing products for automotive, diesel, powersport, and specialty filter markets. Headquartered in New York City with a main distribution center in Memphis TN, Premium Guard Inc. is keenly focused on providing customers with industry leading service, complete filtration solutions, best-in-class-quality products, and leading application coverage.
View original content to download multimedia:
SOURCE Premium Guard Inc. | https://www.whsv.com/prnewswire/2022/09/06/ecogard-launches-improved-ecatalog-adding-innovative-dynamic-search-capabilities-fluid-capacity-data/ | 2022-09-06T11:25:33Z |
TSX.V: EU
OTCQB:ENCUF
www.encoreuranium.com
CORPUS CHRISTI, Texas, Sept. 6, 2022 /PRNewswire/ - enCore Energy Corp. ("enCore" or the "Company") (TSXV: EU) (OTCQB: ENCUF) today announced the completion and installation of all (five) baseline wells within the uranium mineralization at the 100%-owned, fully licensed Rosita Extension Project Production Authorization Area (PAA) wellfield. In addition to establishing baseline conditions in the production area, the wells returned excellent uranium values with Grade Thicknesses (GT*) ranging from 0.932 to 5.139. The Company also reports it has commenced installation of production well patterns (injection and extraction wells) at the Rosita Extension PAA, South Texas as the initial source of uranium feed for the Rosita Central In-Situ Recovery (ISR) Uranium Processing Plant.
- Baseline Drill Hole BL-41 reported 22.0 feet of mineralization grading 0.234% U3O8 from a depth of 184 feet;
- In addition to an indication of grade of mineralization in the PAA, the baselines wells also serve to establish groundwater quality standards;
- Commencement of installation of the production well patterns (injection and recovery wells) with 5 drill rigs are currently active at the Rosita Extension PAA drilling;
- Commencement of hydrologic and water quality testing of the baseline and monitor wells (see enCore news release dated August 25, 2022);
- The Rosita Extension PAA is the first production area planned as a new source of uranium for the Rosita ISR Uranium Processing Plant;
- The Rosita Extension PAA is located within the existing Radioactive Materials License, Underground Injection Control Permit and Aquifer Exemption areas at the Rosita Project;
Please visit https://bit.ly/3CTWeT4 to view Rosita project maps and view the Rosita drill program video at: https://www.youtube.com/watch?v=DlFSTsFvPnA&t=1s. To learn more about the environmental, social and low-cost advantages of uranium in-situ recovery, visit https://encoreuranium.com/industry-and-media/in-situ-recovery/.
All intercepts are between 210 and 245 feet below surface in saturated sands (required for ISR). The water table is located approximately 95 - 115 feet below surface.
*Grade Thickness, or GT, is defined as the product of the mineral grade (at the .02% U3O8 cutoff) multiplied by the thickness of the mineralization at or above the cutoff value. GT values of 0.3 and above are considered to be the minimum for inclusion in a wellfield. Values of 0.45 are considered typical ISR ore-grade for shallow deposits.
enCore's Rosita Plant, located approximately 60 miles from Corpus Christi, Texas, is a licensed, past-producing in-situ recovery (ISR) uranium plant that is completing refurbishment. The final stage of refurbishment work will be completed with the delivery of six pumps that have been delayed due to unexpected supply chain interruptions. We remain on budget and the delay is not expected to impact scheduled production startup in 2023. The Rosita Plant is designed to process uranium feed from multiple satellite operations, all located in the South Texas area, and is 1 of 11 licensed and constructed uranium processing plants in the United States, 2 of which are owned by enCore Energy.
All drill holes are 5.625-inch diameter rotary-mud holes. Each hole is logged with electrical and gamma methods upon completion. Any anomalous gamma readings are followed up with Prompt Fission Neutron (PFN) surveys which provide direct and accurate in-situ uranium values eliminating any concerns over disequilibrium. The Company owns and operates 2 logging trucks and 5 PFN tools.
Many uranium deposits have a degree of disequilibrium, whereby the radioactivity measured in drill holes using traditional gamma methods does not accurately correspond to ore grade, due to the continued decay of uranium daughter products including potassium, thorium, lead and bismuth relative to radium (Ra226), a significant gamma emitter. Traditionally, accurate uranium values are therefore determined by chemical assay of drill core which is time consuming and expensive.
Without accurate uranium values, the potential for inaccurate estimates of mineralization on both the high and low side is ever present. Real-time PFN analysis accurately eliminates potential errors by using neutron activation to directly detect and quantify uranium content in place down the drill hole.
The PFN tool creates very fast neutrons (14MeV) and fires 108 neutrons per second. Therefore, the neutrons emitted by the PFN tool excite, at an atomic level, in-situ uranium atoms in the drill hole, creating fast (epithermal) neutrons and slow (thermal) neutrons. The ratio of epithermal to thermal neutrons is proportional to uranium, allowing the U3O8 ore grade to be accurately calculated. This provides a relatively inexpensive and instantaneous means for accurate assaying of in-situ ore grades over large areas, and it allows for accurate ore body mapping, resource estimation, and wellfield planning.
Mark Pelizza, MSc. Geo. Eng., CPG-11821, a Director for the Company, and a Qualified Person under NI 43-101, has approved the technical disclosure in this news release.
To learn more about the environmental, social and low-cost advantages of uranium in-situ recovery, visit https://encoreuranium.com/industry-and-media/in-situ-recovery/
With approximately 90 million pounds of U3O8 estimated in the measured and indicated categories and 9 million pounds of U3O8 estimated in the inferred category1, enCore is the most diversified in-situ recovery uranium development company in the United States. enCore is focused on becoming the next uranium producer from its licensed and past-producing South Texas Rosita Processing Plant by 2023. The South Dakota-based Dewey Burdock project and the Wyoming Gas Hills project offer mid-term production opportunities, with significant New Mexico uranium resource endowments providing long-term opportunities. The enCore team is led by industry experts with extensive knowledge and experience in all aspects of ISR uranium operations and the nuclear fuel cycle. enCore is committed to engaging and working with local communities and indigenous governments to create positive impact from corporate developments.
1 Mineral resource estimates are based on technical reports prepared in accordance with NI43-101 and available on SEDAR as well as company websites at www.encoreuranium.com.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements relating to the intended use of the net proceeds of the Offering and the completion of any capital project or property acquisitions. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access additional capital; the ability of enCore to implement its business strategies; and other risks. Readers are cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
View original content to download multimedia:
SOURCE enCore Energy Corp. | https://www.whsv.com/prnewswire/2022/09/06/encore-energy-completes-baseline-wells-installation-begins-drilling-injection-recovery-wells-rosita-extension/ | 2022-09-06T11:25:40Z |
TSX-V: MKO; OTCQX: MAKOF
VANCOUVER, BC, Sept. 6, 2022 /PRNewswire/ - Mako Mining Corp. (TSXV: MKO) (OTCQX: MAKOF) ("Mako" or the "Company") is pleased to report additional high-grade drill results from an area adjacent to the current open pit mining operations at the San Albino West Pit in northern Nicaragua. Two of the Company's seven drill rigs are currently focused on this SW Pit area.
The objectives of the SW Pit drilling program are to: 1) increase the overall size of the San Albino Gold Deposit, which remains open along strike and at depth; 2) test extensions of the mineralization beyond the permitted pit limit; and 3) provide information necessary to begin mining this area early next year.
To date a total of 32,436 meters (m) in 259 drill holes (2011-2022) have been completed in the area. Most of the drilling intersected mineralization within, or immediately outside, the current permitted pit.
All intersections described in this press release fall outside the 2020 Mineral Resource Estimate ("2020 Resource").
A technical report for the current mineral resource estimate at San Albino is available under the Company's SEDAR profile at www.sedar.com and available on the Company's website at www.makominingcorp.com (see press release dated October 19, 2020).
- 64.90 g/t Au and 87.7 g/t Ag over 2.00m (Estimated True Width-ETW)
- 34.03 g/t Au and 26.8 g/t Ag over 2.20m (2.1m ETW)
- 36.50 g/t Au and 51.3 g/t Ag over 1.10m (0.7m ETW)
- 68.80 g/t Au and 60.6 g/t Ag over 0.60m (0.5m ETW)
- 15.09 g/t Au and 20.5 g/t Ag over 2.70m (2.4m ETW)
Akiba Leisman, CEO of Mako states, "the 2020 Resource only included a de minimis number of gold ounces in the SW Pit area, as our team was getting a better handle on the geological model for this zone. Over the course of the last 2 years, the geological controls of the SW Pit have been substantively better understood and have been validated by these drill results, and those released earlier this year. Hitting 64.9 g/t Au over 2m (ETW) 50m from surface and 71m up-dip from another potentially open-pittable intersection of 42.9 g/t Au over 4.1m (ETW), bodes well for early next year as we get the SW Pit ready to be our next mining area. Over the course of the next week, we will also be releasing drill results at Las Conchitas which we also plan to begin mining next year."
Drill hole SA22-626 intersected multiple intervals of high-grade, near surface gold mineralization, including 64.90 g/t Au and 87.7 g/t Ag over 2m (ETW), 50m below surface. This intersect is approximately 12m outside the current permitted pit limit and 71m up dip from drill hole SA22-615 which intersected 42.91 g/t Au and 38.3 g/t Ag over 4.50m (4.1m ETW) (see press release dated June 22, 2022). In addition, this hole intersected a mineralized interval grading 4.01 g/t Au and 32.3 g/t Ag over 1.50m (1.3m ETW), 21m from the surface indicating that multiple mineralized structures are open to the south.
Two drill holes, SA22-662 and SA22-663, collared on the same drill pad and 30m along strike from drill hole SA22-615 (described above), intersected multiple mineralized intervals (see table below), including 34.03 g/t Au and 26.8 g/t Ag over 2.20m (2.1m ETW) and 36.50 g/t Au and 51.3 g/t Ag over 1.10m (0.7m ETW), at vertical distance from surface at 32m and 22m respectively. Both drill holes confirmed continuity of high-grade mineralization to the NE along strike and indicate potential to further expand the open pit mineral resources.
In addition, drill hole SA22-662 intersected 1.00 g/t Au and 8.7 g/t Ag over 0.5m (ETW) and 14.90 g/t Au and 23.6 g/t Ag over 1m (ETW), 28m and 65m below surface respectively. Drill hole SA22-663 intersected an additional high-grade interval of 9.09 g/t Au and 11.3 g/t Ag over 2m (1.2m ETW), 36m below surface.
Several drill holes were designed to test the down dip extension of multiple high-grade mineralized zones. SA22-622 intersected three mineralized intervals (see table below), including 68.80 g/t Au and 60.6 g/t Ag over 0.6m (0.5m ETW) 95m from surface. Drill hole SA22-623 also intersected multiple intervals including 15.09 g/t Au and 20.5 g/t Ag over 2.7m (2.4m ETW), 107m below the surface and confirmed the high-grade mineralization remains open down dip. Drill intersection modeling shows irregular branching networks or anastomosing veins composed of two or three separate veins. These anastomosing veins could potentially be treated as a single wide zone amenable to open pit mining.
In addition, the Company has completed the initial phase of drilling at the San Albino North target which lies immediately to the north of the San Albino Gold Deposit straddling two concessions, San Albino-Murra and Potrerillos. Fifteen drill holes totaling 2,552m have been completed at the Cerro Piedra Negra prospect. Three drill holes (see table below) intersected intervals above an internal cut-off grade (1.0 g/t Au), including hole PO22-05 which intersected 13.50 g/t Au and 7.3 g/t Ag over 1.20m (0.7m ETW). Eight drill holes intersected intervals below the cut-off grade and results for two drill holes are still pending.
Drill core was continuously sampled from inception to termination of the entire drill hole. Sample intervals were typically one meter. Drill core diameter was HQ (6.35 centimeters). Geologic and geotechnical data was captured into a digital database, core was photographed, then one-half split of the core was collected for analysis and one-half was retained in the core library. Drill core samples were kept in a secured logging and storage facility until such time that they were delivered to the Managua facilities of Bureau Veritas and pulps were sent to the Bureau Veritas laboratory in Vancouver for analysis. Gold was analyzed by standard fire assay fusion, 30gram aliquot, AAS finish. Samples returning over 10.0 g/t gold are analyzed utilizing standard Fire Assay-Gravimetric method. The Company follows industry standards in its QA&QC procedures. Control samples consisting of duplicates, standards and blanks were inserted into the sample stream at a ratio of 1 control sample per every 10 samples. Analytical results of control samples confirmed reliability of the assay data.
John M. Kowalchuk, P.Geo, a geologist and qualified person (as defined under NI 43-101) has read and approved the technical information contained in this press release. Mr. Kowalchuk is a senior geologist and a consultant to the Company.
On behalf of the Board,
Akiba Leisman
CEO
Mako Mining Corp. is a publicly listed gold mining, development and exploration company. The Company operates the high-grade San Albino gold mine in Nueva Segovia, Nicaragua, which ranks as one of the highest-grade open pit gold mines globally. Mako's primary objective is to operate San Albino profitably and fund exploration of prospective targets on its district-scale land package.
Statements contained herein, other than historical fact, may be considered "forward-looking information" within the meaning of applicable securities laws. The forward-looking information contained herein is based on the Company's plans and certain expectations and assumptions, and includes, without limitation, the objectives of the SW Pit drilling program; that management believes that an increase in the mineral resources at the SW Pit areas at San Albino is likely as a result of the drilling program; the Company is getting the SW Pit ready to be its next mining area; that over the course of the next week, the Company will be releasing drill results at Las Conchitas which it also plans to begin mining next year; and that the Company can operate San Albino profitably in order to fund exploration of prospective targets on its district-scale land package. Such forward-looking information is subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking information, including, without limitation, the risk that the ongoing results of the drilling program do not result in a significant increase in mineral resources at the SW Pit areas; that the SW Pit does not become the Company's next mining area; that the timing for release of additional drilling results is not as stated herein; political risks and uncertainties involving the Company's exploration properties; the inherent uncertainty of cost estimates and the potential for unexpected costs and expense; commodity price fluctuations and other risks and uncertainties as disclosed in the Company's public disclosure filings on SEDAR at www.sedar.com. Such information contained herein represents management's best judgment as of the date hereof, based on information currently available and is included for the purposes of providing investors with the Company's expectations regarding the Company's drilling program at San Albino gold project, and may not be appropriate for other purposes. Mako does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
View original content to download multimedia:
SOURCE Mako Mining Corp. | https://www.whsv.com/prnewswire/2022/09/06/expansion-drilling-sw-pit-intersects-649-gt-au-8772-gt-ag-over-200m-estimated-true-width-50m-surface/ | 2022-09-06T11:25:46Z |
STOCKHOLM, Sept. 6, 2022 /PRNewswire/ -- Fagerhult Group commits to Science Based Targets initiative, SBTi, this was communicated at the Capital Markets Day that was held in Stockholm on August 31st.
During the Capital Markets Day, Fagerhult Group presented a business update with focus on the Group's strategic initiatives and the four Business Areas. Fagerhult Group consider mega trends to be in favour for the business and generate good growth opportunities. Climate change and energy crisis increase the need for energy efficient lighting solutions. By using the latest LED technology and connectivity solutions energy consumption can be reduced by up to 90% compared to conventional lighting solutions.
The Group also presented high level ambitions related to the business with further updates at a later date for connectivity and sustainability. The ambitions are in line with the Group's strong historical development. The growth agenda for the business was supported by specific growth opportunities in each Business Area and the strategic initiatives: Innovation, Sustainability and People & Culture, are all making good progress.
Looking forward, the importance of sustainability will continue to grow. Fagerhult Group's sustainability agenda, called 'Positive change for better living', was launched earlier this year and covers a broad ESG agenda (Environment, Social, Governance). Providing energy efficient lighting solutions, the Group already contributes to make the society more sustainable. Now Fagerhult Group takes the next step and commit to the SBT-initiative. The Group will set targets to align with the Paris agreement, to limit global warming to 1.5°C and become net-zero. Now follows a process to set near-term and net-zero targets and have these validated by SBTi.
"Committing to the Science Based Targets initiative is a natural next step on our sustainability journey. The climate change demands action and through our long-term commitment we want to lead our industry towards a more sustainable future. By committing to the Science Based Targets initiative we want to make sure we as a Group are transparent in our efforts and make a difference. We have committed both to near-term and net-zero targets and will now continue the process to further map and validate our targets", says Bodil Sonesson, President and CEO Fagerhult Group.
The material from the Capital Markets Day can be accessed at: https://www.fagerhultgroup.com/investors/
For more information, please contact:
Bodil Sonesson, President and CEO, +46 722 23 76 02, bodil.sonesson@fagerhultgroup.com
Michael Wood, CFO, +46 730 87 46 47, michael.wood@fagerhultgroup.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:
SOURCE Fagerhult | https://www.whsv.com/prnewswire/2022/09/06/fagerhult-group-commits-science-based-targets-initiative/ | 2022-09-06T11:25:53Z |
Plug Into Fun at North America's Largest Electric Vehicle Festival
MIAMI, Sept. 6, 2022 /PRNewswire/ -- Electrify Expo, North America's largest electric-vehicle festival, rolls into the Magic City this fall, offering Floridians the opportunity to jump in and jump on the latest in electric mobility products, from electric cars, e-bikes, e-motorcycles, e-skateboards, and e-scooters to even water products like electric personal watercraft, e-surfboards, and e-foils. With 1M square feet of festival space occupied by the world's leading manufacturers, this family-friendly festival also includes the Hover-1 Kids Zone with activities for the whole family.
Miami-Dade has called for 30% of the county's vehicles to be all-electric by 2030. Local government officials do plan to add more charging stations to convince local drivers to make the shift. In fact, the county's new policy calls for 20% of all new vehicle purchases to be electric in 2022 and an additional 10% each year through 2023, so now is the time to take a battery-powered spin.
To register for a press pass to attend Electrify Expo, you are invited to apply here https://www.electrifyexpo.com/exhibits-press#Press
Electrify Expo is North America's largest outdoor electric vehicle festival showcasing the latest electric vehicles and products, including EVs, e-motorcycles, e-bikes, e-scooters, e-skateboards, e-boats, e-surfboards, and more from top brands around the world. The festival addresses one of the most challenging barriers to mass adoption of electric vehicles with meaningful hands-on experiences, demonstrations, and test rides. Electrify Expo meets the soaring demand for companies to share new technologies, new modes of mobility and put products in the hands of consumers in a meaningful way. Electrify Expo will feature more than 1M+ square feet of exhibit space in Los Angeles County, Seattle, New York, Miami, and Austin.
Mission Control Communications
electrifyexpo@missionc2.com
View original content to download multimedia:
SOURCE Electrify Expo | https://www.whsv.com/prnewswire/2022/09/06/feel-thrill-electric-vehicles-electrify-expo-miamis-regatta-park-october-8-amp-9/ | 2022-09-06T11:26:00Z |
Metered Cryospray treats damaged airways enabling a rejuvenative healing response
BOSTON, Sept. 6, 2022 /PRNewswire/ -- CSA Medical, Inc., today announced results from the first randomized, controlled study of Metered Cryospray (MCS) utilizing the RejuvenAir® System for the treatment of Chronic Bronchitis. The data was presented at the International Congress of the European Respiratory Society in Barcelona, Spain by Christopher Orton, MD, of The Royal Brompton Hospital, London, UK.
SGRQ and CAT, the gold standard measurement for patient reported symptom scores, were statistically significant and clinically meaningful, respectively. Chronic Bronchitis, the largest subset of COPD, is a progressive, irreversible disease with no cure. Medications merely manage symptoms, but over time, chronic productive cough and breathlessness worsen. As expected, quality of life in the sham group continued to decline. However, sham subjects were offered cross-over to treatment at 6 months and to date, all 32 subjects have completed treatment.
The Royal Brompton team previously reported strong safety and clinically meaningful 24 month results, from an open-label trial, now 36 months out. Together with this new cohort, they have performed over 100 Metered Cryospray treatments with zero pneumothoraces. "This first randomized controlled study data reinforces previous feasibility results showing Quality of Life improvement in patients with chronic bronchitis. RejuvenAir® Metered Cryospray is both safe and effective in a patient population with multiple co-morbidities, in a disease with no established therapies," summarized Pallav Shah, Professor of Respiratory Medicine, Imperial College, London.
The RejuvenAir System is designed to address the underlying cause of Chronic Bronchitis, the damaged cilia and mucus-producing goblet cells lining the airways and enable a rejuvenative healing response. SPRAY-CB, the pivotal study of the RejuvenAir System in patients with COPD with Chronic Bronchitis, is actively enrolling.
Chronic Bronchitis is the largest disease subset of Chronic Obstructive Pulmonary Disease (COPD). Bronchitis is inflammation of the bronchial airways. A chronic bronchitis diagnosis is defined by cough with productive sputum of three months duration for two consecutive years. In addition to a chronic inflammation, cough and increased production of mucus, chronic bronchitis may or may not present with obstruction/partially blocked airways due to swelling and excess mucus in the bronchi, or shortness of breath (dyspnea). In the United States, there are an estimated 16 million people with COPD, of which over 9 million have a diagnosis of chronic bronchitis. Approximately 700,000 people are hospitalized for symptoms/exacerbations of chronic bronchitis every year. In Europe, there are approximately 23 million people with COPD and approximately 1.5 million hospitalizations per year for COPD.
CSA Medical, Inc. develops and manufactures proprietary interventional liquid nitrogen spray cryotherapy systems that utilize software-driven dosimetry and specialty catheters that enable delivery of cryogen spray inside the airways to flash freeze and destroy damaged cells allowing for a rejuvenative pattern of healing.
The RejuvenAir System is approved in the EU and under clinical investigation in the United States. To learn more about our technology or clinical trials, please visit www.rejuvenair.com or www.clinicaltrials.gov [Identifiers: NCT03893370 and NCT03892694].
View original content to download multimedia:
SOURCE CSA Medical | https://www.whsv.com/prnewswire/2022/09/06/first-randomized-controlled-study-with-rejuvenair-chronic-bronchitis-shows-clinically-significant-results/ | 2022-09-06T11:26:06Z |
Gale Strategies Addresses Demand for Results-Driven B2B Technology Marketing
DARIEN, Conn., Sept. 6, 2022 /PRNewswire/ -- Today Gale Strategies announced the launch of its first principles marketing platform. Building on their already widely successful marketing and public relations process - connecting businesses with the audiences that drive their growth - Gale Strategies' new capabilities take marketing performance to a new level.
"We pursue a first principles approach, which is to say we don't just do things for our clients because it's considered marketing," said Gale Strategies co-founder Chris Gale. "We narrow down to a process focused on actually bringing in deals, investments or credible category leadership. We cut away the nonsense and exercise healthy skepticism in selecting, testing and proving the right package and sequence of tactics, and overall strategy for our clients."
Gale Strategies was launched to dispense with B2B technology public relations and marketing that could not show its value and relied on vague measures of success. The new platform includes:
- Publication relations
- Social marketing
- Branding
- SEO
- SalesOps
Gale Strategies' offering is rooted in bringing in specific opportunities in a highly targeted manner that aligns with clients' sales pipelines, investor relations and deal flow. The team was built from the ground up to deliver a scalable, seamless, tech-driven marketing platform. Gale Strategies delivers high touch service with intuitive processes, connecting audiences with businesses through intelligent, efficient production.
The firm's clients include leading private equity, enterprise technology and tech startup teams. Gale Strategies intentionally diversifies the industry verticals they serve to focus on intersections where technology is transforming longstanding, complex, high stakes work.
About Gale Strategies
Gale Strategies streamlines marketing and public relations on a single platform. The firm was founded in Darien, Connecticut in 2019 and operates nationwide and in Europe. For more information visit www.GaleStrategies.com.
CONTACT: Chris Gale at Chris@GaleStrategies.com
View original content:
SOURCE Gale Strategies LLC | https://www.whsv.com/prnewswire/2022/09/06/gale-strategies-launches-first-principles-marketing-platform/ | 2022-09-06T11:26:13Z |
VAUGHAN, ON, Sept. 6, 2022 /PRNewswire/ - GFL Environmental Inc. ("GFL") (TSX: GFL) (NYSE: GFL) has been awarded the National Waste & Recycling Association ("NWRA") 2022 Recycling Facility of the Year for its Multi Material Recovery Campus in Toronto, Ontario. The award recognizes leading material recovery facilities ("MRFs") in North America based on key factors such as innovation, partnership, public education and environmental impact.
"We are proud to receive the NWRA 2022 Recycling Facility of the Year award," said Patrick Dovigi, Founder and Chief Executive Officer. "This is the second time in the last three years that one of our MRFs has received this honor. We have always invested heavily in technology to provide the best in sustainable solutions to our customers. This award supports our vision of always remaining entrepreneurial, investing in leading technology and providing our customers with the very best in recycling services."
GFL's Toronto Multi-Material Recovery Campus is located on a 27-acre site that houses two single stream MRFs that operate 24 hours a day, seven days a week.
122 Arrow Road was the first MRF developed at the Campus. It began operations in 2010, processing mainly commercial material, and has since been modified to house an advanced single stream processing system. 124 Arrow Road was built in 2013 for the City of Toronto single stream processing contract, with excess capacity for future opportunities. As one of the largest, most technologically-advanced single stream facilities in North America, this facility was designed with sustainability and future needs at the forefront of all decision making.
Both facilities are designed with state-of-the-art technology including elliptical fiber separation, optical sorting, fully automated high-speed sorting robots and other mechanical separation processes. This design not only maximizes recovery, it also allows GFL to adapt to changing material composition and ensure the end production of high-quality processed recyclables. A dedicated material composition analysis center is also located on site to facilitate the sorting and analysis of inbound and outbound material.
The Campus has proven to be an overwhelming success for GFL. The Campus serves the material recovery needs of approximately 4 million municipal households and has processed over 3.5 million tons of material from municipal and commercial sources since its inception in 2010.
About GFL
GFL, headquartered in Vaughan, Ontario, is the fourth largest diversified environmental services company in North America, providing a comprehensive line of solid waste management, liquid waste management and soil remediation services through its platform of facilities throughout Canada and in more than half of the U.S. states. Across its organization, GFL has a workforce of more than 19,000 employees.
View original content to download multimedia:
SOURCE GFL Environmental Inc. | https://www.whsv.com/prnewswire/2022/09/06/gfl-environmetnal-awarded-nwra-2022-recycling-facility-year/ | 2022-09-06T11:26:20Z |
The companies are launching Gogoro Network in the Tel Aviv Metro area, and anticipate deploying to 35 battery swapping locations by the end of 2022, and more than 150 stations within 4 years.
TEL AVIV, Israel, Sept. 6, 2022 /PRNewswire/ -- Gogoro Inc. (Nasdaq: GGR), a global technology leader in battery swapping ecosystems that enable sustainable mobility solutions for cities, today announced the launch of its industry leading battery swapping system and Smartscooters in the Tel Aviv metropolitan area. In partnership with market leaders Metro Motor and Paz Group, the companies expect to launch in other cities in Israel in the future.
"I welcome the arrival of Gogoro electric scooters to Israel, as they serve several significant agendas," said Meital Lehavi, Deputy Mayor of Tel Aviv-Jaffa Municipality, managing the Transportation, Road Safety and LGBT Community departments. "First, two-wheeled vehicles are traffic jam busters in an age of road congestion. Second, this is a breakthrough that heralds the transition into smart and green transportation through cooperation that will allow battery swapping at gas stations, turning them into venues for alternative energy supply."
Metro Motor is a top two-wheel vehicle distributor in Israel and Paz Group is a leading energy, gas and retail group in Israel. The companies are launching with 10 battery swapping locations and anticipate deploying to 35 battery swapping stations by the end of 2022 and more than 150 stations within 4 years.
"Gogoro is excited to be launching its battery swapping in Tel Aviv. We are focused on driving the mass market shift to smart electric mobility and battery swapping is one clear path to solving a city's mobility and energy demands in a safe, sustainable, and scalable way. As one of the world's most innovative cities, the people of Tel Aviv can now embrace a new era in smart mobility innovation using Gogoro's Smartscooters and battery swapping," said Horace Luke, founder, chairman, and chief executive officer of Gogoro. "Metro Motor and Paz Group are two industry leaders in Israel, and together, we are introducing a new urban mobility experience that is smart, sustainable and available to everyone. Customers in Tel Aviv can now purchase the high-performance Gogoro S2 ABS or the versatile Gogoro 2 Plus at Metro retail stores in the city."
"We are proud and excited to begin marketing Gogoro products in Israel," said Gadi Aviram, the chairman of the board of Metro Motor. "The introduction of this innovative brand into the Israeli market is a milestone in the Israeli transportation industry and it aligns with Metro Motor's vision of constantly updating the high standards by which we operate."
"The Paz Group, positioned to lead the electric energy revolution in Israel, is proud to launch Gogoro's Swap & Go services for Gogoro's Smartscooters. They are a potential game-changer in their market, allowing electric scooter riders to continue their journey without unnecessary charging breaks," said Nir Stern, CEO of Paz.
Gogoro Smartscooters
Gogoro Smartscooters™ are recognized for their design, performance, and smart technology that enables amazing rider control, safety, and ease of use. Key features of the Gogoro Smartscooter experience include:
- Responsive Power - Hyper-efficient, water-cooled Gogoro motor that delivers incredible power and range.
- iQ System® - Smart vehicle technology that makes every day riding simple and effortless.
- Gogoro App - The Gogoro App provides a variety of smart features and the ability to receive new features over the air (OTA).
- Bio-authentication - Choose from fingerprint, Face-ID, or even Siri voice command to utilize greater security and easy access to your Smartscooter.
- One-click reverse - Get out of any tight spot with a simple click of the reverse button for hassle-free parking.
Gogoro S2 ABS
The Gogoro S2 ABS is a special performance edition of Gogoro's 2 Series. The S2 ABS has a 7,200-watt electric motor with 213 Nm torque that delivers a top speed of nearly 60mph and it accelerates from 0-30 mph in under four seconds. The Smartscooter has many performance enhancements including ABS braking and a 245mm enlarged front disc brake with four piston radial mounted race calipers for improved braking performance.
Gogoro 2 Plus
The Gogoro 2 Plus is designed to be versatile, dependable and safe. The Gogoro 2 Plus is equipped with regenerative braking that returns power to its batteries. It also utilizes Gogoro's Synchronized Braking System (SBS), unique braking that delivers simultaneous braking force to the front and rear wheels, automatically balancing stopping force to reduce skidding when hard braking or during emergency stopping situations. The Gogoro 2 Plus has a 6,400 watt electric motor for a top speed of more than 55 mph and it accelerates from 0 to 30 mph in less than 4.3 seconds. The Gogoro 2 Plus also has 25 liters of storage, ample space to store a helmet and backpack.
Gogoro Network
At the heart of Gogoro's ecosystem is the Gogoro Network, an open and interoperable battery swapping platform that was recognized in 2021 by Guidehouse Insights as the leading battery swapping company for lightweight urban vehicles in the world. Gogoro Network is a new generation of swappable battery refueling that is smart, scalable, and continually optimizing itself to be dynamic and versatile for people, communities, and businesses. With more than a half million riders and nearly 11,000 battery swapping GoStations at over 2,240 locations, Gogoro Network is hosting more than 340,000 daily battery swaps with more than 325 million total battery swaps to date.
ABOUT GOGORO
Founded in 2011 to rethink urban energy and inspire the world to move through cities in smarter and more sustainable ways, Gogoro leverages the power of innovation to change the way urban energy is distributed and consumed. Gogoro's battery swapping and vehicle platforms offer a smart, proven and sustainable long-term ecosystem for delivering a new approach to urban mobility. Gogoro has quickly become an innovation leader in vehicle design and electric propulsion, smart battery design, battery swapping, and advanced cloud services that utilize artificial intelligence to manage battery availability and safety. The challenge is massive, but the opportunity to disrupt the status quo, establish new standards, and achieve new levels of sustainable transportation growth in densely populated cities is even greater. For more information, visit www.gogoro.com/news and follow Gogoro on Twitter: @wearegogoro.
ABOUT METRO MOTOR
Metro Motors Ltd. is Israel's largest power-sports distributor for motorcycles, ATVs, UTVs, and other leisure vehicles. Founded in 1981, Metro Motors are the authorized suppliers of the world's premier motorcycle brands: San Yang, Yamaha, Kawasaki, Beta, and Fantic. The company also retails off-road vehicles, commercial vehicles, and utility vehicles from the likes of Access, Segway, Marshell, and 'Afikim', an Israeli manufacturer of Mobility Scooters. Recently, Metro Motors founded the 'Metro ELECTRIC Division' importing urban electric two-wheel scooters, mopeds and motorcycles from the international brands, Gogoro and Zero. The Metro ELECTRIC Division also franchises American manufacturers KARMA Automotive, and the Chinese Limp Motors. An additional Metro Motors Division of recreational watercraft retail jet skis and personal pump-jet boats from the brands Moomba, Supra, Kawasaki, and Yamaha. Metro Motors is built on the premise of providing the highest possible level of customer service for its Israeli clients. The company operates 10 showrooms, 5 service stations, and 4 logistic centers throughout Israel. Furthermore, Metro Motors provides maintenance services for all of their vehicles from an additional 40 authorized service stations all over the country. Metro Motors head offices are located in Atir Yeda 18, Kfar Saba, Israel. For more details visit: https://www.metro.co.il/
ABOUT PAZ GROUP
The Paz Group is Israel's leading energy corporation, operating real estate and industrial retail branches. Paz is traded publicly on the Tel Aviv Stock Exchange and is valued at NIS 5.5 billion. Paz has 270 refueling complexes nationwide, over 300 minimarkets, and a unique app with over one million users. Paz will take the lead in electric vehicle charging, with the placement of fast charging stations in our stations and additional electric charging services.
Forward Looking Statements
This communication contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward looking statements generally relate to future events or Gogoro's future financial or operating performance. In some cases, you can identify forward looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "going to," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these words or other similar terms or expressions that concern Gogoro's expectations, strategy, priorities, plans or intentions. Forward-looking statements in this communication include, but are not limited to, the potential of the partnership between Gogoro, Metro Motor and Paz Group including the ability of such partnership to achieve its goals, projections of market opportunity, market share and potential growth in Israel, the capability of Gogoro's technology, Gogoro's business plans including related to its expectations related to its plans to launch in Israel including its timeline for such launch, and statements by Gogoro's founder, chairman and chief executive officer. Gogoro's expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks related to the impact of the COVID-19 pandemic, risks related to macroeconomic factors including inflation and consumer confidence, risks related to political tensions, Gogoro's ability to effectively manage its growth, Gogoro's ability to launch and ramp up the production of its products and control its manufacturing costs and manage its supply chain issues, Gogoro's risks related to ability to expand its sales and marketing abilities, Gogoro's ability to expand effectively into new markets, foreign exchange fluctuations, Gogoro's ability to develop and maintain relationships with its partners, risks related to operating in the PRC, regulatory risks and Gogoro's risks related to strategic collaborations, risks related to the China market and other international markets, alliances or joint ventures including Gogoro's ability to enter into and execute its plans related to strategic collaborations, alliances or joint ventures in order for such strategic collaborations, alliances or joint ventures to be successful and generate revenue, Gogoro's ability to raise additional capital, the risks related to the need for Gogoro to invest more capital in strategic collaborations, alliances or joint ventures, and the risk of Gogoro having to update the accounting treatment for its joint ventures. The forward looking statements contained in this communication are also subject to other risks and uncertainties, including those more fully described in Gogoro's filings with the Securities and Exchange Commission ("SEC"), including in Gogoro's Form 20-F for the year ended December 31, 2021, which was filed on May 2, 2022 and in its subsequent filings with the SEC, copies of which are available on our website and on the SEC's website at www.sec.gov. The forward looking statements in this communication are based on information available to Gogoro as of the date hereof, and Gogoro disclaims any obligation to update any forward looking statements, except as required by law.
View original content to download multimedia:
SOURCE Gogoro | https://www.whsv.com/prnewswire/2022/09/06/gogoro-metro-motor-paz-group-launch-two-wheel-battery-swapping-israel/ | 2022-09-06T11:26:27Z |
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated October 15, 2021, to its short form base shelf prospectus dated September 10, 2021.
TSX: GPR | NYSE American: GPL
VANCOUVER, BC, Sept. 6, 2022 /PRNewswire/ - Great Panther Mining Limited (TSX:GPR) (NYSE-A:GPL) ("Great Panther" or the "Company"), reports that, with the authorization and approval of its Board of Directors, it has determined to file a notice of intention to make a proposal (the "NOI") under the Bankruptcy and Insolvency Act (Canada) (the "BIA") today, which will provide creditor protection while the Company seeks to restructure its affairs.
The decision to seek creditor protection was taken after careful consideration of available alternatives, the Company's cash position, forecasted revenue and expenses (including in relation to its subsidiaries), and scheduled debt payments. The Company expects that it is likely to default on several material debtor agreements due to liquidity constraints stemming from the operational challenges previously disclosed, inflationary pressures significantly impacting costs, unforeseen but necessary capital expenditures, and contractor mobilization delays because of equipment availability issues. Following consultation with its legal and financial advisors, the Board of Directors determined that it was in the best interests of the Company and its stakeholders to file the NOI and obtain creditor protection. The Board of Directors also authorized management to seek the conversion of the BIA proceedings into proceedings under the Companies' Creditors Arrangement Act (Canada) (the "CCAA") should management determine that CCAA proceedings would be more appropriate.
The effect of the NOI is an immediate stay of proceedings for 30 days, which may be extended by subsequent court order. Filing the NOI will allow the Company to pursue available options to maximize the Company's value for stakeholders. Importantly, the Company will continue to operate and will remain in control of its business. While the Company is exploring strategic and financial alternatives to maximize stakeholder value in the proposed proceedings, the failure of the Company to achieve its restructuring goals through an approved proposal would result in the Company being deemed to have made an assignment into bankruptcy.
Alvarez & Marsal Canada Inc. has been appointed as proposal trustee pursuant to the BIA (the "Proposal Trustee") to monitor the Company's operations and restructuring. Information and materials filed in connection with the NOI proceedings can be found on the Proposal Trustee's website at www.alvarezandmarsal.com/GPR.
Due to the above-mentioned liquidity constraints, the Company's Brazilian subsidiary, Mina Tucano Ltda. ("Mina Tucano"), intends to enter a temporary care and maintenance period while the Company explores alternatives to maximize value for all stakeholders. As a part of this process, the Company has terminated several material contracts with suppliers. The Company intends to continue to process stockpiles during the care and maintenance period and work with its suppliers to maximize stakeholder value.
Great Panther Mining is a precious metals producer focused on the operation of the Tucano Gold Mine in Brazil where the Company controls a land package covering nearly 200,000 hectares in the prospective Vila Nova Greenstone belt. Great Panther trades on the Toronto Stock Exchange trading under the symbol GPR and on the NYSE American under the symbol GPL.
This news release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of Canadian securities laws (together, "forward-looking statements"). Such forward-looking statements include but are not limited to (i) the Company's continued operation and control of its business, (ii) the Company's consideration of strategic and financial alternatives to maximize shareholder value, (iii) the Company's ability to process stockpiles during the care and maintenance period.
These forward-looking statements and information reflect the Company's current views with respect to future events and are necessarily based upon a number of assumptions that, while considered reasonable by the Company, are inherently subject to significant operational, business, economic and regulatory risks and uncertainties, including risks related to the restructuring process and its impact on the Company's operations and financial conditions, uncertainty regarding the Company's ability to identify and pursue strategic alternatives that will maximize stakeholder value and the risks described in respect of Great Panther in its most recent annual information form and management's discussion and analysis filed with the Canadian Securities Administrators and available at www.sedar.com and its most recent annual report on Form 40-F and management's discussion and analysis on Form 6-K filed with the Securities and Exchange Commission and available at www.sec.gov.
There is no assurance that these forward-looking statements will prove accurate or that actual results will not vary materially from these forward-looking statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated, described, or intended. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Forward-looking statements and information are designed to help readers understand management's current views of our near- and longer-term prospects and may not be appropriate for other purposes. The Company does not intend, nor does it assume any obligation to update or revise forward-looking statements or information, whether as a result of new information, changes in assumptions, future events or otherwise, except to the extent required by applicable law.
View original content to download multimedia:
SOURCE Great Panther Mining Limited | https://www.whsv.com/prnewswire/2022/09/06/great-panther-file-notice-intention-make-proposal-under-bankruptcy-insolvency-act-canada/ | 2022-09-06T11:26:33Z |
CONSHOHOCKEN, Pa., Sept. 6, 2022 /PRNewswire/ -- Leading private markets investment management firm Hamilton Lane (NASDAQ: HLNE) today announced the final closing of Hamilton Lane Strategic Opportunities Fund VII ("the Fund"). The Fund, which is the largest ever within the series, represents approximately $953 million in commitments from a diverse set of institutions, including returning and new investors across North America, Asia, EMEA and Latin America.
The latest close is a testament to the proven strategy of Hamilton Lane's Strategic Opportunities offering, an annual fund series that is focused on delivering attractive, risk-adjusted returns to investors. The Fund will primarily utilize direct credit investments, selectively layering in other credit-like investments to create a portfolio biased toward shorter-duration exposures, seeking downside protection and current cash-pay.
Nayef Perry, Global Co-Head of Direct Credit, commented: "This is a unique moment for private credit as an asset class. Volatility concerns and rising interest rates are attracting investors to private credit due to its floating rate nature and historical consistency of performance through up and down markets. Additionally, periods of market uncertainty tend to negatively impact the public credit markets, which creates opportunities for private lenders who are well-equipped to navigate complexity and provide certainty of capital to borrowers."
Emily Nomeir, Managing Director, Direct Credit Investments, said: "This Fund is structured to demonstrate the stability private credit can offer investors, particularly during times of public market uncertainty. Benefits like cash yield, attractive risk-adjusted returns and the ability to carefully navigate volatility are hallmarks of our strategy, and we're grateful to our limited partners for their continued support. We remain committed to providing solutions for investors of all types and will continue to leverage Hamilton Lane's flexible approach and well-established platform as we deploy the Fund."
Hamilton Lane (NASDAQ: HLNE) is a leading private markets investment management firm providing innovative solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for 30 years, the firm currently employs more than 530 professionals operating in offices throughout North America, Europe, Asia Pacific and the Middle East. Hamilton Lane has more than $832 billion in assets under management and supervision, composed of $108 billion in discretionary assets and more than $724 billion in advisory assets, as of June 30, 2022. Hamilton Lane specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors and geographies. For more information, please visit www.hamiltonlane.com or follow Hamilton Lane on LinkedIn: https://www.linkedin.com/company/hamilton-lane/.
Some of the statements in this release may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Words such as "will," "expect," "believe," "estimate," "continue," "anticipate," "intend," "plan" and similar expressions are intended to identify these forward-looking statements. Forward-looking statements discuss management's current expectations and projections relating to our financial position, results of operations, plans, objectives, future performance and business. All forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause actual results to be materially different, including risks relating to: our ability to manage growth, fund performance, competition in our industry, changes in our regulatory environment and tax status; market conditions generally; our ability to access suitable investment opportunities for our clients; our ability to maintain our fee structure; our ability to attract and retain key employees; our ability to manage our obligations under our debt agreements; defaults by clients and third-party investors on their obligations to fund commitments; our ability to comply with investment guidelines set by our clients; our ability to successfully integrate acquired businesses with ours; our ability to manage risks associated with pursuing new lines of business or entering into strategic partnerships; our ability to anticipate, identify and manage risks we face; our ability to manage the effects of events outside of our control; and our ability to receive distributions from HLA to fund our payment of dividends, taxes and other expenses.
The foregoing list of factors is not exhaustive. For more information regarding these risks and uncertainties as well as additional risks that we face, you should refer to the "Risk Factors" detailed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended March 31, 2022 and in our subsequent reports filed from time to time with the Securities and Exchange Commission. The forward-looking statements included in this release are made only as of the date hereof. We undertake no obligation to update or revise any forward-looking statement as a result of new information or future events, except as otherwise required by law.
View original content:
SOURCE Hamilton Lane | https://www.whsv.com/prnewswire/2022/09/06/hamilton-lane-closes-its-largest-ever-private-credit-fund-more-than-950-million/ | 2022-09-06T11:26:40Z |
LA JOLLA, Calif., Sept. 6, 2022 /PRNewswire/ -- Helixmith announced topline results today from a Phase 2A study in individuals with ALS (Amyotrophic Lateral Sclerosis). ALS is a fatal neurodegenerative disorder of upper and lower motor neurons that causes progressive paralysis and eventual death due to respiratory failure. This Phase 2A was a double-blind placebo controlled multi-center study involving 5 sites (4 in the US and 1 in Korea) and 18 subjects randomized to a 2:1 ratio of Engensis to placebo. In this Phase 2A study, three treatments of Engensis, a plasmid DNA encoding human HGF, or placebo were injected in the upper and lower limbs on months 0, 2 and 4. One treatment consisted of two cycles of injections, on 2-week intervals, of 64 mg of Engensis or placebo in total. Therefore, a total of 192 mg of Engensis was given to each subject over a 4-month period. In addition, there was a follow-up period of 6 months after the first injection on Day 0.
The results of the study demonstrated that Engensis was safe and well tolerated at this dosing regimen. There was no difference in the frequency of TEAEs (83% for each group) between the Engensis and the placebo groups. One TEAE, bronchitis, was reported in the Engensis group but was determined to not be related to the study drug. Injection site reactions were reported by 50% of the Engensis group and by 66.7% of the placebo group. Most of the injection site reactions were Grade 1 or 2 and resolved within a short time, and none of the participants in the study discontinued due to the number of injections. These data suggest that high dose, repeated treatments of Engensis, were safe and well tolerated, providing a great deal of flexibility in designing dosing schemes for future clinical studies.
Given the primary endpoint of this study was to test safety and tolerability, efficacy was measured only as an exploratory parameter. ALSFRS-R scores, muscle functions using handheld dynamometry, and ALSAQ-40 were among the measurements collected. Since the study size was small and 4 subjects dropped out early, we were unable to compare efficacy between the Engensis and placebo groups.
An important component of this study was the collection of biopsy samples from the participants' injections sites. Engensis is an intramuscularly delivered gene therapy. The bulk of the data collected to date, showing effects of HGF expressed from Engensis, has been from animal models. Data collected from clinical trials has been limited thus far. Thanks to our dedicated clinical trial participants, muscle biopsy samples were collected during the course of the trial and will be subjected to histological and molecular biological analyses using RNA-Seq.
Helixmith greatly appreciates the generous and eager participation of the ALS patients. Data from these results are expected to provide valuable information on the understanding of the mechanisms of actions of Engensis, and its effects on the expression of human genes, which will greatly help in the development of innovative medicines based on HGF/c-Met signaling.
Helixmith will continue the analysis of the Phase 2A data upon the receipt of the full report and plan to present results at a future conference and determine next steps for Engensis in ALS at that time.
Helixmith is a clinical-stage gene therapy company headquartered in Seoul, Korea, developing new and innovative biopharmaceuticals to address previously untreated diseases, and is listed on the KOSDAQ. The company has an extensive gene therapy pipeline, including a CAR-T program targeting several different types of solid tumors and an AAV vector program targeting neuromuscular diseases. Engensis (VM202), the most advanced pipeline candidate, is a plasmid DNA therapy being studied for painful diabetic peripheral neuropathy, diabetic foot ulcers, claudication, amyotrophic lateral sclerosis, coronary artery disease, and Charcot-Marie-Tooth disease.
View original content:
SOURCE Helixmith USA Inc. | https://www.whsv.com/prnewswire/2022/09/06/helixmith-announces-topline-results-phase-2a-study-engensis-treatment-als-amyotrophic-lateral-sclerosis/ | 2022-09-06T11:26:48Z |
LEAWOOD, Kan., Sept. 6, 2022 /PRNewswire/ -- Torch.AI, pioneers of Data Infrastructure AI™, is testing a new artificial intelligence application with Henderson Engineers, a national building systems design firm, to unlock the creative and problem solving potential of the firm's more than 1,000 employees.
Henderson, one of the world's most prominent and successful building systems design and engineering firms, works on projects across the business, community, health, retail, and venue sectors, including many high-profile projects, such as SoFi Stadium, host site for the 2022 Super Bowl. The construction & engineering industry is known for sophisticated projects spanning huge supplier networks, strict building design standards, detailed job planning efforts, and tight margins. The industry relies on highly complex information contained in equally complex unstructured data: drawings, images, PDFs, handwriting, raw text.
Earlier this year, Henderson began testing new artificial intelligence from Torch.AI that could learn to read complex construction and engineering documents and diagrams. Past construction & engineering data sets were used to quickly train the AI with more than 340 million parameters and growing, which in turn creates new opportunities for automation and data sharing. The Torch.AI system has already read roughly 100,000 engineering drawings with remarkable accuracy. In one example, in less than one second the AI is able to identify, extract, and compare diagrams from 40+ page project files with an average accuracy of 98.9%.
Torch.AI's software helps unlock human potential by removing impediments to creativity and problem solving, namely mundane tasks created by the explosion of enterprise data and ever-increasing gaps in technology. The software begins by instantly figuring out what the data is and how it can be useful, then applies advanced machine learning to automate the steps necessary to deliver new insights and support decisions; all without human intervention.
"When Kevin Lewis, Henderson's CEO, and I got together to first discuss the partnership, I could tell they were already thinking way ahead of everyone else," says Brian Weaver, Chairman and CEO of Torch.AI. "As an engineering firm they are meticulous, thoughtful, strategic. We quickly saw the potential impact these new AI systems could have for their amazingly talented teams and are excited to continue growing our relationship."
Torch.AI, the Data Infrastructure AI™ Pioneers, are headquartered in Kansas City with offices in Washington, DC. The company developed the use of AI to process data in-flight, radically evolving analytic and operational capabilities in any IT environment. Torch.AI's products and people are currently actively supporting operations in industries including financial services & insurance, construction and engineering, healthcare, and the US Department of Defense, US Department of Homeland Security, and other agencies.
Henderson Engineers provides a wide array of building system design engineering services across a variety of building types, specializing in five market sectors: Business, Community, Health, Retail, and Venue. Their sister company, Henderson Building Solutions, is a turnkey construction management and commissioning services firm that provides a seamless bridge between design, construction, and ongoing maintenance. Together as Henderson Companies, they provide single source solutions for any project.
CONTACT: hello@torch.ai
View original content to download multimedia:
SOURCE Torch.AI | https://www.whsv.com/prnewswire/2022/09/06/henderson-engineers-torchai-test-new-ai-building-systems-design/ | 2022-09-06T11:26:55Z |
With this acquisition, Hitachi will accelerate its offerings between shop floor operations and enterprise systems particularly in North America.
NEW YORK and TOKYO, Sept. 6, 2022 /PRNewswire/ -- Hitachi, Ltd. (TSE: 6501, "Hitachi") today announced that on August 31, 2022 it acquired Flexware Innovation, Inc. ("Flexware Innovation ") which has been a leading manufacturing Systems Integrator (SI) since 1996. Flexware Innovation was a strategic acquisition for Hitachi due to its focus on the TOTAL SEAMLESS SOLUTION*1 that links "shop floor" and "top floor" with data and digital technology.
With this acquisition of Flexware Innovation, Hitachi will strengthen and enhance its business in the domain of MES (Manufacturing Execution Systems), SCADA (Supervisory Control and Data Acquisition), Software Development, Business Intelligence (BI), and ERP (Enterprise Resource Planning) implementation capabilities in North America, and accelerate the digitalization with JR Automation*2 which engages in the robotic SI & automation. Further, through cooperation with Hitachi Vantara which has expertise in building and deploying Enterprise and Cloud applications*5, Hitachi will be able to provide TOTAL SEAMLESS SOLUTION from robotic SI & automation, MES, SCADA, BI, and ERP and help manufacturing leaders increase corporate value.
Background & Business Strategy
Hitachi's basic approach for the industry field is to globally develop TOTAL SEAMLESS SOLUTION that solves issues existing in the boundaries between shop floor, top floor and supply chain to create new business value, by taking advantage of having offerings ranging from products, OT (Operational Technology) and IT (Information Technology) systems integration capabilities.
Above all, it is expected that North America will continue to experience high growth and North America will continue to adopt advanced digital technologies, so Hitachi has positioned North America as a key market. In 2017, Hitachi acquired Sullair*3, which engages in the air compressor business, and it acquired JR Automation in 2019. Further, Hitachi formed Hitachi Industrial Holdings Americas*4 in 2020 to strengthen integrated business operations of industry field in the region. Under the Hitachi Industrial Holdings Americas leadership are Sullair, JR Automation, and Flexware Innovation, the newly acquired company. The global pandemic and resulting supply-chain challenges have caused a continued need for quality and productivity improvements across all industry sectors. Hitachi is uniquely positioned to provide TOTAL SEAMLESS SOLUTION by taking advantage of their global platforms such as Lumada*5 coupled with the strength of JR Automation and Flexware Innovation in the IT/OT space.
The Strategy Behind the Flexware Innovation Acquisition
Many technical firms focused on the manufacturing and industrial sectors are solely focused on a particular industry or are limited to the controls or machinery layer. Flexware Innovation is unique because they focused on the Manufacturing Execution Systems space beginning in 1996 and have proven that they can add value to their enterprise clients in many vertical industries such as Life Sciences, Food & Beverage, Utilities, Metal and Steel, and Automotive and Discrete manufacturing. Their capabilities range from controls engineering and safety assessments all the way up to ERP implementation. Having developed or implemented many complex enterprise MES solutions, Hitachi plans to leverage Flexware Innovation's expertise to compliment the capabilities of JR Automation, and Hitachi Vantara. Hitachi realizes that the North American market is a prime area for growth and is passionate about adding business value to its clients. This synergy with Flexware Innovation's history made this partnership an obvious choice. It is important to note that Hitachi plans to support and grow Flexware Innovation's current customer base which includes notable global brands.
"I am very happy to have Flexware Innovation as a new family member of the Hitachi Group. Moving forward, we will strive to solve customers' challenges and maximize their corporate value in North America through the combination of Hitachi's products, OT, IT, and Lumada which utilizes advanced digital technologies, the SI technologies and development capabilities of Flexware Innovation, the robotic SI & automation of JR Automation, and other resources," said Kazunobu Morita, Vice President and Executive Officer, CEO of the Industrial Digital Business Unit, Hitachi, Ltd.
"Our people are passionate about solving problems for our customers. This new partnership with Hitachi will allow us to do that on a larger stage, with strong vision and backing from a respected global technology company. We have developed a unique culture at Flexware Innovation that merges perfectly with Hitachi's Founding Spirit. I am genuinely excited for our future together." - Scott Whitlock, Founder and President & CEO of Flexware Innovation.
Whitlock will remain as President & CEO of Flexware Innovation in partnership with the leaders of Hitachi Industrial Holdings Americas.
About Hitachi, Ltd.
Hitachi drives Social Innovation Business, creating a sustainable society with data and technology. We will solve customers' and society's challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products, under the business structure of Digital Systems & Services, Green Energy & Mobility, Connective Industries and Automotive Systems. Driven by green, digital, and innovation, we aim for growth through collaboration with our customers. The company's consolidated revenues for fiscal year 2021 (ended March 31, 2022) totaled 10,264.6 billion yen ($84,136 million USD), with 853 consolidated subsidiaries and approximately 370,000 employees worldwide. For more information on Hitachi, please visit the company's website at https://www.hitachi.com.
Media Contact:
Judy Shebib Media Relations
Hitachi America, Ltd
+1-947-957-0314
Judy.shebib@hal.hitachi.com
*1 TOTAL SEAMLESS SOLUTION is a registered trademark of Hitachi, Ltd. in Japan and US.
*2 Hitachi, Ltd. news release titled "Hitachi Agrees to Acquire JR Automation, a Robotic System Integrator in the U.S." announced on April 24, 2019. https://www.hitachi.com/New/cnews/month/2019/04/190424.pdf
*3 Hitachi, Ltd. news release titled "Notice of Determination of Transfer Execution Date Associated with Acquisition of U.S.-based Air Compressor Manufacturer, announced on July 6, 2017.
https://www.hitachi.com/New/cnews/month/2017/07/170706a.html
*4 Hitachi, Ltd. news release titled "Hitachi Announces Establishment of Hitachi Industrial Holdings Americas, Inc. to Strengthen the Industry Business in North America" announced on April 1, 2020
https://www.hitachi.com/New/cnews/month/2020/04/200401a.html
*5 Lumada: A collective term for solutions, services and technologies using Hitachi's advanced digital technologies to generate value from customer data and accelerate digital innovation
View original content to download multimedia:
SOURCE Hitachi | https://www.whsv.com/prnewswire/2022/09/06/hitachi-acquires-key-industry-40-systems-integrator-flexware-innovation/ | 2022-09-06T11:27:02Z |
375 Bitcoin mined, bringing reserves to 8,111
TORONTO, Sept. 6, 2022 /PRNewswire/ - Hut 8 Mining Corp. (Nasdaq: HUT) (TSX: HUT), ("Hut 8" or the "Company") one of North America's largest, innovation-focused digital asset mining pioneers and high performance computing infrastructure provider, increased its Bitcoin holdings by 375 in the period ending August 31, bringing its total self-mined holdings to 8,111 Bitcoin.
- 375 Bitcoin were generated, resulting in an average production rate of approximately 12.1 Bitcoin per day.
- Keeping with our longstanding HODL strategy, 100% of the self-mined Bitcoin in August were deposited into custody.
- Total Bitcoin balance held in reserve is 8,111 as of August 31, 2022.
- Installed ASIC hash rate capacity was 2.98 EH/s at the end of the month, which excludes certain legacy miners that the Company anticipates will be fully replaced by the end of the year.
- Hut 8 produced 125.8 BTC/EH in August.
- In late August, Hut 8 installed 180 NVIDIA GPUs in its flagship data centre in Kelowna, B.C. Currently mining Ethereum, the multi-workload machines will be designed to pivot on demand to provide Artificial Intelligence, Machine Learning, or VFX rendering services to customers.
- Hut 8 is partnering with Zenlayer to bring their on-demand high-performance computing to Canadian Web 3.0 and blockchain customers for the first time.
"Our team delivered very strong results across our mining and high performance infrastructure businesses in August, positioning us well for continued success," said Jaime Leverton, CEO. "We continue to receive and install our monthly shipments of new MicroBT miners on time, while actively adding to the suite of services we offer our data centre customers."
Hut 8 is one of North America's largest innovation-focused digital asset miners, led by a team of business-building technologists, bullish on bitcoin, blockchain, Web 3.0, and bridging the nascent and traditional high performance computing worlds. With two digital asset mining sites located in Southern Alberta and a third site in North Bay, Ontario, all located in Canada, Hut 8 has one of the highest capacity rates in the industry and one of the highest inventories of self-mined Bitcoin of any crypto miner or publicly-traded company globally. With 36,000 square feet of geo-diverse data centre space and cloud capacity connected to electrical grids powered by significant renewables and emission-free resources, Hut 8 is revolutionizing conventional assets to create the first hybrid data centre model that serves both the traditional high performance compute (Web 2.0) and nascent digital asset computing sectors, blockchain gaming, and Web 3.0. Hut 8 was the first Canadian digital asset miner to list on the Nasdaq Global Select Market. Through innovation, imagination, and passion, Hut 8 is helping to define the digital asset revolution to create value and positive impacts for its shareholders and generations to come.
This press release includes "forward-looking information" and "forward-looking statements" within the meaning of Canadian securities laws and United States securities laws, respectively (collectively, "forward-looking information"). All information, other than statements of historical facts, included in this press release that address activities, events or developments that the Company expects or anticipates will or may occur in the future, including such things as future business strategy, competitive strengths, goals, expansion and growth of the Company's businesses, operations, plans and other such matters is forward-looking information. Forward-looking information is often identified by the words "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "allow", "believe", "estimate", "expect", "predict", "can", "might", "potential", "predict", "is designed to", "likely" or similar expressions. In addition, any statements in this press release that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information and include, among others, statements regarding: Bitcoin and Ethereum network dynamics; the Company's ability to advance its longstanding HODL strategy; the Company's ability to produce additional Bitcoin and maintain existing rates of productivity at all sites; the Company's ability to deploy additional miners; the Company's ability to continue mining digital assets efficiently; the Company's expected recurring revenue and growth rate from its high performance computing business; and the Company's ability to successfully navigate the current market.
Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates and projections regarding future events based on certain material factors and assumptions at the time the statement was made. While considered reasonable by Hut 8 as of the date of this press release, such statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to, security and cybersecurity threats and hacks, malicious actors or botnet obtaining control of processing power on the Bitcoin or Ethereum network, further development and acceptance of Bitcoin and Ethereum networks, changes to Bitcoin or Ethereum mining difficulty, loss or destruction of private keys, increases in fees for recording transactions in the Blockchain, erroneous transactions, reliance on a limited number of key employees, reliance on third party mining pool service providers, regulatory changes, classification and tax changes, momentum pricing risk, fraud and failure related to cryptocurrency exchanges, difficulty in obtaining banking services and financing, difficulty in obtaining insurance, permits and licenses, internet and power disruptions, geopolitical events, uncertainty in the development of cryptographic and algorithmic protocols, uncertainty about the acceptance or widespread use of cryptocurrency, failure to anticipate technology innovations, the COVID19 pandemic, climate change, currency risk, lending risk and recovery of potential losses, litigation risk, business integration risk, changes in market demand, changes in network and infrastructure, system interruption, changes in leasing arrangements, and other risks related to the cryptocurrency and data centre business. For a complete list of the factors that could affect the Company, please see the "Risk Factors" section of the Company's Annual Information Form dated March 17, 2022, and Hut 8's other continuous disclosure documents which are available on the Company's profile on the System for Electronic Document Analysis and Retrieval at www.sedar.com and on the EDGAR section of the U.S. Securities and Exchange Commission's website at www.sec.gov.
These factors are not intended to represent a complete list of the factors that could affect Hut 8; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described in this press release as intended, planned, anticipated, believed, sought, proposed, estimated, forecasted, expected, projected or targeted and such forward-looking statements included in this press release should not be unduly relied upon. The impact of any one assumption, risk, uncertainty, or other factor on a particular forward-looking statement cannot be determined with certainty because they are interdependent and Hut 8's future decisions and actions will depend on management's assessment of all information at the relevant time. The forward-looking statements contained in this press release are made as of the date of this press release, and Hut 8 expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
View original content to download multimedia:
SOURCE Hut 8 Mining Corp | https://www.whsv.com/prnewswire/2022/09/06/hut-8-mining-production-operations-update-august-2022/ | 2022-09-06T11:27:08Z |
- Investigator Sponsored Trial sites in Australia include St. Vincent's Hospital, Sydney, Alfred Health, Melbourne, and the Royal Victorian Eye and Ear Hospital, Melbourne
- Preliminary signals of clinical activity observed in the primary uvea, including tumor shrinkage following neoadjuvant darovasertib monotherapy treatment
- (Neo)adjuvant UM represents an unmet medical need and potential clinical expansion opportunity with annual incidence of approximately 8,700 patients in the US and EU
- Clinical proof-of-concept data for use in (neo)adjuvant UM setting will be presented with the interim darovasertib Phase 2 clinical data update in MUM in September 2022
SOUTH SAN FRANCISCO, Calif., Sept. 6, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has initiated an Investigator Sponsored Trial, or IST, in coordination with St. Vincent's Hospital, Sydney, to evaluate darovasertib as monotherapy in neo-adjuvant and adjuvant settings in primary, non-metastatic uveal melanoma (UM) patients.
The study, captioned as "Neoadjuvant / Adjuvant trial of Darovasertib in Ocular Melanoma" (NADOM), is being led by principal investigator Professor Anthony Joshua, MBBS, PhD, FRACP, Head Department of Medical Oncology, Kinghorn Cancer Centre, St. Vincent's Hospital in Sydney with participating sites of Alfred Health and the Royal Victorian Eye and Ear Hospital in Melbourne. Pursuant to the protocol, the NADOM study will evaluate darovasertib as monotherapy in eligible adult patients having ocular melanoma to determine the feasibility and tolerability of (neo)adjuvant treatment.
"We are excited to be leading this ground-breaking clinical study treating patients with darovasertib in the neo-adjuvant and adjuvant settings. The concept for this study originated from anecdotal observations in a MUM patient treated with darovasertib who also had an intact primary lesion in the eye, where a reduction in the eye lesion was observed at an initial scan with improvement in visual symptoms," said Professor Anthony Joshua, MBBS, PhD, FRACP, Head Department of Medical Oncology, Kinghorn Cancer Centre, St. Vincent's Hospital Sydney.
"We are observing an early signal of clinical activity in the first patient enrolled in the NADOM study," said Professor Mark Shackleton MBBS, PhD, FRACP, Director of Oncology at Alfred Health and Professor of Oncology, Monash University. "Our coordinated patient care with eye specialists at the Royal Victorian Eye and Ear Hospital on this trial has enabled a potential paradigm-shifting approach to reduce the size of ocular tumors prior to primary treatment, which we hope will lead to better outcomes for patients," continued Professor Shackleton.
"There are currently limited treatment options for patients with uveal melanoma in the pre-metastatic setting. We are pleased to be collaborating with St. Vincent's Hospital in Sydney and with Alfred Health and Royal Victorian Eye and Ear Hospital in Melbourne to explore the potential for darovasertib monotherapy to be impactful for patients with primary uveal melanoma," said Dr. Matthew Maurer, M.D., Vice President, Head of Clinical Oncology and Medical Affairs, IDEAYA Biosciences.
Uveal melanoma is a rare, lethal form of melanoma that arises from melanocytes of the iris, the ciliary body, or most commonly the choroid, with an annual potential incidence of approximately 8,700 patients aggregate in US and Europe. Current approaches for treatment of primary UM includes radiotherapy (plaque brachytherapy or stereotactic radiosurgery) and, for larger tumors, enucleation of the eye, with consequential patient impact including reduced vision, decreased depth perception, diminished social functioning and unsatisfactory cosmesis.
Darovasertib (IDE196) is a potent, selective small molecule inhibitor of protein kinase C (PKC). Mutations in GNAQ or GNA11 (GNAQ/11) have been identified in approximately 90% of patients with metastatic UM. These mutations are associated with activation of signaling pathways, including oncogenic RAS/RAF/MEK/ERK via Protein Kinase C (PKC) activation, driving tumor progression. In April 2022, the FDA designated darovasertib as an Orphan Drug in Uveal Melanoma.
In addition to supporting the NADOM study with St. Vincent's Hospital Sydney, IDEAYA is also evaluating the synthetic lethal combination of darovasertib and crizotinib, a small molecule cMET inhibitor, in metastatic uveal melanoma (MUM) in an ongoing Phase 2 clinical trial pursuant to a clinical trial collaboration and drug supply agreement with Pfizer.
IDEAYA is targeting interim Phase 2 clinical results for darovasertib and crizotinib synthetic lethal combination in first-line and any-line MUM patients in September 2022, including clinical efficacy in MUM (e.g., confirmed overall response rate by RECIST, median progression-free survival, median duration of response) and an adverse event summary. The company will also present data supporting clinical proof of concept for potential use of darovasertib in primary (neo)adjuvant UM.
About IDEAYA Biosciences
IDEAYA is a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to (i) the potential of darovasertib as a treatment for (neo)adjuvant uveal melanoma and (ii) the timing and content of an additional clinical data update for darovasertib, including the darovasertib and crizotinib combination and the use of darovasertib in primary (neo)adjuvant UM. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, the effects on IDEAYA's business of the worldwide COVID-19 pandemic, the ongoing military conflict between Russia and Ukraine, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Quarterly Report on Form 10-Q filed on August 15, 2022 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.
View original content to download multimedia:
SOURCE IDEAYA Biosciences, Inc. | https://www.whsv.com/prnewswire/2022/09/06/ideaya-announces-first-patient-in-phase-i-clinical-trial-evaluate-darovasertib-monotherapy-neoadjuvant-uveal-melanoma/ | 2022-09-06T11:27:15Z |
Stenfeldt brings world-class enterprise software experience to lead inriver in sustained global growth
MALMÖ, Sweden and CHICAGO, Sept. 6, 2022 /PRNewswire/ -- Inriver, a software company that empowers organizations to deliver revenue-driving product information management (PIM) across every customer touchpoint, is pleased to announce the appointment of Niels Stenfeldt as the company's new CEO, effective September 1. An experienced chief executive with deep domain and industry expertise in product data technologies, Stenfeldt will lead inriver in its next phase of global growth and capture the significant market opportunity for the PIM industry as a whole. He succeeds Thomas Zanzinger, who led the company through COVID and its recent majority growth investment from THL Partners. Zanzinger remains a senior advisor to inriver and its board of directors.
Stenfeldt brings to inriver over 20 years of experience growing B2B enterprise software companies and successfully leading go-to-market strategy. He most recently served as CEO of Stibo Systems, a leader in master data management (MDM), where he played an integral role in growing the company's global customer base. Prior to Stibo, Stenfeldt led a global growth strategy as the head of worldwide sales and services for Esko, a packaging software company. In addition, Stenfeldt has held leadership roles at Oracle, SAP, OpenText, and Evenex (acquired by HighJump). Stenfeldt currently serves as chairman of the board of directors for Boyum IT Solutions and has been a member of the board of directors for inriver since July.
"I am thrilled by the opportunity to lead this exceptional company and work alongside some of the industry's best professionals as we continue to better serve our customers' evolving needs and accelerate growth in new customers across the globe. Inriver has a truly special position in this space of managing product data, and I strongly believe this industry will continue to rise in importance over the next several years as commerce becomes increasingly digital," said Stenfeldt. "I want to commend Thomas for his leadership and accomplishments as CEO, who during his time elevated inriver into one of the world's leading SaaS-based PIM technologies. I am sincerely honored to have the opportunity to succeed him from this point forward."
"Building on our remarkable track record to date and looking toward the next set of growth opportunities still ahead, inriver is very well-positioned for the future. Niels brings valuable understanding of customer needs and go-to-market strategies, and I have the highest confidence that he will help drive the company to new levels of success, accelerating growth globally while continuing to provide excellent software and services to our customers and external partners," said Zanzinger. "I welcome Niels to the inriver family and look forward to continuing to contribute to our mission as a senior advisor."
About inriver:
Inriver empowers organizations to deliver revenue-driving product information at every touchpoint. Inriver's Digital-first PIM™ enables organizations to bring compelling product stories to life for highly customized purchases, obtain actionable guidance on what influences buying decisions, and then quickly adapt to put insights into action. Inriver helps B2B and B2C organizations turn product information into strategic assets to drive revenue for over 1,600 brands and 700 customers globally. Headquartered in Malmö, Sweden, inriver has offices in Amsterdam, Chicago, Davao, London, Manila, Munich and Stockholm. For more information, please visit www.inriver.com.
Press Contact
Inriver
Katja Doemer
Katja.doemer@inriver.com
View original content to download multimedia:
SOURCE inriver | https://www.whsv.com/prnewswire/2022/09/06/inriver-appoints-niels-stenfeldt-chief-executive-officer/ | 2022-09-06T11:27:21Z |
EDMONTON, AB, Sept. 6, 2022 /PRNewswire/ - Intelliwave Technologies, a global leader in providing digital solutions for construction materials management and tracking, is proud to announce a significant expansion of the integration available between SiteSense and Procore Technologies, a leading global provider of construction management software. This integration continues to strengthen the strategic partnership between SiteSense and Procore by providing additional value to mutual customers utilizing leading construction technology tools in one ecosystem.
Intelliwave Technologies was formed in 2007 to increase "Time on Tools" for craft labor productivity and improve overall site safety in construction. The result was the creation of a revolutionary web and mobile-based software solution in one encompassing brand, SiteSense.
SiteSense's integration with Procore's Directory, Financials, Quality and Safety and Field Productivity modules allows construction teams to effectively close the loop for vendor payment for commitments along with defect management, while tracking material, tools, assets, and equipment consumption from one project to another, with support from the existing directory from Procore during these transactions.
This enhanced integration builds on SiteSense's previous integration releases with Procore to provide teams additional touchpoints to further connect the office to the field, driving project performance more effectively. SiteSense and Procore customers can now:
- Utilize Directory records during field transactions: Directory entries in Procore now sync to SiteSense as workers, crews, and jobs to assist with auto populating contact information, company names and e-mails but can also provide support scanning site badges for materials, tools, assets, and equipment handover transactions.
- Manage Delivery Defects with Observations: Defect tickets created during receiving of materials, tools, assets, and equipment transactions in SiteSense sync to Procore as Non-Conformance Observations to ensure the defect is reviewed and resolved with the vendor. Types of defects that can be logged in SiteSense include Unacceptable, Overage, Shortage and Damage (UOS&Ds).
- Support the 3-way match for Commitments: SiteSense Receiving Reports sync to Procore as Commitment Invoices to remove communication issues when closing the loop for jobsite deliveries of materials, tools, assets, and equipment to ensure trust with vendors and continued deliveries.
- Financial Consumption of Resources: SiteSense Issue Tickets for consumption of materials, tools, assets, equipment, and consumables sync to Procore as one of three options, Change Event, Time and Materials Ticket or Direct Cost to ensure cost is either re-captured through or properly allocated to a project budget that is consuming the goods.
- Advanced Project Mapping: Added support for 1-1, 1-many or many-1 Procore to SiteSense Projects to support custom Warehousing and Inventory Management use cases.
- Developer Managed Service Account Configuration: Upgraded set-up of the integration from legacy Service Accounts to the new Developer Managed Service Accounts (DMSA) that drastically reduces the time required to set-up the integration between SiteSense and Procore.
The two-way integration between Intelliwave SiteSense and Procore provides considerable value to our shared clients," stated Dale Beard, CEO of Intelliwave. "We look forward to providing new and prospective clients our enhanced best-in-class integration for inventory control, supply chain and materials management for all types and sizes of construction projects."
The SiteSense integration with Procore provides a connected network of leading construction technology tools that can help*:
- Reduce administration costs by up to 10%
- Craft labor productivity improvement by up to 16%
- Reduce material bulk purchases by up to 40%
"SiteSense by Intelliwave can help reduce data entry errors, transit time, and receipt capture for payment to vendors," said Micah Senen, partner manager at Procore. "The new enhancement to the integration reaffirms how vital SiteSense is for AEC companies looking to bridge the gap between their office and field teams and achieve maximum project performance. By syncing directory entries, defect tickets, and commitment invoices from Procore to SiteSense, we continue to achieve our mutual goal of connecting everything and everyone in construction."
View the full news release on the Intelliwave website and the SiteSense <> Procore Integration Page for more information. Visit the Procore Marketplace to view the Intelliwave listing for SiteSense.
Contact Intelliwave Technologies today to learn more about SiteSense products.
*Reference CII Best Practices Guide: Improving Project Performance
Intelliwave Technologies provides the world's most comprehensive materials management digital solution for construction projects. SiteSense Cloud and Mobile Software enables construction crews to make more informed decisions with accurate real-time information on material status and availability.
To learn more visit www.intelliwavetechnologies.com or on LinkedIn, Facebook, and Twitter.
SiteSense® is a registered trademark of Intelliwave Technologies Inc.
Procore is a leading global provider of construction management software. Over 1 million projects and more than $1 trillion USD in construction volume have run on Procore's platform. Our platform connects every project stakeholder to solutions we've built specifically for the construction industry—for the owner, the general contractor, and the specialty contractor. Procore's App Marketplace has a multitude of partner solutions that integrate seamlessly with our platform, giving construction professionals the freedom to connect with what works best for them. Headquartered in Carpinteria, California, Procore has offices around the globe. Learn more at Procore.com.
View original content:
SOURCE Intelliwave Technologies Inc | https://www.whsv.com/prnewswire/2022/09/06/intelliwave-technologies-releases-enhanced-sitesense-integrations-with-procore-financials-field-productivity-modules/ | 2022-09-06T11:27:28Z |
BEIJING, Sept. 6, 2022 /PRNewswire/ -- iQIYI, an innovative market-leading online entertainment service in China, announced recently that it has further upgraded the revenue sharing system of its Cloud Cinema Premiere model where producers now share most of the revenues earned. The company also disclosed data on the top-earning films that have been released under its Cloud Cinema Premiere model. The developments mark the latest step iQIYI takes to create market incentives and provide transparent disclosure that drive the growth of the online film market.
With the upgrade, producers can now share 90%--compared with the 60%--of the revenue generated for films released via Premium Video on Demand (PVOD), which is one of the two models of streaming under iQIYI's Cloud Cinema Premiere model.
Data on the top-earning films released through Cloud Cinema Premiere attests to the efficacy of iQIYI's strategy. According to the company, Dreams of Getting Rich, Northeastern Bro, and Blind War recorded the highest earnings for producers across all films released under the Cloud Cinema Premiere model from 2021 to date.
In addition to popular Chinese films, the list of films released under iQIYI's Cloud Cinema also included global hits such as Zack Snyder's Justice League. Directed by Zack Snyder and starring Ben Affleck, Henry Cavill, Gal Gadot, Jason Momoa, and others, Zack Snyder's Justice League premiered in China online on iQIYI on May 3, 2021, and has since been a huge success in the Chinese market.
According to SONG Jia, Vice President of iQIYI and General Manager of iQIYI Film Center: "For the past two years, iQIYI has endeavored to working with industry talents, building a cloud cinema platform to grow China's online film market, and bringing more premium films to viewers through online releases. The latest increase in the revenue shared by producers iQIYI announced promises to further iQIYI's long-standing effort in building a fairer and more robust media ecosystem."
iQIYI last revamped its collaboration model for online film distribution in April 2022. Major upgrades included allowing films released under the Cloud Cinema Premiere model to generate revenues from both the Premium Video on Demand (PVOD) and Subscription Video on Demand (SVOD) models of streaming, as well as for the revenue shared with film producers for films released under the Subscription Premiere model to be determined by users' viewing time alone. With the April upgrade, iQIYI deepened the alignment of interest and risk between the producers and video platforms, encouraging the two parties to work more closely together to create quality content and boost revenue.
CONTACT: iQIYI Press, press@qiyi.com
View original content to download multimedia:
SOURCE iQIYI | https://www.whsv.com/prnewswire/2022/09/06/iqiyi-further-upgrades-online-film-distribution-model-increase-revenue-film-producers-driving-industry-growth/ | 2022-09-06T11:27:35Z |
New 'United Against Flu' campaign to educate people about the flu, encourage vaccination
CHICAGO, Sept. 6, 2022 /PRNewswire/ -- September officially kicks off influenza (flu) season in the U.S., and it is time for all eligible Americans to get their annual flu shot. To help educate adults who are at high risk for flu complications and increase vaccination rates, today the American Lung Association launched a new campaign, "United Against Flu."
Flu is a serious and highly contagious respiratory illness. While anyone can get the flu, certain people are at increased risk for developing serious complications, including those living with chronic medical conditions including chronic lung disease, chronic heart disease and diabetes. Racial and ethnic groups also may be at higher risk for developing serious illness. In fact, from 10 flu seasons beginning in 2009, Black Americans had a 1.8 times greater rate of flu hospitalization, and Latino Americans had a 1.2 times greater rate of flu hospitalization compared to white Americans.
"In past flu seasons, nine out of 10 adults hospitalized with the flu had at least one underlying medical condition. In fact, in the 2021-22 flu season, more than 30% of flu related hospitalizations were among adults with chronic lung disease," said American Lung Association President and CEO Harold Wimmer. "This is why it is important for everyone to get their annual flu shot. Getting a flu vaccine is important to protect yourself, your family and your community from the flu."
Flu vaccination is the best way to help protect against flu and severe illness from the virus. The flu shot is recommended annually in September or October for everyone six months of age and older, although it is not too late to vaccinate throughout the flu season. Over the course of more than 50 years, millions of Americans have safely received flu shots.
Through the "United Against Flu" Campaign, the American Lung Association has partnered with Sanofi to educate Americans about the flu and steps they can take to protect themselves from severe flu illness. Learn more at Lung.org/prevent-flu.
The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic imperatives: to defeat lung cancer; to champion clean air for all; to improve the quality of life for those with lung disease and their families; and to create a tobacco-free future. For more information about the American Lung Association, which has a 4-star rating from Charity Navigator and is a Gold-Level GuideStar Member, or to support the work it does, call 1-800-LUNGUSA (1-800-586-4872) or visit: Lung.org.
American Lung Association • 55 W. Wacker Drive, Suite 1150 • Chicago, IL 60601
1331 Pennsylvania Ave. NW, Ste. 1425 North • Washington, D.C. 20004
1-800-LUNGUSA (1-800-586-4872) Lung.org
CONTACT: Jill Dale | American Lung Association
P: 312-940-7001 C:720-438-8289 E: Jill.Dale@Lung.org
View original content to download multimedia:
SOURCE American Lung Association | https://www.whsv.com/prnewswire/2022/09/06/its-time-get-your-flu-shot-what-you-need-know-about-2022-2023-flu-season/ | 2022-09-06T11:27:42Z |
Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors
Published: Sep. 6, 2022 at 7:00 AM EDT|Updated: 27 minutes ago
CAMBRIDGE, Mass., Sept. 6, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the appointment of Richard L. Schilsky, MD, FASCO, FACP, FSCT to its Board of Directors, effective September 1, 2022. Dr. Schilsky brings over 40 years of experience in medicine and clinical research, specializing in new drug development and clinical trials for a wide range of cancers.
"We are honored to welcome Dr. Schilsky, who brings a wealth of experience and deep knowledge to bolster Leap's drug development strategy," said Christopher Mirabelli, PhD, Chairman of Leap Therapeutics' Board. "He is a recognized key opinion leader in cancer research who has served in many academic and cooperative group leadership positions and on the FDA Oncologic Drugs Advisory Committee. We look forward to leveraging his expertise to support our major clinical initiatives and regulatory strategy in the years to come."
"I'm thrilled to join the Board of Leap at such an exciting time for the Company as we continue demonstrating the significant potential that DKN-01 has in treating patients with solid tumors, particularly those whose tumors express high levels of DKK1," said Dr. Schilsky. "I look forward to collaborating with my fellow Board members and the entire Leap management and scientific team to advance the pipeline and deliver meaningful cancer therapies to patients around the world."
Dr. Schilsky is the former Chief Medical Officer and Executive Vice President of the American Society of Clinical Oncology (ASCO), and served as its President from 2008-2009. He spent the majority of his career at the University of Chicago, joining the faculty in 1984, and serving in many leadership positions including as Associate Dean for Clinical Research in the Biological Sciences Division, Chief of Hematology/Oncology in the Department of Medicine, and Director of the University of Chicago Cancer Research Center. From 1995 to 2010, Dr. Schilsky served as Chair of the Cancer and Leukemia Group B (CALGB), a national cooperative clinical research group funded by the National Cancer Institute (NCI). He has extensive experience working with both the NCI and the Food and Drug Administration (FDA) having served as a member and Chair of the NCI Board of Scientific Advisors, member of the NCI Clinical and Translational Research Committee, and member and Chair of the Oncologic Drugs Advisory Committee (ODAC) of the FDA. Dr. Schilsky has served on the editorial boards of many cancer journals, including the Journal of Clinical Oncology, and presently serves on the editorial board of the New England Journal of Medicine. Dr. Schilsky received his BA from the University of Pennsylvania and MD from the University of Chicago Pritzker School of Medicine.
About Leap Therapeutics
Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Leap has entered into a strategic collaboration with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. For more information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements include expectations with respect to the development and advancement of DKN-01, board leadership prospects and strategies, , and other future expectations, plans and prospects. Although Leap believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from our expectations. Such risks and uncertainties include, but are not limited to: that the initiation, conduct, and completion of clinical trials, laboratory operations, manufacturing campaigns, and other studies may be delayed, adversely affected, or impacted by COVID-19, global conflict or supply chain related issues; unstable global market and economic conditions; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; the size and growth potential of the markets for our drug product candidates; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially is included in Leap Therapeutics' periodic filings with the SEC, including Leap's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 11, 2022 and as may be updated by Leap's Quarterly Reports on Form 10-Q and the other reports Leap files from time to time with the SEC. Any forward-looking statement contained in this release speaks only as of its date. Leap undertakes no obligation to update any forward-looking statement contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
CONTACT:
Douglas E. Onsi President & Chief Executive Officer Leap Therapeutics, Inc. 617-714-0360 donsi@leaptx.com
The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc. | https://www.whsv.com/prnewswire/2022/09/06/leap-therapeutics-announces-appointment-richard-l-schilsky-md-its-board-directors/ | 2022-09-06T11:27:49Z |
VISTA, Calif., Sept. 6, 2022 /PRNewswire/ -- Leica Biosystems, a cancer diagnostics company and a global leader in workflow solutions, and Indica Labs, the industry-leading provider of computational and image management software in digital pathology, today announced a partnership focused on delivering compatible digital pathology workflow solutions.
The agreement establishes a cooperation between Leica Biosystems and Indica Labs with a commitment to maintain ongoing file format compatibility between Leica Biosystems Aperio GT 450 family of scanners with Indica Labs Halo family of software solutions, including AI-enabled image analysis and image management workflow software.
"The Indica team is delighted to formalize our relationship with Leica Biosystems. The partnership solidifies our commitment to ensuring that Leica Biosystems state-of-the art slide scanners, reagents, and instrumentation can be coupled with our leading digital workflow and analytics software," said Steven Hashagen, CEO of Indica Labs. "Customers can rest assured that both companies are working proactively to meet the regulatory and technical integration needs of the industry."
"For customers using Leica Biosystems Aperio GT 450 family platforms who are seeking AI-enabled image analysis and image management applications, this new partnership can eliminate integration challenges and provides our customers with peace of mind when implementing a digital pathology workflow with Indica's HALO product portfolio," said Gustavo Perez, President of Leica Biosystems.
Indica Labs is the world's leading provider of computational pathology software and image analysis services. Our flagship HALO® and HALO AI™ platform facilitates quantitative evaluation of digital pathology images. HALO Link™ facilitates research-focused image management and collaboration while HALO AP® enables collaborative clinical case review. Our Pharma Services team leverages all our image analysis platforms to partner with you to advance tissue-based research, clinical trials, and diagnostics.
For more information, please visit https://indicalab.com or contact info@indicalab.com.
Leica Biosystems is a cancer diagnostics company and a global leader in workflow solutions. Only Leica Biosystems offers the most comprehensive portfolio that spans the entire workflow from biopsy to diagnosis. With unique expertise, we are dedicated to driving innovations that connect people across radiology, pathology, surgery and oncology. Our experts are committed to delivering Improved Quality, Integrated Solutions, and Optimized Efficiencies leading to breakthrough advances in diagnostic confidence. Our mission of "Advancing Cancer Diagnostics, Improving Lives" is at the heart of our corporate culture.
For more information, please visit www.LeicaBiosystems.com.
Media Contact: Lauren Meinhardt
Phone: 1.657.226.6970
Email: LBS-GlobalMarketing@leicabiosystems.com
View original content:
SOURCE Leica Biosystems | https://www.whsv.com/prnewswire/2022/09/06/leica-biosystems-announces-partnership-with-indica-labs-deliver-integrated-digital-pathology-workflow-solutions-mutual-customers/ | 2022-09-06T11:27:56Z |
SHANGHAI, Sept. 6, 2022 /PRNewswire/ -- LightInTheBox Holding Co., Ltd. (NYSE: LITB) ("LightInTheBox" or the "Company"), a cross-border e-commerce platform that delivers products directly to consumers around the world, today announced its unaudited financial results for the second quarter ended June 30, 2022.
Second Quarter and First Half 2022 Financial Highlights
Mr. Jian He, Chief Executive Officer of LightInTheBox, commented, "We delivered a solid financial performance in the second quarter of 2022, despite challenges caused by macro headwinds including the COVID resurgence in China, soft consumer sentiment globally and fluctuations in foreign exchange rates. Our top line increased 8.3% year-over-year, returning to growth, while our loss significantly narrowed on a sequential basis due to improvements in our product mix and operating efficiency. During these difficult times, we have proved ourselves as a trusted platform with strong track record, receiving continued support from our long-term partners. Although uncertainties are still ahead of us, we will continue to improve our operational efficiency and customer experience. We have seen definite improvements in our supply chain and logistics, and we are confident of maintaining revenue growth momentum in the second half of 2022."
Second Quarter 2022 Financial Results
Total revenues increased by 8.3% year-over-year to $132.4 million from $122.2 million in the same quarter of 2021. Revenues generated from product sales were $129.8 million, compared with $119.3 million in the same quarter of 2021. Revenues from services and others were $2.6 million, compared with $2.9 million in the same quarter of 2021. Included in product sales, revenues from apparel increased by 44.4% to $108.7 million in the second quarter of 2022, compared with $75.3 million in the same quarter of 2021. Revenues from apparel represented 82.1% of total revenues in the second quarter of 2022, and 61.6% in the same quarter of 2021.
Total cost of revenues was $59.2 million in the second quarter of 2022, compared with $65.1 million in the same quarter of 2021. Cost for product sales was $58.2 million in the second quarter of 2022, compared with $64.0 million in the same quarter of 2021. Cost for services and others was $1.0 million in the second quarter of 2022, compared with $1.1 million in the same quarter of 2021.
Gross profit in the second quarter of 2022 was $73.2 million, compared with $57.1 million in the same quarter of 2021. Gross margin was 55.3% in the second quarter of 2022, compared with 46.8% in the same quarter of 2021. The increase in gross margin was a result of the Company's continuous efforts to optimize our product mix.
Total operating expenses in the second quarter of 2022 were $75.6 million, compared with $60.6 million in the same quarter of 2021
- Fulfillment expenses in the second quarter of 2022 were $7.8 million, compared with $7.6 million in the same quarter of 2021. As a percentage of total revenues, fulfillment expenses were 5.9% in the second quarter of 2022, compared with 6.2% in the same quarter of 2021 and 7.3% in the first quarter of 2022.
- Selling and marketing expenses in the second quarter of 2022 were $58.2 million, compared with $43.5 million in the same quarter of 2021. As a percentage of total revenues, selling and marketing expenses were 44.0% for the second quarter of 2022, compared with 35.6% in the same quarter of 2021 and 41.6% in the first quarter of 2022.
- G&A expenses in the second quarter of 2022 were $9.7 million, compared with $9.5 million in the same quarter of 2021. As a percentage of total revenues, G&A expenses were 7.3% for the second quarter of 2022, compared with 7.8% in the same quarter of 2021 and 8.6% in the first quarter of 2022. Included in G&A expenses, R&D expenses in the second quarter of 2022 were $4.7 million, compared with $5.1 million in the same quarter of 2021 and $4.6 million in the first quarter of 2022.
Loss from operations was $2.5 million in the second quarter of 2022, compared with $3.5 million in the same quarter of 2021.
Other income, net in the second quarter of 2022 was $0.1 million, compared with other income, net of $17.2 million in the same quarter of 2021. Included in other income, net in the second quarter of 2021, $17.1 million was derived from change in fair value on our equity investment. The gain in fair value change on our equity investment, after respective income tax of $4.2 million, was $12.9 million.
Net loss was $2.4 million in the second quarter of 2022, compared with net income of $9.5 million in the same quarter of 2021.
Net loss per American Depository Share ("ADS") was $0.02 in the second quarter of 2022, compared with net income per ADS of $0.08 in the same quarter of 2021. Each ADS represents two ordinary shares. The diluted net loss per ADS in the second quarter of 2022 was $0.02, compared with the diluted net income per ADS of $0.08 in the same quarter of 2021.
In the second quarter of 2022, the Company's basic weighted average number of ADSs used in computing the net income per ADS was 113,070,465.
Adjusted EBITDA, which represents (loss) / income from operations before share-based compensation expense, interest income, interest expense, income tax expense and depreciation and amortization expenses, was negative $1.5 million in the second quarter of 2022, compared with income of $14.5 million in the same quarter of 2021.
As of June 30, 2022, the Company had cash and cash equivalents and restricted cash of $65.7 million, compared with $59.6 million as of December 31, 2021.
First Half 2022 Financial Results
Total revenues decreased 3.5% year-over-year to $226.1 million from $234.2 million in the same half of 2021. Revenues generated from product sales were $221.2 million, compared with $228.7 million in the same half of 2021. Revenues from services and others were $4.9 million, compared with $5.5 million in the same half of 2021. Included in product sales, revenues from apparel increased by 30.9% to $175.9 million in the first half of 2022, compared with $134.4 million in the same half of 2021. Revenues from apparel represented 77.8% of total revenues in the first half of 2021, and 57.4% in the same half of 2021.
Total cost of revenues was $105.5 million in the first half of 2022, compared with $124.8 million in the same half of 2021. Cost for product sales was $103.3 million in the first half of 2022, compared with $123.0 million in the same half of 2021. Cost for services and others was $2.2 million in the first half of 2022, compared with $1.8 million in the same half of 2021.
Gross profit in the first half of 2022 was $120.7 million, compared with $109.4 million in the same half of 2021. Gross margin was 53.4% in the first half of 2022, compared with 46.7% in the same half of 2021. The increase in gross margin was a result of the Company's continuous efforts to drive revenues from product categories with higher margins.
Total operating expenses in the first half of 2022 were $129.5 million, compared with $111.5 million in the same half of 2021.
- Fulfillment expenses in the first half of 2022 were $14.6 million, compared with $14.9 million in the same half of 2021. As a percentage of total revenues, fulfillment expenses were 6.5% in the first half of 2022, compared with 6.3% in the same half of 2021.
- Selling and marketing expenses in the first half of 2022 were $97.3 million, compared with $79.1 million in the same half of 2021. As a percentage of total revenues, selling and marketing expenses were 43.0% for the first half of 2022, compared with 33.8% in the same half of 2021.
- G&A expenses in the first half of 2022 were $17.7 million, compared with $17.9 million in the same half of 2021. As a percentage of total revenues, G&A expenses were 7.8% for the first half of 2022, compared with 7.6% in the same half of 2021. Included in G&A expenses, R&D expenses in the first half of 2022 were $9.3 million, compared with $10.0 million in the same half of 2021.
Loss from operations was $8.9 million in the first half of 2022, compared with $2.1 million in the same half of 2021.
Other income, net was $0.9 million in the first half of 2022, compared with $17.2 million in the same half of 2021. Included in other income, net, change in fair value on our equity investment was $0.8 million in the first half of 2022, compared with $17.1 million in the same half of 2021. The gain in fair value change on our equity investment, after respective income tax of $nil, was $0.8 million in the first half of 2022, compared with $12.9 million after respective income tax of $4.2 million in the same half of 2021.
Net loss was $7.9 million in the first half of 2022, compared with net income of $10.9 million in the same half of 2021.
Net loss per American Depository Share ("ADS") was $0.07 in the first half of 2022, compared with net income per ADS of $0.10 in the same half of 2021. Each ADS represents two ordinary shares. The diluted net loss per ADS for the first half of 2022 was $0.07, compared with the diluted net income per ADS of $0.09 in the same half of 2021.
In the first half of 2022, the Company's basic weighted average number of ADSs used in computing the net income per ADS was 113,062,096.
Adjusted EBITDA, which represents (loss) / income from operations before share-based compensation expense, interest income, interest expense, income tax expense and depreciation and amortization expenses, was negative $6.1 million in the first half of 2022, compared with income of $16.8 million in the same half of 2021.
Non-GAAP Financial Measures
To supplement our consolidated financial statements, which are prepared and presented in accordance with U.S. GAAP, we use the following non-GAAP financial measures to help evaluate our operating performance:
"Adjusted EBITDA" represents income from operations before share-based compensation expense, interest income, interest expense, income tax expense and depreciation and amortization expenses. Although other companies may calculate adjusted EBITDA differently or not present it at all, we believe that the adjusted EBITDA helps to identify underlying trends in our operating results, and facilitate investors' understanding of the past performance and future prospect.
Conference Call
The Company will hold a conference call to discuss the results at 8:00 a.m. Eastern Time on September 6, 2022 (8:00 p.m. Beijing Time on the same day).
Preregistration Information
Participants can register for the conference call by navigating to https://s1.c-conf.com/diamondpass/10024891-4mlfy6f.html. Once preregistration has been completed, participants will receive dial-in numbers, an event passcode, and a unique access PIN.
To join the conference, simply dial the number in the calendar invite you receive after preregistering, enter the event passcode followed by your unique access PIN, and you will be joined to the conference instantly.
A telephone replay will be available two hours after the conclusion of the conference call through September 14, 2022. The dial-in details are:
Additionally, a live and archived webcast of the conference call will be available on the Company's Investor Relations website at http://ir.lightinthebox.com.
About LightInTheBox Holding Co., Ltd.
LightInTheBox is a cross-border e-commerce platform that delivers products directly to consumers around the world. The Company offers customers a convenient way to shop for a wide selection of products at attractive prices through its www.lightinthebox.com, www.miniinthebox.com, www.ezbuy.sg and other websites and mobile applications, which are available in 25 major languages and cover more than 140 countries.
For more information, please visit www.lightinthebox.com.
Investor Relations Contact
Christensen
Ms. Xiaoyan Su
Tel: +86 (10) 5900 1548
Email: ir@lightinthebox.com
OR
Christensen
Ms. Linda Bergkamp
Tel: +1-480-614-3004
Email: lbergkamp@ChristensenIR.com
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "potential," "continue," "ongoing," "targets" and similar statements. Among other things, statements that are not historical facts, including statements about LightInTheBox's beliefs and expectations, the business outlook and quotations from management in this announcement, as well as LightInTheBox's strategic and operational plans, are or contain forward-looking statements.
LightInTheBox may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in press releases and other written materials and in oral statements made by its officers, directors or employees to fourth parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward- looking statement, including but not limited to the following: LightInTheBox's goals and strategies; LightInTheBox's future business development, results of operations and financial condition; the expected growth of the global online retail market; LightInTheBox's ability to attract customers and further enhance customer experience and product offerings; LightInTheBox's ability to strengthen its supply chain efficiency and optimize its logistics network; LightInTheBox's expectations regarding demand for and market acceptance of its products; competition; fluctuations in general economic and business conditions and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in LightInTheBox's filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and LightInTheBox does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
SOURCE LightInTheBox Holding Co., Ltd. | https://www.whsv.com/prnewswire/2022/09/06/lightinthebox-reports-second-quarter-2022-financial-results/ | 2022-09-06T11:28:03Z |
WATERTOWN, Mass., Sept. 6, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced the Company's participation at the H.C. Wainwright 24th Annual Global Investment Conference (the Conference). Maria Palasis, Ph.D., Lyra's President and Chief Executive Officer, will present in person at the conference on Wednesday, September 14th at 12:00 p.m. EDT.
The Conference will be held at the Lotte New York Palace Hotel from September 12-14, during which Lyra will also host one-on-one meetings with investors.
The webcast of the fireside chat will be available on the Investor Relations section of the Company's website at https://investors.lyratherapeutics.com and will be available for at least 30 days following the event.
About Lyra Therapeutics
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, local delivery of medications to diseased tissues not accessible with conventional therapeutic approaches. Lyra's XTreo™ platform is comprised of a biocompatible mesh scaffold, an engineered elastomeric matrix and a versatile polymer-drug complex. The Company's current pipeline of therapeutics target tissues deep in the ear, nose and throat passages and are designed to deliver continuous drug therapy for up to six months following a single non-invasive, in-office administration. Lyra has two product candidates in late-stage development for CRS, a highly prevalent inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities: LYR-210, for surgically naïve patients, is being evaluated in the ENLIGHTEN Phase 3 clinical program, and LYR-220, for patients who have recurrent symptoms despite surgery, is being evaluated in the BEACON Phase 2 clinical trial. These two product candidates are designed to treat the estimated four million CRS patients in the U.S. that fail medical management each year. For more information, please visit lyratherapeutics.com and follow us on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the dates and times of the investor conferences discussed in this press release, our pipeline and development of product candidates, including LYR 210 and LYR 220, and the progress and timing of clinical trials, and the anticipated success of leveraging the XTreo™ platform. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the fact that the Company has incurred significant losses since inception and expects to incur additional losses for the foreseeable future; the Company's need for additional funding, which may not be available; the Company's limited operating history; the fact that the Company has no approved products; the fact that the Company's product candidates are in various stages of development; or the fact that the Company may not be successful in its efforts to identify and successfully commercialize its product candidates; the fact that clinical trials required for the Company's product candidates are expensive and time-consuming, and their outcome is uncertain; the fact that the FDA may not conclude that certain of the Company's product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway; the Company's inability to obtain required regulatory approvals; effects of recently enacted and future legislation; the possibility of system failures or security breaches; effects of significant competition; the fact that the successful commercialization of the Company's product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies; failure to achieve market acceptance; product liability lawsuits; the fact that the Company relies on third parties for the manufacture of materials for its research programs, pre-clinical studies and clinical trials; the Company's reliance on third parties to conduct its preclinical studies and clinical trials; the Company's inability to succeed in establishing and maintaining collaborative relationships; the Company's reliance on certain suppliers critical to its production; failure to obtain and maintain or adequately protect the Company's intellectual property rights; failure to retain key personnel or to recruit qualified personnel; difficulties in managing the Company's growth; effects of natural disasters, terrorism and wars (including the developing conflict between Ukraine and Russia); the fact that the global pandemic caused by COVID-19 could adversely impact the Company's business and operations, including the Company's clinical trials; the fact that the price of the Company's common stock may be volatile and fluctuate substantially; significant costs and required management time as a result of operating as a public company and any securities class action litigation. These and other important factors discussed under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities Exchange Commission (SEC) on August 9, 2022 and its other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.
Contact:
Kathryn Morris
The Yates Network LLC
914-204-6412
kathryn@theyatesnetwork.com
View original content to download multimedia:
SOURCE Lyra Therapeutics, Inc. | https://www.whsv.com/prnewswire/2022/09/06/lyra-therapeutics-present-hc-wainwright-annualglobal-investment-conference-2022/ | 2022-09-06T11:28:09Z |
- 3 new 200V MV MOSFETs will help the company grow its global market share in the LEV motor controller and industrial power supply sectors
SEOUL, South Korea, Sept. 6, 2022 /PRNewswire/ -- Magnachip Semiconductor Corporation ("Magnachip") (NYSE: MX) announced today that the company has introduced its third- generation 200V Medium Voltage (MV) Metal-Oxide-Semiconductor Field-Effect Transistors (MOSFETs) for Light Electric Vehicles (LEV) motor controllers and industrial power supplies.
To maximize energy efficiency in power devices, Magnachip's new 200V MOSFETs incorporate third-generation trench MOSFET technology. The capacitance was reduced by 50% compared to the previous generation 100V MV MOSFET and the enhanced design of the core cell and termination helps lower RDS(on)* and total gate charge** to achieve a high figure of merit.
In addition, these third-generation MOSFETs are available in surface mount device TO-Leadless Package (TOLL), M2PAK and TO-220 of a through-hole type respectively to reduce product size and enhance heat dissipation. Furthermore, the energy efficiency of these MOSFETs is greatly increased by fast switching and high power density. Coupled with a guaranteed operating junction temperature from -55°C up to 175°C and a high level of avalanche ruggedness, these MOSFETs are well-suited for LEV motor controllers and industrial power supplies requiring high efficiency and stable power supply.
Omdia, a global market research firm, estimates that the annual growth rates of the automotive and industrial sectors of the global silicon power MOSFET market will be 11.5% and 9.6% respectively from 2020 to 2025. In particular, LEV markets are expanding quickly alongside efforts to accelerate decarbonisation and demand for efficient and affordable vehicles.
"The development of advanced applications in the automotive and industrial sectors is driving the need for high-performance MV MOSFETs," said YJ Kim, CEO of Magnachip. "Magnachip will continue to upgrade its MV MOSFET product line, ranging from 40V to 200V, which will enable our customers to strengthen their product competitiveness."
*RDS(on): On resistance, the resistance value between the drain and the source of MOSFETs during on-state operation
**Total gate charge (Qg): the amount of charge required to be injected into the gate electrode to turn ON (drive) the MOSFET
Product features
- low RDS(on) and switching loss
- great heat dissipation performance
- guaranteed operating junction temperature from -55°C up to 175°C
- a wide range of application, such as LEVs, battery management systems and switch mode power supplies
Magnachip is a designer and manufacturer of analog and mixed-signal semiconductor platform solutions for communications, IoT, consumer, computing, industrial and automotive applications. The Company provides a broad range of standard products to customers worldwide. Magnachip, with more than 40 years of operating history, owns a portfolio of approximately 1,100 registered patents and pending applications, and has extensive engineering, design and manufacturing process expertise. For more information, please visit www.magnachip.com. Information on or accessible through Magnachip's website is not a part of, and is not incorporated into, this release.
View original content to download multimedia:
SOURCE Magnachip Semiconductor Corporation | https://www.whsv.com/prnewswire/2022/09/06/magnachip-unveils-third-generation-200v-mv-mosfets/ | 2022-09-06T11:28:15Z |
CORAL GABLES, Fla. and INDIANAPOLIS, Sept. 6, 2022 /PRNewswire/ -- MasTec, Inc. (NYSE: MTZ) ("MasTec") and Infrastructure and Energy Alternatives, Inc. ("IEA") (NASDAQ: IEA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, for the previously announced acquisition of IEA by MasTec has expired.
The expiration of the HSR waiting period was a condition to the closing of the pending transaction. Completion of the transaction is expected in October 2022, subject to the satisfaction of the remaining customary closing conditions, including approval of the transaction by IEA stockholders.
About MasTec, Inc.
MasTec is a leading infrastructure construction company operating mainly throughout North America across a range of industries. MasTec's primary activities include the engineering, building, installation, maintenance and upgrade of communications, energy, utility and other infrastructure, such as: power delivery services, including transmission and distribution, wireless, wireline/fiber and customer fulfillment activities; power generation, primarily from clean energy and renewable sources; pipeline infrastructure, including natural gas pipeline and distribution infrastructure; heavy civil; and industrial infrastructure. MasTec's customers are primarily in these industries. The information contained on the Company's website is not incorporated into this press release.
Forward Looking Statements
This press release contains a forward-looking statement regarding the expected timing of completion of MasTec's acquisition of IEA. This statement is based on currently available information, but is subject to a number of uncertainties, including potential delays to the special meeting of the IEA stockholders to be called vote on the transaction and potential delays in, or failure to, satisfy the remaining conditions to closing of the transaction. We do not undertake any obligation to publicly update or revise this forward-looking statement after the date of this press release, except as required by applicable law.
Additional Information and Where to Find It:
This communication relates to a proposed acquisition of Infrastructure and Energy Alternatives, Inc. (IEA) by MasTec, Inc. (MasTec). In connection with the proposed acquisition, MasTec and IEA have filed, and intend to continue to file, relevant materials with the Securities and Exchange Commission (SEC). In that connection on August 29, 2022, MasTec filed with the SEC a Registration Statement on Form S-4, which includes a preliminary proxy statement of IEA and which also constitutes a preliminary prospectus with respect to the shares of common stock of MasTec to be issued in the proposed transaction. The information in the preliminary proxy statement/prospectus is not complete and may be changed. IEA will deliver the definitive proxy statement/prospectus to its stockholders as required by applicable law. This communication is not a substitute for the definitive proxy statement/ prospectus that will be filed with the SEC in connection with the proposed business combination.
INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.
Investors and security holders will be able to obtain these materials (when they are available) and other documents filed with the SEC free of charge at the SEC's website, www.sec.gov. Copies of documents filed with the SEC by MasTec (when they become available) may be obtained free of charge at MasTec's website at MasTec.com. Copies of documents filed with the SEC by IEA (when they become available) may be obtained free of charge on IEA's website at iea.net.
Participants in the Solicitation:
IEA and its directors, executive officers and certain other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information regarding these persons who may, under the rules of the SEC, be considered participants in the solicitation of IEA stockholders in connection with the proposed transaction and their interests in the transaction will be set forth in the proxy statement/prospectus described above filed with the SEC. Additional information regarding IEA's executive officers and directors is included in IEA's annual report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 7, 2022 and IEA's proxy statement for its 2022 annual meeting of stockholders filed with the SEC on March 23, 2022. These documents may be obtained free of charge at the SEC's website, www.sec.gov, or IEA's website, iea.net.
View original content:
SOURCE MasTec, Inc. | https://www.whsv.com/prnewswire/2022/09/06/mastec-iea-announce-expiration-hart-scott-rodino-waiting-period-their-pending-transaction/ | 2022-09-06T11:28:22Z |
Micro Focus Enterprise Suite on Google Cloud accelerates organizations' digital transformation journey
SANTA CLARA, Calif., Sept. 6, 2022 /PRNewswire/ -- Micro Focus (LSE: MCRO; NYSE: MFGP) announced today the availability of its Enterprise Suite for application modernization on Google Cloud Marketplace. With this new Marketplace availability, organizations can more quickly deploy an enterprise-grade mainframe infrastructure solution on Google Cloud at a time when companies are seeking new and cost-effective ways to deliver on IT strategies through continuous modernization and digital transformation initiatives.
The announcement brings together Micro Focus' application modernization capabilities with the powerful security, availability, scalability, and administration features Google Cloud offers as well as Google Compute Engine (GCE) services.
"Moving critical workloads from legacy infrastructure and onto a flexible, scalable, and innovative platform like Google Cloud is an important step in digital transformation. It is imperative that organizations ensure their core business applications can meet the demands of today's ever-changing technology and business needs. Because of this, research shows that 72 percent of COBOL application owners are considering modernization as the best way to digitally transform their strategic core business systems," said Neil Fowler, General Manager and VP of the Application Modernization and Connectivity business at Micro Focus. "The availability of Micro Focus' proven modernization solutions, deployed easily on Google Cloud's trusted infrastructure via the Google Cloud Marketplace, can provide organizations with an easier path to begin their digital transformation journey."
"Legacy infrastructure should not be a barrier to innovation," said Howard Weale, Director, Transformation Practice at Google Cloud. "Bringing Micro Focus to Google Cloud Marketplace will accelerate and simplify organizations' ability to modernize some of the most common mainframe infrastructure in use today, helping them achieve their cloud agendas more quickly while benefiting from leading security, data management, and workload administration capabilities."
Enterprise Suite is a Micro Focus product line that enables modernization of IBM mainframe PL/I and COBOL applications, processes and infrastructure, enabling greater efficiency and time to market. Last month, Micro Focus released the enhanced version of the Enterprise Suite, version 8.0, in conjunction with Visual COBOL 8.0. With this announcement, customers now have the choice and flexibility to deploy their mainframe applications with Micro Focus to any of the major clouds.
The Enterprise Suite of solutions includes:
More Information
Find detailed information about Enterprise Suite 8.0 here or access a free trial.
Explore Micro Focus products on the Google Cloud Marketplace.
Read the blog post "Micro Focus Visual COBOL and Enterprise Suite are now available on the Google Cloud Platform (GCP)!"
Join Micro Focus on LinkedIn and follow @MicroFocus on Twitter.
Micro Focus is one of the world's largest enterprise software providers, focused on solving the IT dilemma—how to balance today's needs with tomorrow's opportunities. We deliver mission-critical technology that helps tens of thousands of customers worldwide manage core IT elements of their business. Strengthened by our strategic services and support organizations, and an extensive partner network, our broad set of technologies for security, IT operations, application delivery, governance, modernization, and analytics provides the innovative solutions organizations need to run and transform— at the same time.
Contact: microfocus@pancomm.com
View original content to download multimedia:
SOURCE Micro Focus | https://www.whsv.com/prnewswire/2022/09/06/micro-focus-extends-its-application-modernization-cloud-solutions-google-cloud-marketplace/ | 2022-09-06T11:28:29Z |
Meet Your Best Friend At The Firm returns on Sept. 10th for the second year in a row to support more than 150 animal adoptions.
SOUTHFIELD, Mich., Sept. 6, 2022 /PRNewswire/ -- Mike Morse Law Firm is once again hosting the Meet Your Best Friend At The Firm pet adoption event this Saturday, Sept. 10 from 10 a.m. – 1 p.m. at the firm's Southfield location (24901 Northwestern Highway, Southfield, MI 48075).
Together with Michigan Humane, Mike Morse Law Firm will welcome more than 150 adoptable pets from various rescue centers around Michigan. Along with Michigan Humane, nine animal welfare partners will be at the event, including Detroit Animal Care and Control. Last year's event facilitated more than 120 pet adoptions, with cats, dogs, kittens, and puppies all going to loving homes.
"Our Meet Your Best Friend adoption events have helped create thousands of new families over the years and we're incredibly excited to continue to promote pet adoption with our friends at the Mike Morse Law Firm," Matt Pepper, Michigan Humane President and CEO said. "Mike and his team are committed to helping spread the word about the positive benefits of pet ownership and promoting the bond between people and pets."
Mike Morse is a proud owner of a rescue dog himself, Jessi, who he met and fell in love with in 2013. "I know first-hand how much joy a pet can bring to a family," Morse said. "I also understand that sometimes our furry friends need a little extra help finding their forever home. That's why we're so proud to host Michigan Humane's Meet Your Best Friend event here at our firm."
The event is open to the public. For more information please visit 855MikeWins.com/MeetYourBestFriend.
About Mike Morse Law Firm
Since 1995, the Mike Morse Law Firm has been protecting the rights of Michigan auto accident and injury victims. They are Michigan's largest personal injury firm, specializing in auto, truck, pedestrian and motorcycle accidents as well as Social Security disability claims. They are experts in Michigan's No-Fault Act. Since opening their doors in 1995, the firm has won over one billion dollars for its clients. Mike Morse Law Firm handles cases throughout the state of Michigan, with a main office in Southfield. To learn more, call (855) 645-3946 or visit www.855mikewins.com.
View original content to download multimedia:
SOURCE Mike Morse Law Firm | https://www.whsv.com/prnewswire/2022/09/06/mike-morse-law-firm-host-pet-adoption-event-with-michigan-humane/ | 2022-09-06T11:28:35Z |
MONTREAL and CHARLOTTE, N.C., Sept. 6, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 12:00 p.m. ET in New York, NY.
A live webcast of the presentation can be accessed in the News & Events section of Milestone's website at www.milestonepharma.com. An archived replay of the presentation will be available on the same website for approximately 90 days following the presentation.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil is currently in a Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit www.milestonepharma.com and follow Milestone on Twitter at @MilestonePharma.
Contact
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com
View original content to download multimedia:
SOURCE Milestone Pharmaceuticals, Inc. | https://www.whsv.com/prnewswire/2022/09/06/milestone-pharmaceuticals-present-hc-wainwright-24th-annual-global-investment-conference/ | 2022-09-06T11:28:42Z |
WAXAHACHIE, Texas, Sept. 6, 2022 /PRNewswire/ -- The board of directors and management team of Minority Equality Opportunities Acquisition Inc. (NASDAQ: MEOA), the first minority-led special purpose acquisition company, or SPAC, listed on the Nasdaq Capital Market ("NASDAQ"), announced today that it had signed a definitive business combination agreement to merge with Digerati Technologies, Inc. (OTCQB: DTGI) ("Digerati"), a Hispanic-led and founded provider of cloud services specializing in UCaaS (Unified Communications as a Service) solutions for the small to medium-sized business market.
Digerati and MEOA will merge to create a combined company listed on NASDAQ. The all-stock transaction forms a company with an initial equity value of approximately $228 million translating into an enterprise value of approximately $145 million, assuming no redemptions from MEOA's shareholders.
The current Digerati management team, led by Arthur L. Smith, will continue to run the Company. Corporate directors for the new entity are current Digerati directors and two new directors, including Shawn D. Rochester, President and CEO of MEOA.
"MEOA's merger announcement with Digerati personifies our mission, vision and purpose," Mr. Rochester said. "Digerati is a minority founded and led business with (1) a very diverse management team (with its CEO, CFO, and EVP of Sales being of Hispanic ethnicity) that has developed great products and solutions, and staked out a strong competitive position in the marketplace, (2) an employee base that is almost 50% minority and (3) a UCaaS platform that has the ability to help empower over 20 million minority and women owned small businesses through its first-class suite of communications products. In addition to our proposed business combination with Digerati, MEOA's deep commitment to equity, inclusion, diverse representation and maximizing shareholder value is further exemplified by our use of a diverse spectrum of extraordinary third-party service providers (and teams within service providers) that are owned and or led by African Americans, Asian Americans, Hispanic Americans, and Women."
"Our merger with MEOA positions Digerati for continued growth in a rapidly expanding and highly fragmented market," said Arthur L. Smith, CEO of Digerati. "We believe a business combination with MEOA will facilitate the acceleration of our M&A strategy in a market with a healthy pipeline of acquisition targets and contribute to the combined company's organic growth as we continue providing small to medium-sized businesses with solutions and superior customer service."
PGP Capital Advisors, LLC and Vaughan Capital Advisors, LLC acted as financial advisors to MEOA and Pryor Cashman LLP acted as legal counsel for MEOA. Maxim Group LLC acted as financial advisor and Lucosky Brookman acted as legal counsel to Digerati in connection with the transaction.
Minority Equality Opportunities Acquisition Inc. is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, organized under the laws of Delaware and formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with companies that are minority owned, led or founded.
Digerati Technologies, Inc. (OTCQB: DTGI) is a provider of cloud services specializing in UCaaS (Unified Communications as a Service) solutions for the business market. Through its operating subsidiaries NextLevel Internet (NextLevelinternet.com), T3 Communications (T3com.com), Nexogy (Nexogy.com), and SkyNet Telecom (Skynettelecom.net), Digerati is meeting the global needs of small businesses seeking simple, flexible, reliable, and cost-effective communication and network solutions including, cloud PBX, cloud telephony, cloud WAN, cloud call center, cloud mobile, and the delivery of digital oxygen on its broadband network. Digerati has developed a robust integration platform to fuel mergers and acquisitions in a highly fragmented market. as it delivers business solutions on its carrier-grade network and Only in the Cloud™. For more information, please visit www.digerati-inc.com and follow DTGI on LinkedIn, Twitter and Facebook.
INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
This press release is being made in respect of the proposed business combination transaction involving MEOA and Digerati. The parties intend to file a registration statement on Form S-4 (or such other form as they might determine to be applicable) with the SEC, which will include a proxy statement for MEOA and Digerati shareholders and which will also serve as a prospectus related to offers and sales of the securities of the combined entity ("Pubco"). MEOA will also file other documents regarding the proposed transaction with the SEC. A definitive proxy statement/prospectus will also be sent to the stockholders of MEOA and Digerati, seeking required stockholder approval. Before making any voting or investment decision, investors and security holders of MEOA and Digerati are urged to carefully read the entire registration statement and proxy statement/prospectus, when they become available, and any other relevant documents filed with the SEC, as well as any amendments or supplements to these documents, because they will contain important information about the proposed transaction. The documents filed with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.
In addition, the documents filed with the SEC may be obtained free of charge from MEOA's website at https://www.meoaus.com and from Digerati's website at https://digerati-inc.com.
MEOA, Digerati and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from stockholders, in favor of the approval of the merger. Information regarding MEOA's and Digerati's directors and executive officers and other persons who may be deemed participants in the solicitation may be obtained by reading the registration statement and the proxy statement/prospectus and other relevant documents filed with the SEC when they become available. Free copies of these documents may be obtained as described above.
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the applicable securities laws. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters.
These forward-looking statements include, but are not limited to, statements regarding the terms and conditions of the proposed business combination and related transactions disclosed herein, the timing of the consummation of such transactions, assumptions regarding shareholder redemptions and the anticipated benefits and financial position of the parties resulting therefrom. These statements are based on various assumptions and/or on the current expectations of MEOA or Digerati's management. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor or other person as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of MEOA and/or Digerati. These forward-looking statements are subject to a number of risks and uncertainties, including but not limited to general economic, financial, legal, political and business conditions and changes in domestic and foreign markets; the amount of redemption requests made by MEOA's public shareholders; NASDAQ's approval of MEOA's initial listing application; changes in the assumptions underlying Digerati's expectations regarding its future business; the effects of competition on Digerati's future business; and the outcome of judicial proceedings to which Digerati is, or may become a party.
If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Digerati and MEOA presently do not know or currently believe are immaterial that could also cause actual results to differ materially from those contained in the forward-looking statements. In addition, forward-looking statements reflect expectations, assumptions, plans or forecasts of future events and views as of the date of this press release. Digerati and MEOA anticipate that subsequent events and developments will cause these assessments to change. However, while Digerati and/or MEOA may elect to update these forward-looking statements at some point in the future, each of Digerati and MEOA specifically disclaims any obligation to do so, except as required by applicable law. These forward-looking statements should not be relied upon as representing Digerati's or MEOA (or their respective affiliates') assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
View original content:
SOURCE Minority Equality Opportunities Acquisition Inc. | https://www.whsv.com/prnewswire/2022/09/06/minority-equality-opportunities-acquisition-inc-announces-merger-with-hispanic-led-founded-cloud-services-company-digerati-technologies/ | 2022-09-06T11:28:49Z |
COPENHAGEN, Denmark, Sept. 6, 2022 /PRNewswire/ -- The more we interact with digital humans and humanoid robots, the more we see them as living beings with consciousness and personality. This raises dangers we need to address before fully integrating human-like technology in society. A Danish philosopher warns us about the biggest risks in a new book.
As humanoid robots move into society on a large scale, many of us will tend to believe they deserve to be treated morally and to some degree be granted rights similar to human rights.
This issue is the focus of a new philosophy book from University Press of Southern Denmark about our robotic present and future. The book's title is Killing Sophia - Consciousness, Empathy and Reason in the Age of Intelligent Robots, and it was written by the Danish philosopher and tech debater Thomas Telving.
"Perceiving humanoids and digital humans as sentient beings is a natural reaction for us, because of our innate ability to empathize. It's almost like kittens instinctually chasing their own tails; we can´t really help it. The problem is that our empathy doesn't know what is sentient and what merely appears sentient. Because of this we will start treating human-like technology morally and eventually grant rights to robots. I warn about it because in the end it is likely to entail sacrificing real human beings on behalf what is basically stone-dead electronic devices," said Thomas Telving.
Engaging Philosophy and Fascinating Popular Science
Killing Sophia - Consciousness, Empathy and Reason in the Age of Intelligent Robots is engaging philosophy and fascinating popular science. The author is neutral on the subject, but the reader is urged to take a stand. She or he is involved in vivid thought experiments and is presented with the latest experimental research in human-robot interaction. Research that does not always provide clear answers, but which we nevertheless must relate to.
"Human-like technology will affect the future for all of us in ways few can imagine. Knowing the hard dilemmas it poses and discussing them should not be limited to a narrow circle of academics. I tried to write a book that is both fun and dramatic so that people can engage and take a personal stand. Even if some of the dilemmas I present seem both strange and difficult," said Thomas Telving.
Killing Sophia is 137 pages and costs $20 or £16. It is published by University Press of Southern Denmark and available on Amazon by the end August 2022.
Order and read advance praise, US: https://www.amazon.com/Killing-Sophia-Consciousness-Intelligent-University/dp/8740834220
Order and read advance praise, UK: https://www.amazon.co.uk/Killing-Sophia-Consciousness-Intelligent-University/dp/8740834220/
About the Author
Thomas Telving holds an MA in Philosophy and Political Science from the University of Southern Denmark. He is the author of several articles on the ethics of artificial intelligence and robotics and frequently appears as keynote speaker on the same topics. His first book "Killing Sophia – Consciousness, Empathy, and Reason in the Age of Intelligent Robots" was published by University Press of Southern Denmark.
View original content:
SOURCE Telving & Co | https://www.whsv.com/prnewswire/2022/09/06/new-book-humans-are-predisposed-grant-rights-human-like-robots/ | 2022-09-06T11:28:55Z |
WASHINGTON, Sept. 6, 2022 /PRNewswire/ -- A brand new, 7-part podcast miniseries about the lived experience of Parkinson's disease is now available.
The whole series can be found on all major podcast platforms.
The Parkinson's Disease Podcast is a short-format, narrative miniseries that shares important insights and information for the millions of people affected by this condition.
It is part of the Health Unmuted audio library by Mission Based Media, and joins other titles including Alzheimer's Disease Podcast and COPD Podcast. Each miniseries in Health Unmuted focuses on a specific health topic and features the voices of medical professionals, caregivers and, importantly, people living with the condition.
"Parkinson's disease affects over 8 million people worldwide, and advances in diagnostics and treatments can have a tremendous impact on the course of the disease. Our mission is to help people have a deeper understanding about their health, and creating accessible, engaging content is a key part of fulfilling that mission," said Dan Kendall, founder of Mission Based Media and executive producer of Health Unmuted.
The podcast is available for free for listeners and was made possible with support from Altoida, a leading platform to improve drug development, research, and care for patients with neurological diseases including Parkinson's.
"Our team at Altoida is delighted to partner with Mission Based Media to make the Parkinson's Disease Podcast a reality," said Travis Bond, CEO at Altoida. "Our vision to unlock neurology diagnostics at scale and revolutionize brain health management aligns with the podcast's goal of equipping listeners with the information and resources necessary to make informed health decisions. We are thrilled to collaborate with forward thinking partners to share the important stories behind neurological disease, and help pioneer innovative technologies in support."
"Effective and accessible health education is critically important, particularly at the early stages of living with a chronic condition," added Kendall. "Health Unmuted podcasts cover topics ranging from symptoms and diagnosis, through to lifestyle changes and treatment options. Each episode helps combat the misinformation that can lead to confusion, anxiety and poor outcomes."
Find Health Unmuted podcasts on major podcast platforms including Apple Podcasts, Google Podcasts, Amazon Music and Spotify, as well as HealthUnmuted.com. More than 50 other health conditions are planned for Health Unmuted including diabetes, multiple sclerosis, breast cancer and gastrointestinal conditions. Healthcare providers and patient-focused organizations can learn about distribution opportunities by visiting https://partners.healthunmuted.com or emailing partners@healthunmuted.com
About Mission Based Media Ltd.
Mission Based Media is a digital media company and podcast network creating and sharing trustworthy podcasts about health, care and well-being. We have a comprehensive library of podcasts across a broad scope of health topics, conditions and therapies. Our content features insights and information from top health professionals and organizations, and highlights engaging patient stories and perspectives. For more information, visit Health Podcast Network, Digital Health Today and Health Unmuted.
About Altoida, Inc.
Altoida is building the world's leading platform to accelerate and improve drug development, research, and care for patients with neurological diseases. The company's innovative AI-driven approach leverages immersive augmented reality (AR) to evaluate the brain in a comprehensive, real-world mode of functioning using data captured with a standard smartphone or tablet. Altoida's validated and evidence-based digital biomarker platform received FDA Breakthrough Device Designation and is supported by more than 20 years of scientific research and publications in journals like Nature Digital Medicine. Altoida is based in Washington, DC. For more information, visit www.altoida.com. Follow us on LinkedIn and Twitter at @altoida.
View original content to download multimedia:
SOURCE Mission Based Media Ltd. | https://www.whsv.com/prnewswire/2022/09/06/new-health-education-podcast-breaks-down-barriers-people-with-parkinsons-disease/ | 2022-09-06T11:29:02Z |
TORONTO, Sept. 6, 2022 /PRNewswire/ - O3 Mining Inc. (TSX.V: OIII) (OTCQX: OIIIF) ("O3 Mining" or the "Corporation") is pleased to announce the completion of the Pre-Feasibility Study ("PFS"), prepared in accordance with the National Instrument 43-101 – Standards of Disclosure for Mineral Projects ("NI 43-101"), for its 100% owned Marban Engineering gold project, in the world-class mining region of Val-d'Or in Québec, Canada. All figures are expressed in Canadian dollars unless otherwise stated.
- Robust Project Economics: Post-tax net present value ("NPV") (discount rate 5%) of C$463 million and post-tax unlevered internal rate of return ("IRR") of 23.2% using a long-term gold price of US$1,700 per ounce and an exchange rate of C$1.00 = US$0.77.
- Increased production profile: Annual average production increased from 115,000 ounces of gold ("oz Au") in the Preliminary Economic Assessment ("PEA") to 161,000 oz Au supported by a 50% increase in mill throughput, 15% increase in peak mine rate, lower cut-off grade of 0.30 g/t Au compared to 0.35 g/t Au in the PEA, lower strip ratio of 5.1 and increased mill gold recovery.
- Low capital intensity: Initial capital ("CAPEX") of C$435 million including mine preproduction, processing, and infrastructure (roads, power distribution, tailings facility, ancillary buildings, and water management). Capital intensity ratio ("NPV/CAPEX") of 1.1x per dollar invested.
- Competitive cost profile and rapid payback: All-in-Sustaining Cost ("AISC") of US$882 per ounce, a post-tax payback of 3.5 years, with C$1,971 million EBITDA and C$760 million post-tax free cash flow over the life of mine ("LOM").
- Optimization and exploration upside towards Feasibility Study in 2023: Well-funded to perform trade-off studies assessing new technologies including autonomous haulage and trolley assist mine fleet that may impact project economics and reduce environmental footprint. Additionally, O3 Mining will continue with a brownfield exploration program on Marban Engineering including the expansion of all lateral extensions of the near-surface mineralization, unlock the potential in the Hygrade Fold area (North-West of Kierens pit) as well as the downdip extension of the Marban deposit.
Jose Vizquerra, President and CEO, states: "We are pleased with the results of our PFS for the Marban Engineering Project which demonstrates the potential to be the next gold producer in the Abitibi region in Val-d'Or, Quebec, the next step in delivering on our promise to be in production by 2026. With robust economics, Marban has shown itself to be a profitable standalone project. Using a long-term gold price of US$1,700 oz gold, the project has a post-tax unlevered IRR of 23.2% well above the 15% IRR investment threshold used by many larger gold miners, and a post-tax NPV of C$463M as well as an NPV/CAPEX ratio of 1.1x, with an AISC of US$882 per ounce. This is a key achievement in an inflationary environment in which mining companies are seeing higher cost increases. The project has an improved production profile of over 160,000 oz Au annually, for an approximately 10-year life of mine compared with our 2020 PEA. We believe the opportunity to grow Marban remains high, with many mineralized zones not included in the Mineral Resource Estimate, which could add to the LOM, and further improve Marban's economics. Current drilling at the Hygrade Fold area (North-west of Kierens pit) has the potential to add to the current resource within the greater Marban Engineering Project. We have the privilege to be developing Marban in a jurisdiction that has a green-powered grid with 99.6% renewable power and that has a strong carbon policy. Compared to other jurisdictions developing gold mines, Quebec's carbon intensity is one of the lowest in the world. Work on the feasibility-level studies has begun which we expect to complete in 2023. O3 Mining continues to deliver on all milestones and stated goals as we continue our progress towards production, and creating fundamental value with the Marban project for our shareholders and other stakeholders."
O3 Mining Webinar to be held on September 6th, 2022 at 11:00 a.m. EST – REGISTER HERE
Marban Engineering PFS Presentation available here: VRIFY Presentation
The Marban project is located between the cities of Malartic and Val d'Or in the Abitibi gold district of Québec, Canada. The project area contains six past-producing mines, which collectively produced 585,000 ounces of gold between 1959 and 1992. The land package owned by O3 Mining, in the heart of these mining camps, covers 125 square kilometres and is located 12 kilometres from the Canadian Malartic Mine and along the same shear structure as Wesdome Gold Mine's Kiena deposit.
- The PFS is based on the updated Mineral Resource Estimate ("MRE") from March 1, 2022 (see press release).
- The PFS project team was led by Ausenco Engineering Canada Inc. ("Ausenco"), an industry leader in cost-effective design and construction. Ausenco was supported by G Mining Services ("G Mining") and WSP Canada ("WSP").
The economic analysis was performed assuming a 5% discount rate. On a pre-tax basis, the NPV is $775 million, the IRR is 30.2% and the payback period is 2.8 years. On a post-tax basis, the NPV is $463 million, the IRR is 23.2% and the payback period is 3.5 years. A summary of the project economics is listed in Table 1 and shown graphically in the figures below.
Table 1: Summary of project economics
A sensitivity analysis was conducted on the base case after-tax NPV and IRR of the Marban project, using the following variables: gold price, total CAPEX (initial + sustaining), total operating cost, and US$:C$ exchange rate. The tables below provide a summary.
Table 2a: Post-Tax NPV (5%) Sensitivity, C$M
Table 2b: Post-Tax IRR Sensitivity
The PFS is based on the Open Pit Indicated portion of the Marban Mineral Resource Estimate, as published in "Marban Engineering NI 43-101 Technical Report & Mineral Resource Estimate".
The Proven and Probable Ore Reserves for the Marban project are estimated at 56.4 Mt at an average grade of 0.91 g/t Au for 1,807 Koz of contained gold at 0.3 g/t Au cut-off grade as summarized in Table 3. The Mineral Reserve is included within the Mineral Resource.
Table 3: Open-Pit Mineral Reserve (effective date August 17, 2022)
The Marban Engineering project will be mined with a conventional drill, blast, and haul setup. The project is split into three mining pit groups: Marban, Norlartic, and Kierens which are further split into nine sub pits and phases.
- The peak mining rate is 52.3 million tonnes per year over a mine life of 9.6 years.
- A total of 56.4 million tonnes (Mt) of ore will be mined at an average grade of 0.91 g/t, with a total of 286.1 Mt of waste mined, resulting in a stripping ratio of 5.07 tonnes waste per tonne of ore.
- The primary production equipment includes 16 m3 electric production shovels and 150 tonne off highway mining trucks augmented by a smaller overburden focused secondary fleet of 100 tonne trucks and 5 m3 excavators.
- Stockpile rehandling is minimal with a peak inventory of low-grade material consisting of 0.5 Mt in Production Year 7.
Special considerations are made in the mine plan to mine out the smaller northern pits (Kierens and Norlartic) early to allow in-pit deposition of the processing plant tailings and reduce the project footprint.
Table 4: PFS Mine Plan Production Summary
Metallurgical testing was completed at Base Metallurgical Laboratories ("BaseMet") (independent of O3 Mining) in Q1 2022. The gravity leach test results were analyzed to provide recovery models for use with the mine production schedule.
In addition to the predicted extraction, plant losses include:
- Soluble losses of 0.01 g/t Au
- Carbon losses of 40 g/t
- Fine carbon assays of 80 g/t Au for carbon losses
- Other plant losses of 0.2% Au
Recoveries for ore mined from the Marban and Kierens pits were estimated as 94.9% after plant losses based on the recovery model derived from the gravity leach test results. The Norlartic pit gravity leach tests results provided an estimated leach extraction as a function of head grade, outlined in Table 6.
Table 6: PFS Calculated Recoveries (Gold)
The process flowsheet was designed based on historical and recent test work carried out by Base Metallurgical Laboratories in 2022. The 2022 test work program investigated comminution (Bond Ball Mill Work Index tests), gravity separation, leach optimization, leach variability test work, cyanide detoxification, solid-liquid separation, and pressure filtration. The results indicate that the samples were of medium hardness, with Bond Ball Mill Work Index results ranging from 9.6 to 14.6 kWh/t, and the 75th percentile of the samples tested was 14.1 kWh/t. Historical comminution data was utilized for the balance of crushing and grinding circuits design.
Based on a mine-to-mill analysis, the processing plant capacity has been increased to 6.0 million tonnes per year or 17,900 tonnes per day at 92% availability.
The process design for the project consists of:
- Two-stage crushing, consisting of a primary jaw crusher and a secondary cone crusher with material handling equipment.
- Grinding of crushed material to 80% passing size of 85 μm with a 9.14 m diameter by 4.88 m length SAG mill and a 6.71 m diameter by 10.2 m length ball mill in a closed circuit with hydrocyclones. The SAG mill and ball mill are equipped with 8.0 MW and 8.7 MW motors, respectively.
- A gravity concentration circuit is included in the grinding area. Gravity concentrate will feed intensive cyanidation and will be recovered by electrowinning. Gold recovery of 24.6% is expected from the gravity concentrate.
- Leaching and adsorption circuit includes four leach tanks and six carbon-in-pulp (CIP) tanks, for a total leach and adsorption circuit retention time of 24 hours.
- Cyanide destruction using an SO2/air system on the final tailings slurry.
- Final tails from the cyanide destruction circuit will be thickened and discharged to the tailings storage facility.
The tailings management design was completed by Ausenco, and it is based on conventional thickened tailings storage. There are two storage facilities for the project:
- An initial "starter" tailings storage facility for the first 3.5 years of mill production. This facility is of ring dyke construction type and is located immediately south of the process plant. The design incorporates three phases to build the embankment over the life of the facility. Ultimate storage capacity of this facility is 13.2M m3 (19.3 Mt).
- In-pit deposition in the exhausted Norlartic pit, following the first 3.5 years of mill production through the end of the mine life. Total storage capacity of this pit is 25.4M m3 (37.1 Mt).
The total initial (pre-production) capital cost for the Marban project is estimated to be C$435 million including allowances for contingency of C$44 million. Sustaining costs are estimated to be C$283 million over the life of mine.
Capital and sustaining costs were compiled by Ausenco from the following sources:
- Mining initial capital costs were developed by G Mining, based on the final mine plan. Pre-production of one year was assumed with an owner-purchased and operated fleet.
- Mining sustaining capital costs were developed by G Mining and include major equipment repairs and equipment down payments and loan repayments.
- Processing, infrastructure, project delivery and project indirects were developed by Ausenco, and are inclusive of 6 Mtpa conventional leach/CIP processing plant, power substation, tailings facility initial construction, diversion of Keriens Creek, realignment of Chemin Gervais and other required infrastructure.
- Sustaining capital costs for infrastructure consist of lease repayments for mobile equipment, additional truck shop bays, permanent stockpile cover for the ore reclaim stockpile, two lifts for the initial tailings facility and overland piping installation for in-pit tailings deposition in production Year 4.
Table 7: Initial and Sustaining Capital Costs (C$M)
Operating costs have been compiled based on the following sources and assumptions:
- Mining unit costs have been estimated by G Mining based on 2022 quotes and database costs.
- Processing units costs have been estimated by Ausenco from first principles, using 2022 prices for major reagents and media.
- G&A costs are based on benchmark salary tables for staff positions and other costs from Ausenco databases. Due to the location of the project close to the town of Val D'Or, a camp and general administration offices are not included in the project scope; skilled workers are available locally and offices will be rented in Val D'Or for administrative staff.
Table 8: Total Life of Mine Operating Costs
In addition to applicable regulations, the Marban project will require social acceptability. Early information and consultation meetings have been held with local communities, First Nations Communities, local, provincial, and federal governmental authorities to initiate collaborative work to obtain social acceptability of the project.
The project will be subject to the regulations under the Canadian Impact Assessment Act and Québec's Environmental Quality Act. The environmental baseline studies are well advanced which will permit the initiation of the environmental impact studies.
O3 Mining will continue to regularly meet stakeholders as project milestones are reached and will be presenting and discussing the PFS results with the host communities.
Following the release of this PFS, O3 Mining will move the project forward towards the necessary bridging work for the commencement of the feasibility-level studies. The Corporation is well-funded to continue the drilling program on Marban Engineering including the expansion of all lateral extensions of the near-surface mineralization. Additionally, the O3 Mining will be looking to unlock the potential in the Hygrade Fold area (North-West of Kierens pit) as well as the downdip extension of the Marban deposit. Furthermore, an initial project description will be filed with the environmental agencies to initiate the impact process.
Additional trade-off studies will be completed during the bridging phase to the Feasibility Study assessing new technologies including autonomous haulage and trolley assist mine fleet that may impact project economics and environmental footprint.
O3 Mining will conduct a webinar to discuss the positive PFS results for Marban Project.
Date and Time: Tuesday, September 6th, 2022, 11:00 a.m. EST
Registration: O3 Mining Marban PFS Update
Details: Participants will be able to submit questions. A recording of the webinar will be made available on o3mining.com following the webinar. If you have any technical difficulties, please email info@o3mining.com
The scientific and technical information contained in this news release has been reviewed and approved by Mr. Louis Gariépy, P.Geo (OIQ #107538), Vice President Exploration of O3 Mining, who is a "qualified person" within the meaning of NI 43-101.
Half-core samples are shipped to Agat laboratory in Val-d'Or, Québec and Mississauga, Ontario for assaying. The core is crushed to 75% passing -2 mm (10 mesh), a 250 g split of this material is pulverized to 85% passing 75 microns (200 mesh) and 50 g is analyzed by Fire Assay (FA) with an Atomic Absorption Spectrometry (AAS) finish. Samples assaying >10.0 g/t Au are re-analyzed with a gravimetric finish using a 50 g charge. Commercial certified standard material and blanks are systematically inserted by O3 Mining's geologists into the sample chain after every 18 core samples as part of the Quality Assurance, Quality Control ("QA/QC") program. Third-party assays are submitted to other designated laboratories for 5% of all samples.
Historic assays have been validated through extensive validation procedures and analyses. Re-assaying of historic drilling is ongoing with re-assayed values included in the resource estimate. Data prior to 1984 that has not been re-assayed has not been included in the resource estimate due to lack of QA/QC. The drill program design, QA/QC and interpretation of results are performed by qualified persons employing a QA/QC program consistent with NI 43-101 and industry best practices.
The Corporation has included certain non-IFRS financial measures in this news release, such as initial capital cost, sustaining capital cost, total capital cost, AISC, and capital intensity, which are not measures recognized under IFRS and do not have a standardized meaning prescribed by IFRS. As a result, these measures may not be comparable to similar measures reported by other corporations. Each of these measures used are intended to provide additional information to the user and should not be considered in isolation or as a substitute for measures prepared in accordance with IFRS.
Non-IFRS financial measures used in this news release and common to the gold mining industry are defined below.
Total Cash Costs and Total Cash Costs per Ounce
Total cash costs are reflective of the cost of production. Total cash costs reported in the PFS include mining costs, processing, general and administrative costs of the mine, off-site costs, refining costs, transportation costs and royalties. Total cash costs per ounce is calculated as total cash costs divided by payable gold ounces.
AISC and AISC per Ounce
AISC (all-in sustaining cost) is reflective of all of the expenditures that are required to produce an ounce of gold from operations. AISC reported in the PFS includes total cash costs, sustaining capital, closure costs and salvage, but excludes corporate general and administrative costs. AISC per ounce is calculated as AISC divided by payable gold ounces.
O3 Mining Inc., an Osisko Group company, is a gold explorer and mine developer on the road to produce from its highly prospective gold camps in Québec, Canada. O3 Mining benefits from the support, previous mine-building success, and expertise of the Osisko team as it grows towards being a gold producer with several multi-million-ounce deposits in Québec.
O3 Mining is well-capitalized and owns a 100% interest in all its properties (66,000 hectares) in Québec. O3 Mining trades on the TSX Venture Exchange (TSXV: OIII) and OTC Markets (OTCQX: OIIIF). The Corporation is focused on delivering superior returns to its shareholders and long-term benefits to its stakeholders. Further information can be found on our website at https://o3mining.com
This news release contains "forward-looking information" within the meaning of the applicable Canadian securities legislation that is based on expectations, estimates, projections, and interpretations as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, interpretations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "interpreted", "management's view", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information and are intended to identify forward-looking information. This forward-looking information is based on reasonable assumptions and estimates of management of the Corporation, at the time it was made, involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the companies to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Although the forward-looking information contained in this news release is based upon what management believes, or believed at the time, to be reasonable assumptions, the parties cannot assure shareholders and prospective purchasers of securities that actual results will be consistent with such forward-looking information, as there may be other factors that cause results not to be as anticipated, estimated or intended, and neither the Corporation nor any other person assumes responsibility for the accuracy and completeness of any such forward-looking information. The Corporation does not undertake, and assumes no obligation, to update or revise any such forward-looking statements or forward-looking information contained herein to reflect new events or circumstances, except as may be required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
View original content to download multimedia:
SOURCE O3 Mining Inc. | https://www.whsv.com/prnewswire/2022/09/06/o3-mining-completes-pre-feasibility-study-marban-engineering-with-post-tax-npv-c463-million-unlevered-irr-232-annual-production-over-160koz-gold/ | 2022-09-06T11:29:10Z |
CAMBRIDGE, Mass., Sept. 6, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (NASDAQ: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform, today announced that management will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022, at 10 a.m. ET.
A live webcast of the fireside chat will be available on the Investors & Media section of the Company's website at www.omegatherapeutics.com. An archived replay of the fireside chat will be available on the same website for approximately 90 days.
Omega Therapeutics, founded by Flagship Pioneering, is a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines. The company's OMEGA Epigenomic Programming™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth, and differentiation to cell death. Using a suite of technologies, paired with Omega's process of systematic, rational, and integrative drug design, the OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega's modular and programmable mRNA medicines, Omega Epigenomic Controllers™, are designed to target specific epigenomic loci within insulated genomic domains, EpiZips, from amongst thousands of unique, mapped, and validated genome-wide DNA-sequences, with high specificity to durably tune single or multiple genes to treat and cure diseases through Precision Genomic Control™. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases, including alopecia.
For more information, visit omegatherapeutics.com, or follow us on Twitter and LinkedIn.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our participation in upcoming events and presentations and expectations regarding our business strategy and product candidate pipeline, including efficacy, trial design, regulatory submissions, approvals and timing thereof, and initiation of preclinical studies and advancement of multiple preclinical development programs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the novel technology on which our product candidates are based makes it difficult to predict the time and cost of preclinical and clinical development and subsequently obtaining regulatory approval, if at all; the substantial development and regulatory risks associated with epigenomic controller machines due to the novel and unprecedented nature of this new category of medicines; our limited operating history; the incurrence of significant losses and the fact that we expect to continue to incur significant additional losses for the foreseeable future; our need for substantial additional financing; our investments in research and development efforts that further enhance the OMEGA platform, and their impact on our results; uncertainty regarding preclinical development, especially for a new class of medicines such as epigenomic controllers; the fact that our product candidates may be associated with serious adverse events, undesirable side effects or have other properties that could halt their regulatory development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences; the impact of increased demand for the manufacture of mRNA and LNP based vaccines to treat COVID-19 on our development plans; difficulties manufacturing the novel technology on which our OEC candidates are based; our ability to adapt to rapid and significant technological change; our reliance on third parties for the manufacture of materials; our ability to successfully acquire and establish our own manufacturing facilities and infrastructure; our reliance on a limited number of suppliers for lipid excipients used in our product candidates; our ability to advance our product candidates to clinical development; and our ability to obtain, maintain, enforce and adequately protect our intellectual property rights. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Media contact:
Jason Braco
LifeSci Communications
646.751.4361
jbraco@lifescicomms.com
Investor contact:
Kevin Murphy
Argot Partners
212.600.1902
ArgotOmega@argotpartners.com
View original content to download multimedia:
SOURCE Omega Therapeutics | https://www.whsv.com/prnewswire/2022/09/06/omega-therapeutics-participate-hc-wainwright-24th-annual-global-investment-conference/ | 2022-09-06T11:29:17Z |
Supplemental Draft Environmental Impact Statement publication anticipated in Q4 2022.
The Stibnite Gold Project is designed to responsibly source gold and the only domestically mined source of antimony, essential for clean energy and defense supply chains.
BOISE, Idaho, Sept. 6, 2022 /PRNewswire/ - Perpetua Resources Corp. (Nasdaq: PPTA) (TSX: PPTA) ("Perpetua Resources" or "Perpetua" or the "Company") announced today that the Company expects the United States Forest Service ("USFS") to publish a Supplemental Draft Environmental Impact Statement ("SDEIS" or "Supplemental DEIS") for public review in the fourth quarter of 2022. The USFS has confirmed that cooperating agency review is complete and the SDEIS is currently progressing through final reviews in Washington D.C. The USFS is concurrently working with Idaho tribes to inform meaningful consultation.
Perpetua is confident the additional evaluation contained within the SDEIS will show improved environmental outcomes that directly address issues raised during the public review of the 2020 Draft Environmental Impact Statement ("DEIS") and believes the additional analysis and detailed review should lead to the USFS designating a preferred alternative in the SDEIS. This key designation would further narrow the scope of review for the remainder of the process. Nearly two years of additional and comprehensive scientific analysis by the USFS and cooperating agencies, combined with the additional public review of the SDEIS, fortify the rigorous process mandated by the National Environmental Policy Act ("NEPA").
"We remain eager to show how our project improvements are designed to leave water quality and overall habitat in this historic mining district in better shape than they are in today," said Laurel Sayer, President and CEO of Perpetua Resources. "Today, more than ever, a secure source of domestically produced antimony is essential for our national security and energy future. Perpetua is ready to be the responsible solution our country needs."
The Stibnite Gold Project in central Idaho is designed to restore environmental conditions at a legacy mine site while responsibly developing one of the highest-grade, open pit gold resources in the United States and becoming the only domestically mined source of the critical mineral antimony. Antimony is essential to defense, technology and energy products and is a listed critical mineral by the United States Geological Survey (USGS) and a mineral of interest by the Department of Defense (DOD) and Defense Logistics Agency (DLA).
Antimony is critical to the U.S. defense industrial supply chain for materials ranging from ammunition to night vision goggles. Without a domestically mined source, the United States is reliant on nations like China, Russia and Tajikistan that control 90% of the global supply. The Stibnite Gold Project has one of the world's largest independent reserves of antimony and is positioned to provide a secure source of antimony for defense and commercial needs.
Attention to antimony, and related defense materials, is growing amid heightened geopolitical tension and supply chain disruptions. Last week, military leaders voiced concern that the war in Ukraine has strained ammunition supplies. This comes just after Congress called for increased attention to antimony in the National Defense Authorization Act (NDAA).
Congress recently authorized a 10% production tax credit for certain critical minerals including antimony in the Inflation Reduction Act. Antimony is a key component for the long-duration grid storage battery technology developed by Ambri. The Massachusetts-based company recently announced the expansion of its U.S. manufacturing capacity along with a renewable energy demonstration project with Xcel Energy in Colorado. In August 2021, Perpetua Resources entered into a partnership agreement with Ambri to provide antimony from the Stibnite Gold Project for battery production.
Perpetua Resources Corp., through its wholly owned subsidiaries, is focused on the exploration, site restoration and redevelopment of gold-antimony-silver deposits in the Stibnite-Yellow Pine district of central Idaho that are encompassed by the Stibnite Gold Project. The Project is one of the highest-grade, open pit gold deposits in the United States and is designed to apply a modern, responsible mining approach to restore an abandoned mine site and produce both gold and the only mined source of antimony in the United States. Further advancing Perpetua Resources' ESG and sustainable mining goals, the Project will be powered by the lowest carbon emissions grid in the nation and a portion of the antimony produced from the Project will be supplied to Ambri, a US-based company commercializing a low-cost liquid metal battery essential for the low-carbon energy transition. In addition to the company's commitments to transparency, accountability, environmental stewardship, safety and community engagement, Perpetua Resources adopted formal ESG commitments which can be found here.
Statements contained in this news release that are not historical facts are "forward-looking information" or "forward-looking statements" (collectively, "Forward-Looking Information") within the meaning of applicable Canadian securities legislation and the United States Private Securities Litigation Reform Act of 1995. Forward-Looking Information includes, but is not limited to, disclosure regarding possible events, next steps and courses of action including environmental clean up actions by us and our contractors; our ability to comply with and obtain permits related to the Stibnite Gold Project; actions to be taken by the USFS, the State of Idaho and other government agencies and regulatory bodies and the expected results of their review; plans with respect to the issuance of an SDEIS and any designations thereunder; the anticipated timing for release of the SDEIS; predictions regarding improvements to water quality and other environmental conditions at the site; reduction of the Project footprint and the anticipated benefits and other effects thereof; our and Ambri, Inc.'s ability to perform under the supply agreement, which agreement is subject to certain conditions, including identification of one or more refiners to transform our antimony concentrate into antimony metal, and mutual agreement on certain material terms, including volume and pricing. In certain cases, Forward-Looking Information can be identified by the use of words and phrases or variations of such words and phrases or statements such as "anticipate", "expect" "plan", "likely", "believe", "intend", "forecast", "project", "estimate", "potential", "could", "may", "will", "would" or "should". In preparing the Forward-Looking Information in this news release, Perpetua Resources has applied several material assumptions, including, but not limited to, assumptions that the current exploration, development, environmental and other objectives concerning the Stibnite Gold Project can be achieved and that its other corporate activities will proceed as expected; that we and Ambri will be able to agree on the terms of the Ambri agreement; that the general business and economic conditions will not change in a materially adverse manner and that permitting and operations costs will not materially increase; and that the review process under the NEPA (including the review process involving the USFS, any review process by the State of Idaho and other agencies and regulatory bodies and consultation with Idaho tribes) as well as the public review process and SDEIS will proceed in a timely manner and as expected; and that all requisite information will be available in a timely manner. Forward-Looking Information are based on certain material assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Perpetua Resources to be materially different from any future results, performance or achievements expressed or implied by the Forward-Looking Information. Such risks and other factors include, among others, changes in laws and regulations and changes in the application of standards pursuant to existing laws and regulations which may result in unforeseen results in the permitting process; uncertainty surrounding input to be received from regulators and community stakeholders; risks related to unforeseen delays in the review process including availability of personnel from the USFS, State of Idaho and other stated, federal and local agencies and regulatory bodies (including, but not limited to, future US government shutdowns); risks related to opposition to the Project; risks related to increased or unexpected costs in operations or the permitting process; risks that estimates used in budgeting and financial statements may prove to be incorrect; risks related to the outcome of litigation and potential for delay of the Project, as well as those factors discussed in Perpetua Resources' public filings with the U.S. Securities and Exchange Commission (the "SEC") and its Canadian disclosure record. Although Perpetua Resources has attempted to identify important factors that could affect Perpetua Resources and may cause actual actions, events or results to differ materially from those described in Forward-Looking Information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that Forward-Looking Information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on Forward-Looking Information. For further information on these and other risks and uncertainties that may affect the Company's business, see the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's filings with the SEC, which are available at www.sec.gov and with the Canadian securities regulators, which are available at www.sedar.com. Except as required by law, Perpetua Resources does not assume any obligation to release publicly any revisions to Forward-Looking Information contained in this news release to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
View original content:
SOURCE Perpetua Resources Corp. | https://www.whsv.com/prnewswire/2022/09/06/perpetua-resources-announces-stibnite-gold-project-moves-toward-public-review/ | 2022-09-06T11:29:24Z |
- From 24th September to 13th November, PortAventura World will be celebrating the longest edition in its history with top new additions such as the first Halloween passage of terror for children, Trick or Treat, and MTV Hor-Rock in Texas, a spooky musical circuit.
- The 12,000 pumpkins that will decorate PortAventura World are locally sourced and will be used after Halloween as food for the animals from nearby farms as an example of circular economy.
- Last year more than 800,000 people visited PortAventura World during Halloween, and the 2022 edition it is expected to surpass this number and the turnover of previous years
TARRAGONA, Spain, Sept. 6, 2022 /PRNewswire/ -- The longest and most terrifying season in PortAventura World's history, which will last for more than 50 days, is here with big new additions. From 24th September until 13th November, thrill-seekers will be able to visit 6 passages of terror, as well as a wide range of shows involving more than 200 artists with almost 200 hours of shows per week. One of the most special new additions is the first children's horror show, Trick or Treat, and MTV Hor-Rock in Texas. The resort will also celebrate its black edition on the night of 8th October at MTV Hor-Rock Night.
For David García Blancas, General Business Manager at PortAventura World, "Halloween is one of the most anticipated times of the year for our customers and this was proven last year with our more than 800,000 visitors. This year we will be celebrating one of the longest seasons ever, with more than 50 days to have a scarily great time, with the aim of reaching record figures yet again and surpassing the revenues of previous years".
Sustainability and good environmental practices will also play their part during the season. As has become tradition, every corner of the park will be decorated with over 12,000 pumpkins, which will weigh more than 120,000 kg in total and will be grown on a farm in the Penedés region near the resort, following the circular economy and zero waste strategy implemented by the company. Halloween will also be celebrated in a special way at PortAventura's Village Dreams, the PortAventura Foundation's play area where families with children with serious illnesses are staying as part of their emotional recovery therapy.
Photo: https://mma.prnewswire.com/media/1892218/Halloween_celebration.jpg
View original content to download multimedia:
SOURCE PortAventura World | https://www.whsv.com/prnewswire/2022/09/06/portaventura-world-is-showcasing-its-longest-most-sustainable-halloween-celebration-yet-with-two-new-passages-terror/ | 2022-09-06T11:29:30Z |
CARMIEL, Israel, Sept. 6, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that the Company will present at the H.C. Wainwright 24th Annual Global Investment Conference, a hybrid conference. The conference is being held on September 12-14, 2022 at the Lotte New York Palace Hotel in New York City. Virtual participation will also be available.
Dror Bashan, the Company's President and Chief Executive Officer, will provide a corporate overview at the conference. A webcast of the presentation will be available commencing on Monday, September 12, 2022 at 7:00 AM, Eastern time, and will be archived.
Webcast Details:
The conference will be webcast live from the Company's website and will be available via the following links:
Company Link: https://protalixbiotherapeutics.gcs-web.com/events0
Webcast Link: https://journey.ct.events/view/326342b0-083d-4eca-81f7-f93cc78d3394
The Company's management will participate in one-on-one meetings with investors who are registered to attend the conference. If you are an institutional investor and would like to attend the Company's presentation, registration for the conference is available at https://hcwevents.com. Once your registration is confirmed, you will be prompted to log onto the conference website to request a one-on-one meeting with the Company.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.
Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.
Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human α–Galactosidase–A protein for the treatment of Fabry disease; alidornase alfa or PRX–110, for the treatment of various human respiratory diseases or conditions; PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX–119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.
Investor Contact
Chuck Padala, Managing Director
LifeSci Advisors
646-627-8390
chuck@lifesciadvisors.com
Logo: https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg
View original content:
SOURCE Protalix BioTherapeutics, Inc. | https://www.whsv.com/prnewswire/2022/09/06/protalix-biotherapeutics-present-hc-wainwright-24th-annual-global-investment-conference/ | 2022-09-06T11:29:37Z |
Premium Guard Announces Innovative Application Lookup Capabilities
NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Premium Guard Inc. (PGI) www.premiumguard.com, the first-to-market leader and pioneer in aftermarket automotive filtration solutions, is pleased to announce the inclusion of "Push-To-Talk" (PTT) parts lookup capabilities in their online catalogs and mobile apps. This cutting-edge parts lookup technology is unique in the filtration segment with Premium Guard and ECOGARD brands the first to introduce this capability in the automotive filtration market. The inclusion of PTT is a significant enhancement in data accessibility and reflects the company's deep understanding of the professional installer and how to make their jobs easier. With PTT included, Premium Guard is offering a comprehensive catalog solution that is dynamic and easy to use allowing customers one touch access to the company's extensive parts catalogs.
"When we see technological innovation in other facets of our lives, we always ask ourselves 'How could this benefit our customers?'" said Anan Bishara, CEO of Premium Guard. "We see Push-to-Talk as yet another tool to help simplify the way our customers look up our products. Incorporating Push-to-Talk accessibility in our catalogs for our family of brands is an example of how we deliver on our core principles of putting customers first and being ahead of the market in service and technology. We're more committed than ever to offering a complete product and service solution for oil change service."
"Push-to-Talk is another key feature of our catalog program that distinguishes Premium Guard and our family of brands from our competitors" say John Etheridge, Director of Product Management. "And we're not done, we are always looking for opportunities to bring more innovative catalog and parts lookup tools to market."
Push-to Talk functionality is now included at www.pgfilters.com, www.ecogard.com, and in the Premium Guard and ECOGARD apps found in the App Store and Google Play. Push-to-Talk capabilities will soon be rolled out to Premium Guard supplied private label programs and the PWR Steer website and app.
Premium Guard Inc. (PGI) specializes in designing, manufacturing, and distributing products for automotive, diesel, powersport, and specialty filter markets. Headquartered in New York City with a main distribution center in Memphis TN, Premium Guard Inc. is keenly focused on providing customers with industry leading service, complete filtration solutions, best-in-class-quality products, and leading application coverage. www.premiumguard.com
View original content to download multimedia:
SOURCE Premium Guard Inc. | https://www.whsv.com/prnewswire/2022/09/06/push-to-talk-automotive-aftermarket/ | 2022-09-06T11:29:44Z |
XIAMEN, China, Sept. 6, 2022 /PRNewswire/ -- Qudian Inc. ("Qudian" or "the Company" or "We") (NYSE: QD), a consumer-oriented technology company in China, today announced its unaudited financial results for the quarter ended June 30, 2022.
Second Quarter 2022 Operational Highlights:
- Number of outstanding borrowers[1] from loan book business as of June 30, 2022 decreased by 6.7% to 2.4 million from 2.6 million as of March 31, 2022, as a result of the Company's deployment of a conservative and prudent strategy
- Total outstanding loan balance from loan book business[2] decreased by 54.4% to RMB0.7 billion as of June 30, 2022 from RMB1.5 billion as of March 31, 2022
- Amount of transactions from loan book business for this quarter decreased by 31.0% to RMB1.5 billion from the first quarter of 2022
- Weighted average loan tenure for our loan book business was 2.0 months for this quarter, compared to 2.3 months for the first quarter of 2022
Second Quarter 2022 Financial Highlights:
- Total revenues were RMB105.4 million (US$15.7 million), compared to RMB412.1 million for the same period of last year
- Net loss attributable to Qudian's shareholders was RMB61.3 million (US$9.2 million), compared to an income of RMB269.9 million for the same period of last year, or net loss of RMB0.25 (US$0.04) per diluted ADS
- Non-GAAP net loss attributable to Qudian's shareholders[3] was RMB52.8 million (US$7.9 million), compared to non-GAAP net income attributable to Qudian's shareholders of RMB282.5 million for the same period of last year, or Non-GAAP net loss of RMB0.21 (US$0.03) per diluted ADS
Recent Developments
Loan Book Business
After careful evaluation, the Company has decided to cease new credit offerings as of September 6, 2022. As of August 31, the Company's total outstanding loan balance from the loan book business was below RMB500 million, with an average loan tenure of approximately three months. The existing outstanding loans continue to generate revenue and will be collected in an orderly manner. As a result of this business adjustment, the Company expects its revenues to significantly decline in the coming quarters compared with the previous quarters.
QD Food Business
After assessing current market conditions, the Company has decided to streamline its QD Food business. With the streamlining in QD Food operations, the Company expects to incur employee severance costs, termination fees for business partners and inventory write offs, which may adversely affect its financial condition and results of operations.
Second Quarter Financial Results
Total revenues were RMB105.4 million (US$15.7 million), representing a decrease of 74.4% from RMB412.1 million for the second quarter of 2021.
Financing income totaled RMB66.2 million (US$9.9 million), representing a decrease of 78.8% from RMB311.8 million for the second quarter of 2021, as a result of the decrease in the average on-balance sheet loan balance.
Loan facilitation income and other related income decreased by 47.6% to RMB6.6 million (US$1.0 million) from RMB12.6 million for the second quarter of 2021, as a result of the reduction in transaction volume of off-balance sheet loans during this quarter.
Transaction services fee and other related income decreased to RMB6.5 million (US$1.0 million) from RMB38.5 million for the second quarter of 2021, mainly as a result of the winding down of the transaction service business.
Sales income and others decreased to RMB8.8 million (US$1.3 million), which was mainly attributable to sales income generated by QD Food, from RMB23.7 million for the second quarter of 2021, which was mainly attributable to sales generated by the Wanlimu e-commerce platform. We have wound down the Wanlimu e-commerce platform.
Total operating costs and expenses increased to RMB135.9 million (US$20.3 million) from RMB89.3 million for the second quarter of 2021.
Cost of revenues decreased by 36.7% to RMB41.1 million (US$6.1 million) from RMB64.9 million for the second quarter of 2022, primarily due to the decrease in cost of goods sold as a result of the wind-down of the Wanlimu e-commerce platform, partially offset by the cost of goods sold relating to QD Food.
Sales and marketing expenses increased by 82.6% to RMB53.2 million (US$7.9 million) from RMB29.1 million for the second quarter of 2021, primarily due to the increase in marketing expenses related to QD Food.
General and administrative expenses decreased by 68.1% to RMB34.8 million (US$5.2 million) from RMB109.1 million for the second quarter of 2021, primarily due to the downsizing of the WLM Kids business.
Research and development expenses decreased by 52.1% to RMB18.8 million (US$2.8 million) from RMB39.2 million for the second quarter of 2021, as a result of the decrease in staff head count, which led to a corresponding decrease in staff salaries.
Provision for receivables and other assets was a reversal of RMB28.7 million (US$4.3 million) for the second quarter of 2022, mainly due to the decrease in past-due on-balance sheet outstanding principal receivables compared to the second quarter of 2021
Impairment loss from long-lived assets was RMB45.5 million (US$6.8 million) for this quarter, as a result of the downsizing of the WLM Kids business.
As of June 30, 2022, the total balance of outstanding principal and financing service fee receivables for on-balance sheet transactions for which any installment payment was more than 30 calendar days past due was RMB124.0 million (US$18.5 million), and the balance of allowance for principal and financing service fee receivables at the end of the period was RMB147.2 million (US$22.0 million), indicating M1+ Delinquency Coverage Ratio of 1.2x.
The following charts display the "vintage charge-off rate." Total potential receivables at risk vintage charge-off rate refers to, with respect to on- and off-balance sheet transactions facilitated under the loan book business during a specified time period, the total potential outstanding principal balance of the transactions that are delinquent for more than 180 days up to twelve months after origination, divided by the total initial principal of the transactions facilitated in such vintage. Delinquencies may increase or decrease after such 12-month period.
Current receivables at risk vintage charge-off rate refers to, with respect to on- and off-balance sheet transactions facilitated under the loan book business during a specified time period, the actual outstanding principal balance of the transactions that are delinquent for more than 180 days up to twelve months after origination, divided by the total initial principal of the transactions facilitated in such vintage. Delinquencies may increase or decrease after such 12-month period.
Total potential receivables at risk M1+ delinquency rate by vintage refers to, with respect to on- and off-balance sheet transactions facilitated under the loan book business during a specified time period, the total potential outstanding principal balance of the transactions that are delinquent for more than 30 days up to twelve months after origination, divided by the total initial principal of the transactions facilitated in such vintage. Delinquencies may increase or decrease after such 12-month period.
Current receivables at risk M1+ delinquency rate by vintage refers to, with respect to on- and off-balance sheet transactions facilitated under the loan book business during a specified time period, the actual outstanding principal balance of the transactions that are delinquent for more than 30 days up to twelve months after origination, divided by the total initial principal of the transactions facilitated in such vintage. Delinquencies may increase or decrease after such 12-month period.
Loss from operations was RMB29.4 million (US$4.4 million), compared to income from operations of RMB327.2 million for the second quarter of 2021.
Net loss attributable to Qudian's shareholders was RMB61.3 million (US$9.2 million), or net loss of RMB0.25 (US$0.04) per diluted ADS.
Non-GAAP net loss attributable to Qudian's shareholders was RMB52.8 million (US$7.9 million), or Non-GAAP net loss of RMB0.21 (US$0.03) per diluted ADS.
Cash Flow
As of June 30, 2022, the Company had cash and cash equivalents of RMB3,099.0 million (US$462.7 million) and restricted cash of RMB257.8 million (US$38.5 million). Restricted cash mainly represents security deposits held in designated bank accounts for the guarantee of on-and-off balance sheet transactions. Such restricted cash is not available to fund the general liquidity needs of the Company.
For the second quarter of 2022, net cash used in operating activities was RMB365.7 million (US$54.6 million), mainly due to the decrease in other current and non-current assets. Net cash provided by investing activities was RMB1,454.7 million (US$217.8 million), mainly due to the net proceeds from the redemption of short-term investments. Net cash used in financing activities was RMB227.3 million (US$33.9 million), mainly due to the repurchase of ordinary shares and convertible senior notes.
Update on Share Repurchase and Convertible Bond Repurchase
As of the date of this release, the Company has repurchased all of the convertible senior notes of US$345 million. The Company has cumulatively completed total share repurchases of approximately US$584.8 million.
About Qudian Inc.
Qudian Inc. ("Qudian") is a consumer-oriented technology company in China. The Company historically focused on providing credit solutions to consumers. Qudian is exploring innovative consumer products and services to satisfy Chinese consumers' fundamental and daily needs by leveraging its technology capabilities. In March 2022, it launched a ready-to-cook meal business catering to working-class consumers in China.
For more information, please visit http://ir.qudian.com.
Use of Non-GAAP Financial Measures
We use adjusted net income/loss, a Non-GAAP financial measure, in evaluating our operating results and for financial and operational decision-making purposes. We believe that adjusted net income/loss helps identify underlying trends in our business by excluding the impact of share-based compensation expenses, which are non-cash charges, and convertible bonds buyback income, which is non-cash and non-recurring. We believe that adjusted net income/loss provides useful information about our operating results, enhances the overall understanding of our past performance and future prospects and allows for greater visibility with respect to key metrics used by our management in its financial and operational decision-making.
Adjusted net income/loss is not defined under U.S. GAAP and is not presented in accordance with U.S. GAAP. This Non-GAAP financial measure has limitations as analytical tools, and when assessing our operating performance, cash flows or our liquidity, investors should not consider them in isolation, or as a substitute for net loss /income, cash flows provided by operating activities or other consolidated statements of operation and cash flow data prepared in accordance with U.S. GAAP.
We mitigate these limitations by reconciling the Non-GAAP financial measure to the most comparable U.S. GAAP performance measure, all of which should be considered when evaluating our performance.
For more information on this Non-GAAP financial measure, please see the table captioned "Unaudited Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.
Exchange Rate Information
This announcement contains translations of certain RMB amounts into U.S. dollars ("US$") at specified rates solely for the convenience of the reader. Unless otherwise stated, all translations from RMB to US$ were made at the rate of RMB6.6981 to US$1.00, the noon buying rate in effect on June 30, 2022 in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or US$ amounts referred could be converted into US$ or RMB, as the case may be, at any particular rate or at all.
Statement Regarding Preliminary Unaudited Financial Information
The unaudited financial information set out in this earnings release is preliminary and subject to potential adjustments. Adjustments to the consolidated financial statements may be identified when audit work has been performed for the Company's year-end audit, which could result in significant differences from this preliminary unaudited financial information.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the expectation of its collection efficiency and delinquency, contain forward-looking statements. Qudian may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Qudian's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Qudian's goal and strategies; Qudian's expansion plans; Qudian's future business development, financial condition and results of operations; Qudian's expectations regarding demand for, and market acceptance of, its products; Qudian's expectations regarding keeping and strengthening its relationships with customers, business partners and other parties it collaborates with; general economic and business conditions; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in Qudian's filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and Qudian does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
For investor and media inquiries, please contact:
In China:
Qudian Inc.
Tel: +86-592-596-8208
E-mail: ir@qudian.com
The Piacente Group, Inc.
Jenny Cai
Tel: +86 (10) 6508-0677
E-mail: qudian@tpg-ir.com
In the United States:
The Piacente Group, Inc.
Brandi Piacente
Tel: +1-212-481-2050
E-mail: qudian@tpg-ir.com
View original content to download multimedia:
SOURCE Qudian Inc. | https://www.whsv.com/prnewswire/2022/09/06/qudian-inc-reports-second-quarter-2022-unaudited-financial-results/ | 2022-09-06T11:29:50Z |
Health & Wellness Advocate, Entrepreneur, Podcast Host and Mother Assumes Role of Brand
Spokesperson For Groundbreaking Natural Stress Management Supplement That Harnesses the
Power of Cortisol Optimization
BOULDER, Colo., Sept. 6, 2022 /PRNewswire/ -- Rebalance Health, Inc., the health and wellness innovators emphasizing stress and cortisol's critical role in optimizing human performance, today announced former professional volleyball player, fitness guru, and New York Times best-selling author Gabrielle Reece has signed on as a brand advocate user and ambassador.
An inspirational health leader who has made a career out of achieving the highest level of physical and emotional well-being, Reece is well known for the high standard she places on using only the most-effective, natural supplements. As is the case with any product with which she associates herself, Reece conducted a diligent and relentless research and trial process before becoming a believer in the power of Rebalance's stress management system and the wide range of benefits it delivers.
"I've been a competitive athlete my entire life and tried everything under the sun, but what Rebalance is doing with its complete cortisol modulation solution is a game-changer, and I'm thrilled to partner with a company that's truly at the forefront of innovation. I am impressed with the ingredients and results I have felt over the past several months," said Reece. "The Directline™ delivery method is a game changer especially with four times the absorption rate in lozenges over supplement pills. I want to help spread the word and educate consumers about the critical role of optimized hormonal balance and its positive impact on things like stress, anxiety, energy, sleep, recovery, mental clarity and so much more. Stress management is arguably the most under-emphasized aspect of performance and overall wellness as we age, especially once we get into our mid-30s and the effects of aging start to show up."
Rebalance designed its groundbreaking system of "SuperceuticalsTM" specifically formulated for men and women, which was an essential component to Reece joining the team. Many "solutions" out there are band aids that address symptoms like low energy, brain fog, or low libido at the surface, whereas Rebalance addresses the root of the symptoms: stress and hormonal imbalance. Reece has been entrenched in the health, wellness, and supplement space for a long time and quickly latched on to Rebalance's approach of functional health, knowing it's critical to address imbalanced cortisol levels in the body. Effective cortisol "stress hormone" management is a critical factor to Reece utilizing the product and ensuring her body is functioning at its peak, especially as she gets older and manages an endless daily to-do list.
"Partnering with someone of Gabby's stature is a true testament to the hard work and determination of our entire team, and most of all, the legitimacy of The Rebalance System™," said Justin Hai, president & CEO, Rebalance Health, Inc. "Gabby's credibility as an athlete and expertise in human performance, not to mention her ever-generous approach to make the most of every part of her life, will be invaluable to the ongoing efforts to educate and raise awareness about the wide-ranging benefits of stress management with Rebalance."
Reece will be featured in a variety of marketing campaigns with an emphasis on engaging an active female demographic in a relatable way.
People looking to master their mojo and optimize daily performance can take a "1 – 2 – Z approach" with The Rebalance System's core products: With Energize + Relax and Dream Catcher™ completing the System. The simple three-step routine begins with Directline delivery patented by Rebalance. One Energize lozenge starts the day, followed by a Relax lozenge in the early evening, and ends with Dream Catcher before bed. Combined, these supplements provide optimal stress managing, cortisol balance throughout the day, in line with the body's circadian rhythm of higher cortisol levels in the morning for peak energy, to lower cortisol levels in the evening for winding down.
The Rebalance System is available now for $144 with free shipping is available at RebalanceHealth.com. This includes a month's supply of Energize + Relax and Dream Catcher and is available via a subscription or one-time trial purchase.
For more information on Rebalance Health's products, please visit www.RebalanceHealth.com or check out Instagram and Facebook.
ABOUT REBALANCE HEALTH
Rebalance Health, Inc. is an optimal health and performance company reinventing how and why we take supplements, aka nutraceuticals. Rebalance Superceuticals™ are their evolutionary, proprietary biotechnology, providing greater delivery of natural ingredients that optimize performance by managing stress and balancing cortisol levels in the body, creating a positive cascading effect on hormones. Led by an esteemed team of medical experts and knowledgeable board members in health & wellness categories, and utilizing its proprietary Directline™ delivery method, Rebalance Health is well equipped to empower people to reach their full and complete potential as a human being.
View original content to download multimedia:
SOURCE Rebalance Health | https://www.whsv.com/prnewswire/2022/09/06/rebalance-health-inc-partners-with-former-professional-volleyball-athlete-fitness-guru-new-york-times-best-selling-author-gabrielle-reece-help-reduce-stress-levels-amp-improve-your-quality-life/ | 2022-09-06T11:29:57Z |
ROCKVILLE, Md., Sept. 6, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:
Morgan Stanley 20th Annual Global Healthcare Conference
Date: Wednesday, September 14, 2022
Fireside chat: 2:55 p.m. ET
Location: Sheraton Hotel, New York, NY
UBS Biotech South Beach Conference 2022
Date: September 29, 2022
Location: Mondrian South Beach, Miami, FL
A live webcast of the Morgan Stanley 20th Annual Global Healthcare Conference fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download multimedia:
SOURCE REGENXBIO Inc. | https://www.whsv.com/prnewswire/2022/09/06/regenxbio-participate-upcoming-investor-conferences/ | 2022-09-06T11:30:05Z |
Acquisition significantly advances Scholastic's literacy platform, integrating assessments, data-driven learning and professional learning with Scholastic's broad portfolio of digital and blended children's content and instructional resources
Provides educators with proven screening, data-driven guidance for instructional planning and research-driven professional learning, aligned to the Science of Reading
Technology-based system proven to raise students' literacy outcomes in grades preK-3, backed by ESSA Tier 1 (strongest) evidence of efficacy
NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Scholastic Corporation (NASDAQ: SCHL), the global children's publishing, education and media company, announced today that it has acquired Learning Ovations, the creator of A2i ("Assessment to Instruction"), a literacy screening, progress monitoring assessment and instructional planning system for classrooms and community organizations. The addition of A2i and the Learning Ovations team will significantly advance the development of Scholastic Education Solutions' literacy platform, which integrates screening and progress monitoring assessments, data-driven instructional planning and professional learning with Scholastic's bestselling books and e-books, print and technology-based learning programs, and other products and services that support children's learning and literacy, both in school and at home. The terms of the transaction were not disclosed.
A2i is backed by over 12 years of rigorous research and more than 2,000 hours of classroom observation by the late Dr. Carol Connor and collaborators at Florida Center for Reading Research (FCRR) and University of California, Irvine. Its robust efficacy has earned A2i the highest efficacy rating possible under the Every Student Succeeds Act (ESSA), is considered a "Tier 1" by the Institute of Education Science, and meets all What Works Clearinghouse standards. The system provides educators with easy-to-administer, data-driven guidance for instructional planning for both small-group and individualized learning in comprehension and decoding. The program embeds highly-effective teaching practices aligned to the Science of Reading, which are supported with robust, virtual professional development. With direct connections to hundreds of thousands of resources that address essential reading skills, soon to include Scholastic's unique instructional and curricular resources, the technology's research-validated and patented algorithms generate unique and differentiated learning pathways, customized to match the reading needs of individual students.
"Carol Connor was a teachers' teacher, dedicated both to helping every child learn to read – regardless of background, disadvantage or learning challenge – and to supporting teachers with tools that are both deeply rigorous and easy to use," said Rose Else-Mitchell, Executive Vice President, President, Scholastic Education Solutions. "We are committed to those same values of equity, engagement and effectiveness at Scholastic. We feel privileged to continue Carol's work and welcome the mission-aligned Learning Ovations team of researchers, practitioners and technologists to Scholastic, as we continue to advance our mission to help kids learn to read, read to learn, and discover the joy in reading."
The integration of Learning Ovations technology and team advances Scholastic's literacy platform, in service to Scholastic's ultimate mission – to get kids reading successfully – which has never been more important than today, after the COVID years of disrupted reading instruction. As schools and districts currently implementing A2i continue to make progress against learning outcomes, the integrated Scholastic Education Solutions team will work over the course of this next year to bring the combined strengths of this acquisition to their shared school and district partners.
About Scholastic
For more than 100 years, Scholastic Corporation (NASDAQ: SCHL) has been encouraging the personal and intellectual growth of all children, beginning with literacy. Having earned a reputation as a trusted partner to educators and families, Scholastic is the world's largest publisher and distributor of children's books, a leading provider of literacy curriculum, professional services, and classroom magazines, and a producer of educational and entertaining children's media. The Company creates and distributes bestselling books and e-books, print and technology-based learning programs for pre-K to grade 12, and other products and services that support children's learning and literacy, both in school and at home. With 15 international operations and exports to 165 countries, Scholastic makes quality, affordable books available to all children around the world through school-based book clubs and book fairs, classroom libraries, school and public libraries, retail, and online. Learn more at www.scholastic.com.
View original content to download multimedia:
SOURCE Scholastic | https://www.whsv.com/prnewswire/2022/09/06/scholastic-acquires-learning-ovations-creator-a2i-literacy-assessment-instructional-system/ | 2022-09-06T11:30:13Z |
Fast implementation enables dramatic increase in referrer integration and loyalty.
WEST PALM BEACH, Fla., Sept. 6, 2022 /PRNewswire/ -- ScriptSender, a leader in enabling secure, one-click communication between healthcare providers, announced today that Chesapeake Medical Imaging has deployed its suite of solutions to optimize continuity of care.
Chesapeake Medical Imaging (CMI) operates 12 outpatient imaging centers in Maryland and integrated more than 85 referring practices within six months of the ScriptSender deployment. After a one-click integration, the referrer can transmit directly to CMI's server, using a virtual printer activated with a simple point-and-click. They can securely send any document—including prescriptions, clinical notes, insurance information, or even an entire patient folder—without the expense and complexity of setting up a VPN or HL7 connection to CMI, and without the inefficiency of faxing.
Tom Marshall, Director of Marketing and Practice Development for CMI, said, "With HL7, this would take years. Even a referrer who doesn't have an EMR can create web orders with ScriptSender technology. There is no cost to our referrers, and we tell them they can always go back to faxing. They never do."
ScriptSender also automates the process of sending for prior authorizations. Data on an order, received directly into CMI's system, triggers the authorization workflow. "This eliminates multiple steps that required manual entry before, and referrers can monitor their orders and authorizations," said Kristen Stokes, Global Project Manager for CMI. "This is a differentiator that enables us to stay competitive in our market."
Stokes also noted that ScriptSender's Image View / Image Share (IVIS) module is "another value-add." Images are embedded into CMI's reports and can be securely and instantly shared with other clinicians, on any platform, through IVIS. "IVIS is the only platform I've seen that enables secure access and image sharing in one click," said Stokes.
Chris Craft, CEO and founder of ScriptSender, said, "CMI understands that breaking down barriers to information sharing is absolutely central to patient care. By taking full advantage of our innovative technology, they are part of the revolution in healthcare. They are fostering a much cleaner, faster, and more accurate collaboration with their referring community, and we're proud to be part of their success."
Chesapeake Medical Imaging was established more than 20 years ago in Annapolis. The vision was to provide a higher quality of care and technology to the patient community, and that aim is now realized in 12 centers across the state. CMI is owned and operated by medical professionals, who leverage their expertise to deliver the most advanced insights to patients and referrers. CMI enjoys an extraordinary reputation, thanks to its commitment to innovative services. For more information, visit www.cmirad.net/
ScriptSender enables secure, one-click communication between healthcare providers. Integration is made easy—without the complexities and costs associated with new interfaces, site-to-site VPN issues, and lost faxes. With a portfolio that includes its flagship product, ScriptSender, plus Web Orders, ReportSender, Image Viewer, and other solutions, ScriptSender aims to enhance relationships among healthcare providers of every size. Our solutions are the result of years of executive leadership in healthcare along with hands-on technical expertise.
For more information, visit www.scriptsender.com.
View original content to download multimedia:
SOURCE ScriptSender | https://www.whsv.com/prnewswire/2022/09/06/scriptsender-streamlines-referrals-prior-authorizations-chesapeake-medical-imaging/ | 2022-09-06T11:30:20Z |
Reliable and cost-effective hybrid delivery of live sports, cultural events and breaking news with simplified production workflow to the widest global audience
LUXEMBOURG and HACKENSACK, N.J., Sept. 6, 2022 /PRNewswire/ -- SES, the leader in global content connectivity solutions, and LiveU, a leading provider of live video and remote production solutions, have partnered to offer an innovative end-to-end solution for live video contribution and distribution combined with premium content aggregation. Customers looking to broadcast live sports, news and other events from stadiums, sports facilities and remote sites now have access to the most reliable and cost-effective creation and delivery of live video to the widest audience – combining satellite, fibre, IP and cellular capabilities.
The fully integrated and turnkey solution based on the latest broadcast technologies gives global customers access to new services and levels of redundancy, including:
- Contribution: LiveU's cost-efficient mobile field units for live video transmission from outdoor locations and venues connected to SES teleports via 4G/5G. This direct connection offers an alternative to an on-site SNG truck or can be used as a redundant back-up feed.
- Aggregation: Customers now have the ability to instantly aggregate their content in the LiveU Matrix IP cloud live video service, including from LiveU's mobile field units and through SES's satellite and IP connections.
- Distribution: Customers can now reach widest possible audiences with simultaneous access to live video distribution over SES's global satellite and IP network and LiveU Matrix's global customers' endpoints.
Customers will also have access to leading sports brands using their preferred technology (IP or satellite) while benefiting from SES's dedicated project management team and LiveU's 24/7 support and service.
One of the first customers, Oranda Singapore, recently deployed the joint solution for live broadcasts of sports climbing in Korea to viewers across EMEA, Americas and Asia using LiveU's portable units with SES's satellite distribution. Floris Molijn, CEO, Oranda, said, "We are thrilled with the level of quality and flexibility that SES and LiveU have provided in finding a tailor-made solution for Oranda that combined SES's knowledge, reach and satellite capability with LiveU's production capabilities to deliver broadcast-quality signals over mobile data networks. Bringing it all together required out of the box thinking to turn around a project with very tight lead times, and SES and LiveU provided 100% reliability of signal distribution."
Michele Gosetti, Head of Sales, Sports & Events at SES, said, "LiveU is a leader in mobile and cloud-based broadcast video technologies, and they perfectly complement our vision of enabling our customers to broadcast live sports and events from nearly anywhere to the widest global audience possible. Combining our expertise in sports and events and our global reach with LiveU's mobile units and cellular technologies gives our customers the ability to deliver high-quality, professional broadcasts whether athletes are climbing up a remote mountain or competing in an urban professional sports stadium."
Ronen Artman, VP Marketing, LiveU said, "The synergy of our joint offering is clear. We are delighted to work with the SES team and already see the benefits, delivering connectivity for our global customers using optimised IP, cellular, satellite, and fibre. As well as delivering a highly cost-effective solution for all sports tiers for greater fan engagement, our solution provides robust broadcast-quality live coverage and back-up. There are also last mile benefits – customers can deliver the aggregated feeds easily in a direct seamless delivery to their Matrix account and receiver. Combining mobile and cloud, with satellite, fibre and IP offers the widest choice of technologies and remote production workflows to customers on a global scale."
An enabler of content and connectivity, SES reaches more than 366 million TV households and a billion people worldwide while broadcasting more than 700 hours of premium sports and live events every day. LiveU is recognised as the brand name in portable live video solutions, used by the world's top news broadcasters and sports organizations.
The joint offering will be presented at IBC2022 in Amsterdam (LiveU stand 7.C30 / SES Meeting Rooms at Hall 1, Balcony suites BS10-BS11).
For further information, please contact:
SES
Suzanne Ong
External Communications
Tel. +352 710 725 500
suzanne.ong@ses.com
LiveU
Joyce Essig
201-906-9367
joyce@liveu.tv
Joss Armitage (Int'l)
+44-7979-908-547
joss@jumppr.tv
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world's only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world's leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES's video network carries ~8,000 channels and has an unparalleled reach of 366 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com.
About LiveU
LiveU is shaping the future of live video, powering video production workflows and cloud services for news, sports, and other verticals. Building on our global market leadership and innovation, LiveU offers the highest quality, reliable and cost-effective end-to-end solutions for all types of live productions – producing more for less. Our broad portfolio ranges from our portable production-level field units and smartphone apps to satellite/cellular hybrid solutions and next-gen cloud-based IP management, orchestration, ingest and distribution solutions. With over 5,000 customers in 150 countries, LiveU's technology is the solution of choice for global broadcasters, sports, and other organizations (including government, education, public safety, enterprise, and production houses), streaming live video to TV, mobile, online, and social media. LiveU is a recipient of Frost & Sullivan's 2021 North America New Product Innovation Award for its LU800 unit and a winner of the 71st Annual Technology & Engineering Emmy® Awards in recognition of its innovation and achievement in Video over Cellular Internet Protocol (VoCIP) technology. For more information, visit www.liveu.tv, or follow us on Twitter, Facebook, YouTube, LinkedIn or Instagram.
View original content to download multimedia:
SOURCE LiveU | https://www.whsv.com/prnewswire/2022/09/06/ses-liveu-launch-integrated-video-contribution-distribution-solution-global-live-events/ | 2022-09-06T11:30:26Z |
Advanced design offers the highest availability, reliability and density, resulting in lower total cost of ownership
HERNDON, Va. and AMSTERDAM, Sept. 6, 2022 /PRNewswire/ -- ST Engineering iDirect, a global leader in satellite communications, will be launching its new MCX8000 multi-carrier satellite gateway at IBC2022 in Amsterdam. The MCX8000 enables broadcasters to cater for every type of broadcast scenario, including high IP encapsulation rates for Over the Top (OTT) applications.
The MCX8000 is a high density, high availability and fully redundant modular system that is suitable for a variety of broadcast use cases. These include direct-to-home broadcasting, where bringing quality content to the largest possible subscriber base with high reliability is key. The MCX8000 Multi-Carrier Satellite Gateway is highly bandwidth efficient, thus maximizing the throughput. It utilizes the DVB-S, DVB-S2, or DVB-S2X standard, assuring highly reliable transport stream delivery.
In Distribution to Towers (DTT), the MCX8000 ideally fits as a satellite front-end, feeding multiple Integrated Receiver Decoders (IRDs), and one MCX8000 in a multi-carrier, multi-stream configuration can be used for hundreds of TV channels.
For OTT delivery, the MCX8000's high IP encapsulation rates and efficient multicast capabilities uniquely position it to provide a path to support the transport of today´s traditional broadcasts and tomorrow´s OTT services.
Built upon the trusted technology of the MDM6100 and MCX7000 software suite capabilities, the MCX8000 offers users higher density and reduced total cost of ownership (TCO) through its unique features:
With its modular design and functionality, users can easily swap out modem boards and power supply units (PSUs) without interrupting the system setup and with no requirement for tools, thus avoiding downtime for repairs and reducing operating expenses (OPEX). In the unlikely event of a failure in one PSU, the other can still power both modem boards and the redundancy switch. The MCX8000 also features ST Engineering iDirect's Clean Channel Technology which ensures the highest bandwidth efficiency, also resulting in lower OPEX. The MCX8000's energy efficient design means that this is also a more environmentally friendly option.
The MCX8000 offers higher availability to broadcasters and by combining two modem boards and a 1+1 redundancy switch in one unit, it becomes a three-in-one solution. This results in lower TCO due to reduced downtime for repairs and low power consumption.
Simple configuration and ease of use is critical, and the MCX8000 features a brand new, intuitive interface designed to streamline the entire process, reducing the requirement for specialist knowledge. This focuses on the logical flow of configuration, from general system settings to configuring inputs/outputs and defining monitoring requirements. The system also benefits from over-the-air updates rather than suspending services to carry them out manually.
"The broadcast sector relies on equipment that will promote maximum uptime, allowing operations to continue at all times," said Sean Yarborough, Vice President of Product Management at ST Engineering iDirect. "Broadcasters are also looking to lower CAPEX and OPEX and be more cost-effective in a competitive landscape. We designed the MCX8000 with the idea of bringing together the best of both worlds - high density and high reliability - through robust design and industry-leading redundancy solutions. The result is a future proof system that combines video and IP multiservice capabilities to support the transport of today´s and tomorrow´s services."
Visit ST Engineering iDirect at IBC2022, September 9-12, in Hall 1, stand #1.A49 where there will be a live demonstration of the MCX8000.
ST Engineering iDirect, a subsidiary of ST Engineering, is a global leader in satellite communications (satcom) providing technology and solutions that enable its customers to expand their business, differentiate their services and optimize their satcom networks. With over 35 years of innovation focused on solving satellite's most critical economic and technology challenges we are committed to shaping the future of how the world connects. The product portfolio, branded under the names iDirect and Newtec, represents the highest standards in performance, efficiency, and reliability, making it possible for its customers to deliver the best satcom connectivity experience anywhere in the world. ST Engineering iDirect is the world's largest TDMA enterprise VSAT manufacturer and is the leader in key industries including broadcast, mobility and military/government. In 2007, iDirect Government was formed to better serve the U.S. government and defense communities. For more information on our platforms please visit www.idirect.net.
View original content to download multimedia:
SOURCE ST Engineering iDirect | https://www.whsv.com/prnewswire/2022/09/06/st-engineering-idirect-introduces-mcx8000-multi-carrier-satellite-gateway-future-broadcasting/ | 2022-09-06T11:30:32Z |
AI-based software delivers actionable insights for manufacturers to optimize and maintain production output quality
WOBURN, Mass., Sept. 6, 2022 /PRNewswire/ -- SymphonyAI Industrial announced today the launch of two new AI-based processes and performance software solutions to improve manufacturing output and quality. Batch 360, a process performance and optimization solution, and Vision 360, a computer vision solution, use next-generation predictive intelligence to help manufacturers achieve accuracy and efficiency from assembly line processes to individual machines. These solutions apply to a broad range of manufacturing processes, including discrete and batch continuous applications.
Batch 360 is a solution that helps manufacturers maintain high-quality production batches within tighter specifications and lowers costs. Through an Al-driven multivariate model that harnesses and analyzes all available manufacturing data – including imagery, metrology, logs, and time-series data – Batch 360 delivers actionable insights that maximize production. Using domain-specific rules and failure modes effect analysis (FMEA), Batch 360 helps facilitate the production of a "golden batch" by providing manufacturers with set point recommendations based upon dynamic operating conditions.
Vision 360 combines image-based AI with deep learning models to enhance individual manufacturing machine inspection accuracy. Using the latest advantages of GPU computing, Vision 360 analyzes and organizes an incoming stream of visual data to detect anomalies and provide insights, trends, and forecasts that operators can use to tune and adjust for yield and quality during the manufacturing process. With real-time clustering, classification, and forecasting of key KPIs, Vision 360 provides early identification of potential problem areas and continuously steers production to operate at its highest point of efficiency.
"Process and discrete manufacturers are under tremendous pressure to ensure that plants are running as efficiently as possible," said Dominic Gallello, CEO of SymphonyAI Industrial. "Batch 360 and Vision 360 combine our deep knowledge of the plant floor with all the benefits that IIoT and AI can deliver to provide our customers with faster and more accurate decisions during the manufacturing process. The results for our early users have been terrific."
Batch 360 and Vision 360 will be supported on the SymphonyAI Industrial MOM 360 platform. Launched in May, MOM 360 is a software-only manufacturing execution system (MES) system that connects machines and data operations across a global network of plants to help optimize data-driven processes at an enterprise scale.
SymphonyAI Industrial, a SymphonyAI vertical, is an innovator in industrial insight, accelerating autonomous plant operations. The industry-leading Eureka AI/IoT platform and industrial optimization solutions connect tens of thousands of assets and workflows in manufacturing plants globally and process billions of data points daily, pushing new plateaus in operational intelligence.
- Digital manufacturing composable enterprise MOM/MES solutions can be operational in 90 days to connect devices, processes, people, and systems with harmonizing plant automation and control.
- Plant performance applications span asset predictive maintenance and process health and optimization, maintaining high availability of equipment, extending the life of capital assets, and reducing process variability.
- Connected worker solutions mobilize people to handle complex processes with human-driven procedure and instruction support, using a combination of glasses, smartphones, tablets, and PCs.
SymphonyAI Industrial solutions provide high value to users by driving variability out of processes and optimizing operations for throughput, yield, energy efficiency, and sustainability.
SymphonyAI is building the leading enterprise AI company for digital transformation across the most important and resilient growth industries, including retail, consumer packaged goods, financial services, manufacturing, media, and IT service management. SymphonyAI businesses have many leading enterprises as clients in each of these industries. Since its founding in 2017, SymphonyAI has grown rapidly, approaching 2,000 talented leaders, data scientists, and other professionals. SymphonyAI is an SAIGroup company, backed by a $1 billion commitment from successful entrepreneur and philanthropist Dr. Romesh Wadhwani.
PR contact: Nicole Katzin – nicole@galestrategies.com
View original content:
SOURCE SymphonyAI Industrial | https://www.whsv.com/prnewswire/2022/09/06/symphonyai-industrial-launches-batch-360-vision-360-high-quality-manufacturing-production/ | 2022-09-06T11:30:39Z |
KPI 360 combines multiple data sources into a single intuitive, visual dashboard so manufacturers can get actionable operating insights at all levels of a plant
WOBURN, Mass., Sept. 6, 2022 /PRNewswire/ -- SymphonyAI Industrial announced today the launch of KPI 360, an AI-driven solution that uses real-time data monitoring and prediction to help manufacturing companies view different operational data sources through a single, complete industrial intelligence dashboard that sets up in hours.
Backed by SymphonyAI's Eureka industrial AI platform, KPI 360 lets any type of user quickly set up monitoring for strategic KPIs through a visual, no-code builder interface. Leveraging SymphonyAI Industrial's proprietary domain knowledge engine, KPI 360 comes with pre-built KPIs for industrial assets and applications. The KPI 360 solution allows manufacturers to pull from data sources directly or through an application programming interface (API) such as Maximo, OSIsoft, SAP, and Siemens. These unique features make it easy to set up without a large project and maintain and expand over time without the need for any software expertise.
"KPI 360 is our first self-service product," said Dominic Gallello, CEO of SymphonyAI Industrial. "This approach enables our customers to set up everything from data pipelines to data visualization and allows everyone in a company to get a clear view of all business operations from the shop floor to the top floor. Flexibility and extensibility are built into KPI 360, so our customers can choose the visualization of their choice, link it to one or more KPIs, configure interactions with the visualizations, and change the visual appearance without writing a single line of code."
SymphonyAI Industrial, a SymphonyAI vertical, is an innovator in industrial insight, accelerating autonomous plant operations. The industry-leading Eureka AI/IoT platform and industrial optimization solutions connect tens of thousands of assets and workflows in manufacturing plants globally and process billions of data points daily, pushing new plateaus in operational intelligence.
- Digital manufacturing composable enterprise MOM/MES solutions can be operational in 90 days to connect devices, processes, people, and systems with harmonizing plant automation and control.
- Plant performance applications span asset predictive maintenance and process health and optimization, maintaining high availability of equipment, extending the life of capital assets, and reducing process variability.
- Connected worker solutions mobilize people to handle even their most complex processes with human-driven procedure and instruction support, using a combination of glasses, smartphones, tablets, and PCs.
SymphonyAI Industrial solutions provide high value to users by driving variability out of processes and optimizing operations for throughput, yield, energy efficiency, and sustainability.
SymphonyAI is building the leading enterprise AI company for digital transformation across the most important and resilient growth industries, including retail, consumer packaged goods, financial services, manufacturing, media, and IT service management. SymphonyAI businesses have many leading enterprises as clients in each of these industries. Since its founding in 2017, SymphonyAI has grown rapidly, approaching 2,000 talented leaders, data scientists, and other professionals. SymphonyAI is an SAIGroup company, backed by a $1 billion commitment from successful entrepreneur and philanthropist Dr. Romesh Wadhwani.
PR contact: Nicole Katzin – nicole@galestrategies.com
View original content:
SOURCE SymphonyAI Industrial | https://www.whsv.com/prnewswire/2022/09/06/symphonyai-industrial-launches-kpi-360-optimize-manufacturing-operations-with-ai-physics-driven-kpis/ | 2022-09-06T11:30:45Z |
DUBLIN, Sept. 6, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) will be participating in the following Fireside Chats, both of which will be webcast:
- Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13 at 11:10 am ET (8:10 am PT/4:10 pm IST)
- H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14 at 1:30 pm ET (10:30 am PT/6:30 pm IST)
Webcasts of the events may be accessed by visiting Theravance.com, under the Investors section, Presentations and Events. Replay of the webcast will be archived on the Company's website for 30 days.
Theravance Biopharma, Inc.'s overarching purpose and goal as a biopharmaceutical company is focused on delivering Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant unmet patient needs.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris Company. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.
Contact: Gail B. Cohen
Corporate Communications / 917-214-6603
View original content to download multimedia:
SOURCE Theravance Biopharma, Inc. | https://www.whsv.com/prnewswire/2022/09/06/theravance-biopharma-present-upcoming-investor-conferences/ | 2022-09-06T11:30:57Z |
NORTH CANTON, Ohio, Sept. 6, 2022 /PRNewswire/ -- The Timken Company (NYSE: TKR; www.timken.com), a global leader in engineered bearings and industrial motion products, has reached an agreement to acquire GGB Bearing Technology (GGB), a division of Enpro, Industries (including exclusive negotiations with respect to the French operations of GGB). Founded in 1899, GGB serves a variety of diverse customers, markets, geographies and applications with a product portfolio that complements existing Timken industry-leading engineered bearing solutions. GGB revenue is expected to be around $200 million in fiscal year 2022.
"GGB has a strong heritage of delivering high-performance products to well-established customers who are leaders in their respective industries," said Richard G. Kyle, Timken president and chief executive officer. "This acquisition provides strong synergies and meaningfully expands our business by adding complementary products with a solid growth outlook. GGB's leading portfolio of metal-polymer bearings will further Timken's ability to deliver the best solution to our customers' most challenging friction management applications. GGB also presents an excellent cultural fit for Timken, including a commitment to corporate social responsibility with a portfolio of environmentally sustainable solutions."
GGB is a global technology and market leader of premium engineered metal-polymer plain bearings with expertise in material science, surface engineering and tribology. With manufacturing facilities across the United States, Europe and China, GGB employs approximately 900 people and has a global engineering, distribution and sales footprint. The company's tribology solutions in plain bearing coatings complements Timken's leading positions in roller and ball bearings. GGB's products are used mainly in industrial applications, including pumps and compressors, HVAC, off-highway, energy, material handling and aerospace.
Timken will fund the transaction with cash on hand and its existing revolving credit facility. The deal is subject to customary closing conditions and is expected to close in the fourth quarter of this year. Timken anticipates the acquisition will be accretive to earnings in the first full quarter after closing.
The Timken Company (NYSE: TKR; www.timken.com) designs a growing portfolio of engineered bearings and industrial motion products. With more than a century of knowledge and innovation, we continuously improve the reliability and efficiency of global machinery and equipment to move the world forward. Timken posted $4.1 billion in sales in 2021 and employs more than 18,000 people globally, operating from 43 countries. Timken has been recognized among America's Most Responsible Companies by Newsweek, the World's Most Ethical Companies® by Ethisphere, and America's Best Employers, Best Employers for New Graduates and Best Employers for Women by Forbes.
Certain statements in this release (including statements regarding the company's forecasts, estimates, plans and expectations) that are not historical in nature are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, the statements related to expectations regarding realization of synergies, accretion, the expected future financial performance of the newly acquired business, and the timing of the closing of this transaction are forward-looking. The company cautions that actual results may differ materially from those projected or implied in forward-looking statements due to a variety of important factors, including: the inability to successfully acquire and integrate the newly acquired business into the company's operations or achieve the expected synergies associated with the acquisition; negative impacts to the newly acquired business as a result of global conflicts and hostilities or inflation; unanticipated changes in business relationships with customers or their purchases from the newly acquired business; unanticipated litigation, claims, investigations or assessments; and adverse changes in the markets served by the newly acquired business. Additional factors are discussed in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended Dec. 31, 2021, quarterly reports on Form 10-Q and current reports on Form 8-K. Except as required by the federal securities laws, the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Media Relations:
Scott Schroeder
234.262.6420
scott.shroeder@timken.com
Investor Relations:
Neil Frohnapple
234.262.2310
neil.frohnapple@timken.com
View original content to download multimedia:
SOURCE The Timken Company | https://www.whsv.com/prnewswire/2022/09/06/timken-acquire-ggb-bearing-technology-expanding-its-engineered-bearing-portfolio-with-complementary-products/ | 2022-09-06T11:31:03Z |
SHANGHAI, Sept. 6, 2022 /PRNewswire/ -- Trip.com Group Limited (Nasdaq: TCOM; HKEX: 9961), a leading one-stop travel service provider of accommodation reservation, transportation ticketing, packaged tours and corporate travel management, will announce its financial results for the three months and six months ended June 30, 2022 on Wednesday, September 21, 2022, U.S. Time, after the market closes.
Trip.com Group's management team will host a conference call at 8:00 PM U.S. Eastern Time on September 21, 2022 (or 8:00 AM on September 22, 2022 in the Shanghai/Hong Kong Time) following the announcement.
The conference call will be available on Webcast live and replay at: http://investors.trip.com. The call will be archived for twelve months at this website.
All participants must pre-register to join this conference call using the Participant Registration link below:
https://register.vevent.com/register/BIe6a1088f8c3f4a77a18a7d5b03d2bc2e.
Upon registration, each participant will receive details for this conference call, including dial-in numbers and a unique access PIN. To join the conference, please dial the number provided, enter your PIN, and you will join the conference instantly.
About Trip.com Group Limited
Trip.com Group Limited (Nasdaq: TCOM; HKEX: 9961) is a leading global one-stop travel platform, integrating a comprehensive suite of travel products and services and differentiated travel content. It is the go-to destination for travelers in China, and increasingly for travelers around the world, to explore travel, get inspired, make informed and cost-effective travel bookings, enjoy hassle-free on-the-go support, and share travel experience. Founded in 1999 and listed on Nasdaq in 2003 and HKEX in 2021, the Company currently operates under a portfolio of brands, including Ctrip, Qunar, Trip.com and Skyscanner, with the mission "to pursue the perfect trip for a better world."
For further information, please contact:
Investor Relations
Trip.com Group Limited
Tel: +86 (21) 3406-4880 X 12229
Email: iremail@trip.com
View original content:
SOURCE Trip.com Group Limited | https://www.whsv.com/prnewswire/2022/09/06/tripcom-group-limited-report-second-quarter-first-half-2022-financial-results-september-21-2022-us-time/ | 2022-09-06T11:31:10Z |
Karen Cohen Khazon, "Turpaz's double-digit growth and strong profit, profitability, and EBITDA stem from our combined growth strategy, which proves effective despite challenging macroeconomic conditions"
Company completes three acquisitions YTD, reaching a total of six acquisitions since it's IPO in May 2021
HOLON, Israel, Sept. 6, 2022 /PRNewswire/ -- Turpaz Industries (Turpaz) (TASE: TRPZ), the developer, manufacturer, and marketer of fragrance and flavor extracts, intermediates for the pharma industry, specialty ingredients for the agrochemical and fine chemicals industries, as well as citrus products and aroma chemicals for the flavor and fragrance industry., reported its financial results for the second quarter of the year, today. The Q2 and H2 results set new records thanks to high growth rates in sales, gross profit, operating profit, and adjusted EBITDA.
Karen Cohen Khazon, Turpaz's CEO, commented on the results, "the record results we reported today reflect double-digit revenues and profit growth stemming from the company's growth strategy. Our strategy combines organic growth and acquisitions. The strong capital structure, low leveraging, and the experienced global management team allow Turpaz to deal effectively with challenging global macroeconomic conditions and persist with our acquisition strategy."
The double-digit growth presented by Turpaz was evident in all parameters reviewed, reflecting the management's global growth strategy. The sales in Q2 2022 grew by 50% to $30.3 million compared with $20.2 million in the same quarter of last year. The sales in the first half of 2022 grew by 46.3% to $57.7 million compared with $39.4 million in the same period last year. The growth is due to acquisitions completed during 2021 and 2022 as well as from organic growth net of currency fluctuations impact that accounted for 11% in the second quarter of 2022 and 10.3% in the first half of the year. These financial outcomes were achieved despite currency fluctuations, particularly in the markets in which the company trades in US$. These fluctuations impaired the sales in the second quarter by 7.7% and 5% in the first half of the year.
The gross profit in the first quarter of 2022 grew by 40.7% to $11.7 million, compared with $8.3 million in the same quarter of last year. The gross profit grew by 41.7% in the first half of 2022 to $22.4 million compared with $15.8 million in the same period last year. The growth in the gross profit and the stability of the gross profitability occurred despite the global increase in raw material and shipping costs.
The adjusted EBITDA grew by 34.7% in the first quarter of 2022 to $7 million, compared with $5.2 million in the same quarter of last year. The adjusted EBITDA grew to $13.3 million, compared with $9.9 million in the same period last year, an increase of 35%. The operating profit in the second quarter of 2022 has expanded by 19.8% to $5 million, as compared with $4.1 in the same quarter of last year. The operating profit in the first half of 2022 grew by 18.8% to $9.5 million, compared with $8 million in the same period of last year.
The net profit in the second quarter of 2022 grew by 32.7% to a total of $ 4.2 million, compared with $ 3.2 million in the same quarter last year. The net profit in the first half of 2022 grew by 29.8%, totaling $8.2 million, as opposed to $6.3 million in the same period of last year.
For more information about Turpaz, and the full financial report, visit ir.turpaz.co.il
Contact:
Yoni Adini
Yoni@turpaz.co.il
View original content:
SOURCE Turpaz Industries Ltd. | https://www.whsv.com/prnewswire/2022/09/06/turpaz-reports-record-results-q22022-sales-grow-by-50-303-million-net-profit-increased-by-327-42-million/ | 2022-09-06T11:31:17Z |
Digital pathology platform will improve collaboration across multi-site network and lay the foundation for unlocking new diagnostic insights with AI
JAÉN, Spain and PHILADELPHIA, Sept. 6, 2022 /PRNewswire/ -- Proscia®, a leader in digital and computational pathology solutions, and University Hospital of Jaén have partnered to modernize the hospital's pathology practice. University Hospital of Jaén will leverage Proscia's Concentriq® Dx to optimize routine diagnosis while laying the foundation for implementing artificial intelligence (AI), better informing patient care. This news comes on the heels of Proscia's formal expansion into Spain to accelerate its international growth.
Laboratories are rapidly adopting digital pathology, which shifts the 150-year-old standard of care from microscope to whole slide image, to overcome systemic challenges in the traditional laboratory model and capitalize on the growing potential to improve treatment decisions. These digital laboratories are not only driving quality and efficiency gains in routine workflows but also streamlining collaboration among distributed teams and unlocking new diagnostic insights with AI. As University Hospital of Jaén sits at the center of a multi-site network in Andalusia, it recognized that it was in prime position to benefit from digital pathology and selected the scalable, highly-interoperable Concentriq Dx to enable its digital transformation.
CE-marked under IVDR, Concentriq Dx is a singular, secure digital pathology platform that powers routine workflows across the connected enterprise.* Pathologists at University Hospital of Jaén will draw on its intuitive experience for viewing and accessing images to optimize their primary diagnostic workflows. Concentriq Dx also offers live, asynchronous, and remote access to whole slide images, enabling the hospital to streamline collaboration among sites and provide patients with faster access to expertise. The platform's best-of-breed interoperability will further help pathologists to make more confident diagnoses by unifying siloed data across the network.
"We are excited to have found a platform that will empower us to remain at the forefront of diagnostic medicine," said Rafael J. Luque Barona, MD Ph.D., Director of the Pathological Anatomy Laboratory at the University Hospital of Jaén. "As Concentriq Dx is flexible and open, it will allow us to leverage the latest innovations in digital and computational pathology throughout the Andalusian region to best serve our patients."
In addition to integrating with leading scanners, laboratory information systems, and image analysis applications, Concentriq Dx is AI-ready and designed to support laboratories in realizing pathology's computational future. The platform will support the future integration of AI applications into clinical workflows, enabling pathologists to expand the breadth of diagnostic information available and view these insights alongside all of their other pathology data to better inform diagnosis.
"Digital pathology is delivering real benefits today and holds even more promise for tomorrow," said Arun Ananth, Proscia's Chief Commercial Officer. "As we formally expand into Spain, it is especially energizing to work with a laboratory that is eager to capitalize on the unfolding potential in seeing through its commitment to excellent patient care."
*Concentriq Dx is CE-marked under IVDR and is available for primary diagnosis in the US during the COVID-19 public health emergency.
Proscia is a software company that is accelerating pathology's digital transformation to change the way we understand diseases like cancer. Its Concentriq digital pathology platform and powerful AI applications are advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate discovery, improve patient outcomes, and fulfill the promise of precision care. Leading diagnostic laboratories and 10 of the top 20 pharmaceutical companies rely on Proscia's software each day. For more information, visit proscia.com.
The University Hospital of Jaén is the result of the merger of the hospitals of the city of Jaén that took place on June 28, 2003. It is made up of a Diagnosis and Treatment Center, the Doctor Sagaz Hospital, the Maternal-Infant Hospital, the General Hospital and Neurotramatological Hospital. Its main axes are to orient the center to citizens, improve efficiency in management and healthcare provision, expand training and promote research at the University Hospital of Jaén.
Responding to the user's health demand and effectively attending to the health needs of the people of Jaén are some of the priority lines, so that the patient is provided with comprehensive, personalized and top-quality care, betting on the technological innovation, continuous training of its professionals and research. The objective is to offer care focused on the needs of the patient, to offer an increasingly agile, accessible, humane service, where assistance is based on the development of knowledge, innovation, motivation and teamwork of our professionals. For more information, visit hospitaljaen.es.
CONTACT: Sydney Fenkell, Sydney@proscia.com
View original content to download multimedia:
SOURCE Proscia | https://www.whsv.com/prnewswire/2022/09/06/university-hospital-jan-adopts-proscias-concentriq-dx-better-inform-patient-care/ | 2022-09-06T11:31:23Z |
Veriff technology enables seamless, scalable verification capabilities for Certific and supports international expansion
NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Veriff, a global identity verification provider, today announced a partnership with Certific, a remote medical testing platform. The partnership will enhance and streamline Certific's remote medical diagnostics capabilities and support the company's global expansion - Veriff can verify over 10,200 different identity documents from more than 190 different countries and in over 45 languages.
Veriff's streamlined, AI-powered identity verification technology will provide Certific customers with a simpler and faster identity verification process, mitigating fraud risks and building trust within remote medical testing.
The partnership follows Certific's announcement that it has raised €7.4M of investment, led by European investment platform Plural, to advance remote medical diagnostics, support product expansion and entry into new markets.
As the use of telehealth and other digital health services continues to rise across the globe, there is a growing need for patients to digitally validate their identities. This ensures patients are linked to the correct medical history, their privacy is protected, and medical providers can avoid instances of malpractice and fraud. Cases of medical identity theft reported to the Federal Trade Commission (FTC) rose from approximately 6,800 in 2017 to nearly 43,000 in 2021, a trend that is being replicated globally.
"The COVID-19 crisis forced companies to go digital overnight to remain competitive. As a result, the demand for secure, remote identity verification has continued to grow globally across industries, including health services," said Kaarel Kotkas, founder and CEO of Veriff. "Veriff's solution, combined with Certific's remote medical testing platform, enables users to more securely and effectively access their personal medical records and telehealth services through advanced biometric identity verification technology, helping to significantly reduce security risk in digital health processes."
Liis Narusk, CEO of Certific, said: "Demand for remote medical services is rising and Veriff's technology will enable us to expand globally and securely, reducing the risk of identity fraud and malpractice on a grand scale. It will make the identity verification process quicker and more convenient for our customers and protect the data and integrity of the platform."
About Certific:
Founded in September 2020 by Taavet Hinrikus, Liis Narusk and Dr Jack Kreindler, Certific is the digital disruptor in healthcare. Providing pioneering and scalable technology that enables remote testing, diagnostics and monitoring for multiple conditions, Certific was created to radically improve the cost and convenience for patients and healthcare providers alike. To ensure quality and compliance, Certific works with leading organizations and independent, internationally recognised academic institutions to validate its processes and professional standards. By empowering patients with the knowledge and tools to safely self-test, Certific enables people to become co-contributors to their health, improving patient outcomes by providing technology that enables self-testing at scale, which helps detect illnesses at an earlier stage. Certific provides a safe, certified service that will ease the burden on routine services, so that healthcare professionals can focus on more complex tasks.
About Veriff
Veriff is an industry leader in online identity verification, helping businesses to build trust with their customers. Veriff's intelligent decision engine analyzes thousands of technological and behavioral variables in seconds, matching people to more than 10,200 government-issued IDs from over 190 countries. Founded in 2015, Veriff serves a global portfolio of organizations across financial services, crypto, gaming and mobility sectors. Veriff's clients include Blockchain, Bolt, Deel, Starship, Trustpilot, Uphold, Wise and others. Veriff's latest $100 million investment round brings its total funding to $200M and its valuation to $1.5B. The investors include Tiger Capital, Alkeon, IVP, Accel, Mosaic Ventures, Y Combinator, and others. With offices in the U.S., UK, Spain and Estonia, Veriff employs over 550 people from 60 different nationalities who are dedicated to helping businesses to build a more secure world. To learn more, visit www.veriff.com.
Logo - https://mma.prnewswire.com/media/1875368/Veriff_Logo.jpg
View original content:
SOURCE Veriff | https://www.whsv.com/prnewswire/2022/09/06/veriff-certific-partner-enhance-identity-verification-services-remote-medical-testing/ | 2022-09-06T11:31:30Z |
PITTSBURGH, Sept. 6, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today announced the company will participate in the BofA Global Research Global Healthcare Conference in London on Thursday, September 15, 2022. Chief Executive Officer Michael Goettler, President Rajiv Malik and Chief Financial Officer Sanjeev Narula will represent the company in a fireside chat scheduled at 4:45 p.m. BST / 11:45 a.m. ET.
Interested parties can access a live webcast of the event at investor.viatris.com. An archived version also will be available following the live event and can be accessed at the same location for a limited time.
Viatris Inc. (NASDAQ: VTRS), is a global pharmaceutical company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a portfolio of biosimilars and a variety of over-the-counter consumer products. With approximately 37,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.
View original content to download multimedia:
SOURCE Viatris Inc. | https://www.whsv.com/prnewswire/2022/09/06/viatris-inc-participate-bofa-global-research-global-healthcare-conference/ | 2022-09-06T11:31:36Z |
Contract awarded for products that bring improvement to health care industry
SCOTTSDALE, Ariz., Sept. 6, 2022 /PRNewswire/ -- NeoLight announced its Skylife Neonatal Phototherapy System has received an Innovative Technology contract from Vizient, Inc. the nation's largest member-driven health care performance improvement company. The contract was awarded based on the recommendation of the Skylife Neonatal Phototherapy System by hospital experts who serve on one of Vizient's member-led councils, and it signifies to Vizient members unique qualities that potentially enhance clinical care, patient safety, or improve business operations of health care organizations.
The Skylife™ Neonatal Phototherapy System provides Best-in-Class Spectral Power which exceeds AAP Guidelines to
- Reduce Bedside Equipment
- Decrease Nurse Workload
- Provide for Intermittent Phototherapy which promotes Breast Feeding Success, Kangaroo Care, and Skin-to-skin time with Families.
The Skylife 3D Light Array™ creates 40% body surface coverage with effective, uniform light and allows the clinician to choose between three levels of irradiance for optimal control for the care of the neonate.
"We are thrilled to receive the Innovative Technology contract from Vizient, as it highlights the importance of the best-in-class technology in our Skylife Neonatal Phototherapy System," said Arik Anderson, NeoLight's CEO. "Vizient serves an important and large member base, and with this contract award, we are now even more accessible to this extensive network. We are committed to collaborating with Vizient member hospitals across the country in their mission to reduce jaundice related complications, quickly and efficiently reduce bilirubin levels and significantly reduce hospital costs."
"Congratulations to NeoLight for being awarded an Innovative Technology contract," said Kelly Flaharty, senior director of contract process for Vizient. "Our member council recommended Sklife Neonatal Phototherapy System for this contract based on the efficiencies it offers and its potential to make an incremental difference in health care."
Vizient represents a diverse membership base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers and represents more than $130 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with member-led councils and task forces to evaluate products for their potential to bring real innovation to health care. Vizient may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle.
NeoLight is a medical device company that develops empathy driven, best in class technologies for treating preventable conditions in the newborn care market. Empathy driven solutions are a framework that has the doctor-nurse-mother-infant ecosystem at the center. It fosters the emotional connection that happens, thereby providing not just treatment but also providing care. Driving neonatal care beyond the traditional hospital setting, NeoLight is also creating a robust home market to treat neonatal conditions in the home. To learn more, visit www.theneolight.com and follow us on Twitter, LinkedIn, and Facebook.
Contact: Kelly Johnson, kelly@theneolight.com
View original content:
SOURCE NeoLight | https://www.whsv.com/prnewswire/2022/09/06/vizient-innovative-technology-contract-awarded-neolight-skylife-neonatal-phototherapy-system/ | 2022-09-06T11:31:43Z |
PARK CITY, Utah, Sept. 6, 2022 /PRNewswire/ -- Wolfgramm Capital has acquired the Waldorf Astoria Park City hotel in Park City, Utah, according to Co-Founder and CEO of Wolfgramm Capital, Phil Wolfgramm. The property was acquired off-market and as part of an all-cash deal. Wolfgramm Capital impressively adds the luxury hotel to its portfolio within its first year of business. The luxury resort continues to be managed by Hilton.
Waldorf Astoria Park City is part of Waldorf Astoria Hotels & Resorts, one of Hilton's three distinct luxury brands. Situated at the base of Park City Mountain Resort, Waldorf Astoria Park City offers an ideal setting for an unforgettable luxury mountain vacation featuring spectacular views of the ski slopes and picturesque Wasatch Mountains. As Park City's only luxury hotel with slope-side and ski in ski out access to the largest ski and snowboard resort in the U.S, guests can discover all that the destination has to offer year-round from winter activities including skiing, snowshoeing and bobsledding to summer activities from fly fishing, biking, hiking and more.
The resort's authentic sense of place is reflected throughout the property from its distinct design aesthetic and locally-inspired food and beverage scene to its custom amenities, services and array of signature experiences. Its guest rooms and suites are appointed with custom furnishings and for suites, top-of-the-line kitchens. Integral to the guest experience is the hotel's 16,000-square-foot award-winning Waldorf Astoria Spa as well as the resort's all-day dining signature restaurant and bar, Powder. Additionally, Waldorf Astoria Park City features intimate meeting and event space as well as an expansive outdoor patio with fire pits, a heated pool and Jacuzzis.
"Wolfgramm Capital is delighted to be working with Hilton, the current lodging unit owners, the HOA, and their asset manager, CooperWynn Capital, in this endeavor. We are enthusiastic about taking this hotel to the next level and intend to infuse approximately sixty million dollars into the property. We look forward to sharing more about these enhancements at a later date," said Koloa Wolfgramm, COO, Wolfgramm Capital.
Waldorf Astoria Park City has been a crowd favorite since its opening in 2009. Commensurate with the surrounding mountainside aesthetic, the luxury hotel provides authentic dining and lodging experiences unique to the bustling ski-town. Just a 10-minute drive from Park City's historic Main Street laden with shops, boutiques, art galleries and more than 60 bars and restaurants, it is also only 35 minutes from Salt Lake City International Airport.
Formed in 2021 by Phil Wolfgramm, Koloa Wolfgramm, and Russell Handy, the new private equity real estate firm has amassed an impressive 200-million-dollar asset portfolio in its first eight months. With decades of combined experience in operating hotels, asset managing luxury resorts, consulting in the real estate legal field, and managing funds in the private equity sector, the principals of Wolfgramm Capital are uniquely positioned to capitalize on their experience to take the Waldorf Astoria Park City to the next level.
For more information regarding Wolfgramm Capital, please visit https://www.wolfgramm.com/ or email pr@wolfgramm.com
View original content to download multimedia:
SOURCE Wolfgramm Capital | https://www.whsv.com/prnewswire/2022/09/06/wolfgramm-capital-acquires-waldorf-astoria-park-city/ | 2022-09-06T11:31:49Z |
SINGAPORE, Sept. 6, 2022 /PRNewswire/ -- XT.COM, the world's first social-infused crypto exchange, is happy to announce new developments in its growing trading platform—the integration of the FIO Protocol and the listing of its native token FIO.
Through this incorporation, FIO users can register using their FIO Crypto Handles and send/receive not just FIO tokens, but the following coins and tokens supported by XT.COM — BTC, ETH, TRX, BNB, MATIC, SOL, DOT, XWC, LTC and EOS. In addition, with the FIO Protocol present, traders can take advantage of linking an easy-to-read address rather than the usual long-string public wallet address. This makes sending and receiving cryptocurrency as easy as sending and receiving an email. A FIO Crypto Handle is in the format of username@domain, for example, janedoe@xtcom. No longer will users have to worry about mistyping a character or any hack or exploit that alters the address where the user is trying to send funds.
Complex addresses consisting of long strings of letters and numbers have long been a pain point for many involved in the cryptocurrency space. Even a seasoned veteran in the cryptocurrency space has a level of uneasiness every time they send cryptocurrency by copying and pasting the wallet address being sent.
Moving forward to the second half of the news, XT.COM has added FIO to its roster of listed tokens. As the native crypto of the FIO chain, the token is mainly used for any transaction made on the network. As traders use FIO for registering FIO Crypto Handles, voting, staking, and more, the demand for the token will continue to rise.
"XT.COM brings forth two pieces of good news - FIO Protocol Integration and FIO token listing. With the addition of the FIO Protocol, transacting in cryptocurrency becomes easier for users of XT.COM. We aim to give our users the best service and experience they deserve; and we believe that through this, we have accomplished one of our goals." CEO of XT.COM shared.
Meanwhile, the entire XT.COM team affirms that the introduction of the FIO Protocol to its exchange provides an easier-to-use platform that makes cryptocurrency trading simple for everyone—even for beginners.
With that in mind, crypto enthusiasts and traders are highly urged to get a chance to be one of the first to trade FIO and enjoy the newly-enhanced exchange. As a promise, XT.COM will continue welcoming projects for crypto listings and achieve growth hand-in-hand.
About FIO
FIO, the Foundation for Interwallet Operability, is a decentralized consortium of blockchain organizations and community members supporting the ongoing development, integration, and promotion of the FIO Protocol. The protocol is an open-source, decentralized usability layer solution that works across all blockchains, and uses human-readable Crypto Handles to replace the complexity, risk, and inconvenience that come with blockchain-based transactions using public addresses.
Website: https://fioprotocol.io/
Twitter: https://twitter.com/joinFIO
About XT.COM
By consistently expanding its ecosystem, XT.COM is dedicated to providing users with the most secure, trusted, and hassle-free digital asset trading services. Our exchange is built from a desire to give everyone access to digital assets regardless where you are.
Founded in 2018, XT.COM now serves more than 6 million registered users, over 500,000+ monthly active users and 40+ million users in the ecosystem. Covering a rich variety of trading categories together with an NFT aggregated marketplace, our platform strives to cater to its large user base by providing a secure, trusted and intuitive trading experience.
As the world's first social-infused digital assets trading platform, XT.COM also supports social networking platform based transactions to make our crypto services more accessible to users all over the world. Furthermore, to ensure optimal data integrity and security, we see user security as our top priority at XT.COM.
Website: https://www.xt.com/
Telegram: https://t.me/XTsupport_EN
Twitter: https://twitter.com/XTexchange
View original content:
SOURCE XT.com | https://www.whsv.com/prnewswire/2022/09/06/xtcom-adds-fio-following-fio-protocol-integration/ | 2022-09-06T11:31:56Z |
BEIJING, Sept. 6, 2022 /PRNewswire/ -- Yiren Digital Ltd. ("Yiren Digital" or the "Company") (NYSE: YRD), a leading digital personal financial management platform in China, today announced that its board of directors has adopted a share repurchase program, which approves and authorizes the Company to repurchase through one or more transactions up to US$20 million worth of its own American depositary shares ("ADSs") representing its ordinary shares. The share repurchase program previously adopted by the Company in 2018 has been simultaneously terminated.
The Company may effect the proposed share repurchase in compliance with Rule 10b5-1 and Rule 10b-18 of the Securities Exchange Act of 1934, as amended. The number of ADSs repurchased and the timing of repurchases will depend on a number of factors, including, but not limited to, share price, trading volume and general market conditions, along with the Company's working capital requirements, general business conditions and other factors. Yiren Digital's board of directors will review the share repurchase program periodically, and may modify, suspend or terminate the share repurchase program at any time.
About Yiren Digital
Yiren Digital Ltd. is a leading digital personal financial management platform in China. The Company provides customized asset allocation based wealth management solutions to China's mass affluent population as well as utilizes online and offline channels to provide retail credit facilitation services to individual borrowers and small business owners.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Yiren Digital's control. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Yiren Digital does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
View original content:
SOURCE Yiren Digital | https://www.whsv.com/prnewswire/2022/09/06/yiren-digital-announces-up-us20-million-share-repurchase-program/ | 2022-09-06T11:32:03Z |
There is freedom to be found in dreaming despite the chaos going on in the world, and in Adeolu Osibodu's mind-bending photographic work, he invites the viewer to join him on a journey through space and time as he navigates reality, traversing sky, land and sea. Born and raised in Lagos, Nigeria, Osibodu spent his adolescent years evolving into a phase of creating images. Inspired by music and cinema, he aims to capture the motion in stillness, and to celebrate his cultural upbringing through his imagery.
As a child of ministers, Osibodu moved to Redemption Camp, a Pentecostal Evangelical mega church in Mowe, in the state of Ogun, in Nigeria, around the age of 10. It was here that he developed a sense of spirituality outside of religion and expanded his imagination while roaming the campground's many fields and open spaces.
"Being in Lagos, we're used to the hectic lifestyle of traffic and the population density, but back here, it's very spaced out — you have a lot of time to think for yourself; there are less distractions — so having that experience inspired part of my photography," Osibodu says. "When I started creating images, I saw that I was being drawn to surrealism and a form of distortion of reality. [...] Everything is slipping as it's coming to you — it's just slipping out of your hands — so that whole sense of time is what I try to explore with my work."
Feeling an urge to express himself without words as a teenager, Osibodu began to make images of the natural world around him with his smartphone. "I didn't have a lot of money then, so I couldn't buy too many expensive things; I had to work with the things around me." Osibodu says he didn't have an explicit narrative he was trying to convey, he just wanted to channel his emotions into a visual diary — his anger over something that happened at school or experiencing heartbreak.
At first, photography was more of a hobby — a way to respond to the world around him — but Osibodu's recovery from a skateboarding accident in 2016 made his passion clear.
"I broke my femur in two and I went unconscious during the accident. I couldn't work for about eight months," Osibodu recalls. "That whole phase in my life gave me a sort of redirection and it gave me this strong sense of gratitude for time, for life and for being able to experience this craft. Before the accident, I didn't have a camera. But, spending more time with myself, getting to think of ideas and getting to see my life very objectively — once I recovered, I knew what I wanted to do with my life at that point. Within two months of recovering, I got my camera and it has just been nonstop from there. Even though it was a painful phase in my life, I think it was very necessary and I'm so grateful for it."
In the process, Osibodu got in touch with his inner child, and he's continued to expand his approach to photography through the use of new, illusory Photoshop techniques. His dreamlike environmental portraits, which depict himself, his family and his close friends as models and people and objects soaring or evaporating into thin air, seem almost three-dimensional. "I used to be a very big movie person," he says. "I used to watch a lot of films — not necessarily sci-fi, but a lot of period dramas, a lot of old movies, and a lot of movies that make you feel like you're time-traveling."
Osibodu also purposefully employs black and white through much of his imagery. "I got to discover for myself that creating images without colors could help you or could help the viewer see a stronger form of the picture, or the naked form of the picture, stripping it of all the distractions." Bodies of water are also a huge component of his work, which often illustrates people wading through the sea. He feels peace and serenity at the beach, and aims to visualize a sense of calmness and cleansing, amplified by his use of grayscale.
Osibodu's cultural identity also plays a role in his work, with the majority of the people who appear in front of his lens being African. He appreciates the feedback he receives about representing Black people in a contemporary, yet futuristic, form. "Africans are in my photographs because I've always been in Africa. I have always been inspired by people who are around me. So, it's not even intentional; it's just things happening naturally, as they should," he says. "I get to tell stories that reflect their truth."
What's next? On the heels of a recent show in Berlin and being chosen as a 2022 PhotoVogue Festival Grantee, Osibodu says he's simply going to keep creating. His advice for emerging artists: "Everything can happen at once, so you just have to start where you are with what you have. Just start with you."
Adeolu Osibodu is a freelance photographer from Lagos, Nigeria and a 2022 PhotoVogue Festival Grantee. Follow him on Instagram @adeoluosibodu.
Copyright 2022 NPR. To see more, visit https://www.npr.org. | https://www.wyomingpublicmedia.org/2022-09-06/a-skateboarding-accident-led-this-photographer-to-find-his-passion | 2022-09-06T11:40:25Z |
American Frances Tiafoe, 24, has reached the quarterfinals for the first time. Of the eight men left at the U.S Open, six are ranked outside of the top 10.
Copyright 2022 NPR
American Frances Tiafoe, 24, has reached the quarterfinals for the first time. Of the eight men left at the U.S Open, six are ranked outside of the top 10.
Copyright 2022 NPR | https://www.wyomingpublicmedia.org/2022-09-06/no-22-seed-ends-rafael-nadals-22-match-grand-slam-streak-at-the-u-s-open | 2022-09-06T11:40:32Z |
Liz Truss becomes Britain’s new prime minister
LONDON (AP) — Liz Truss became U.K. prime minister on Tuesday and immediately confronted the enormous task ahead of her amid increasing pressure to curb soaring prices, ease labor unrest and fix a health care system burdened by long waiting lists and staff shortages.
At the top of her in-box is the energy crisis triggered by Russia’s invasion of Ukraine, which threatens to push energy bills to unaffordable levels, shuttering businesses and leaving the nation’s poorest people shivering in icy homes this winter.
Truss, who refused to spell out her energy strategy during the two-month campaign to succeed Boris Johnson, now plans to cap energy bills at a cost to taxpayers of as much as 100 billion pounds ($116 billion), British news media reported Tuesday. She is expected to unveil her plan on Thursday.
“You must know about the cost of living crisis in England, which is really quite bad at the moment,” Rebecca Macdougal, 55, who works in law enforcement, said outside the Houses of Parliament.
“She’s making promises for that, as she says she’s going to deliver, deliver, deliver,” she said. “But we will see in, hopefully, the next few weeks there’ll be some announcements which will help the normal working person.”
Truss took office Tuesday afternoon at Balmoral Castle in Scotland, when Queen Elizabeth II formally asked her to form a new government in a carefully choreographed ceremony dictated by centuries of tradition. Johnson, who announced his intention to step down two months ago, formally resigned during his own audience with the queen a short time earlier.
It was the first time in the queen’s 70-year reign that the handover of power took place at Balmoral, rather than at Buckingham Palace in London. The ceremony was moved to Scotland to provide certainty about the schedule because the 96-year-old queen has experienced problems getting around that have forced palace officials to make decisions about her travel on a day-to-day basis.
Truss, 47, took office a day after the ruling Conservative Party chose her as its leader in an election where the party’s 172,000 dues-paying members were the only voters. As party leader, Truss automatically became prime minister without the need for a general election because the Conservatives still have a majority in the House of Commons.
But as a prime minister selected by less than 0.5% of British adults, Truss is under pressure to show quick results.
Ed Davey, leader of the opposition Liberal Democrats, on Tuesday called for an early election in October.
“I’ve listened to Liz Truss during the Tory leadership (campaign) and I was looking for a plan to help people with their skyrocketing energy bills, with the NHS crisis and so on, and I heard no plan at all,” he told the BBC.
“Given people are really worried, given people are losing sleep over their energy bills, businesses aren’t investing because of the crisis, I think that’s really wrong,” Davey said.
Johnson took note of the strains facing Britain as he left the prime minister’s official residence at No. 10 Downing Street for the last time, saying his policies had left the government with the economic strength to help people weather the energy crisis.
While many observers expect Johnson to attempt a political comeback, he backed Truss and compared himself to Cincinnatus, the Roman dictator who relinquished power and returned to his farm to live in peace.
“Like Cincinnatus, I am returning to my plow,” he said. “And I will be offering this government nothing but the most fervent support.”
___
Susie Blann contributed to this story.
Copyright 2022 The Associated Press. All rights reserved. | https://www.whsv.com/2022/09/06/liz-truss-becomes-britains-new-prime-minister/ | 2022-09-06T12:54:12Z |
Massive UPS strike may happen next year, experts warn
(CNN) - Labor experts say a massive strike could be brewing within the next year at UPS, the world’s biggest package courier.
It comes ahead of a high-stakes showdown between the company and the Teamsters, one of America’s oldest labor unions.
Their current contract is set to expire at the end of July 2023, and contract negotiations between UPS and the Teamsters are set to begin in the spring.
But before talks have even started, experts are predicting the company’s drivers and package handlers will end up going on strike.
It would be the largest strike against a single business in U.S. history and would affect nearly every household in America.
An estimated 6% of the nation’s gross domestic product is moved in UPS trucks every year.
The shipping giant moves 21.5 million U.S. packages a day.
The U.S. Postal Service, Amazon and Fed-Ex wouldn’t be able to cover the shortfall in the event of a strike at UPS.
Copyright 2022 CNN Newsource. All rights reserved. | https://www.whsv.com/2022/09/06/massive-ups-strike-could-be-looming/ | 2022-09-06T12:54:19Z |
Search for missing jogger enters day 4; suspect to appear in court for first hearing
MEMPHIS, Tenn. (WMC/Gray News) - The search for Eliza Fletcher is now entering day four. The Memphis wife and mom of two was reported missing Friday after not returning from her morning jog.
Memphis Police Department hasn’t yet identified a body found Monday night in South Memphis, near where investigators say the man charged in Fletcher’s disappearance, Cleotha Abston, was seen cleaning his vehicle after her abduction.
Fletcher was reported missing early Friday morning, WMC reported. She was last seen jogging on Central Avenue near the University of Memphis.
Later that day, Fletcher’s cell phone and a pair of Champion slides were turned over to the police.
Police were later able to link those slides back to Abston.
Police said they believe he is the man seen on surveillance video, forcing Fletcher in a black GMC Terrain Friday morning.
After the incident, witnesses reported Abston cleaning out that SUV and said his behavior was odd.
In a few hours, Abston will make his first court appearance on kidnapping and tampering with evidence charges in Fletcher’s abduction.
The especially aggravated kidnapping charge falls under Tennessee’s new truth in sentencing law. If he is found guilty of this charge, he would have to serve 100% of the sentence.
It’s a class A felony where a sentence could be anywhere between 15 and 60 years in prison.
While awaiting arraignment on these charges, Abston received new charges in an unrelated case.
A report from Memphis police says a woman reported someone was using her Cash App account and Wisely card at gas stations, totaling more than $900.
He is charged with identity theft, theft of property under $1,000 and fraudulent use of a debit or credit card.
This police report was filed one day before Eliza Fletcher was abducted.
Copyright 2022 WMC via Gray Media Group, Inc. All rights reserved. | https://www.whsv.com/2022/09/06/search-missing-jogger-enters-day-4-suspect-appear-court-first-hearing/ | 2022-09-06T12:54:25Z |
States’ plans to make school safer reflect political divides
LITTLE ROCK, Ark. (AP) — In the aftermath of the school shooting in Uvalde, Texas, governors around the country vowed to take steps to ensure their students would be kept safe.
Months later, as students return to classrooms, money has begun to flow for school security upgrades, training and other new efforts to make classrooms safer.
But the responses have often reflected political divisions: Many Republicans have emphasized school security spending, while Democrats have called for tighter gun control.
At every step, the actions have stirred debate over whether states are doing the right things to address the scourge of school shootings.
In a special legislative session in Arkansas last month, lawmakers set aside $50 million for a school safety fund proposed by Republican Gov. Asa Hutchinson. The rules for distributing the money haven’t been finalized, but Hutchinson has said he wants it to help implement recommendations from a school safety commission he reinstated following the May shooting in Texas, where 19 students and two teachers were killed.
The shooting “served as a reminder that the threat of violence in our schools has not abated,” Hutchinson said. “It continues to be real, and we have to act with a renewed sense of urgency to protect our children.”
Texas was among several other states that set aside money for school security. Gov. Greg Abbott and other top Republican leaders announced $105.5 million for school safety initiatives. Nearly half of that was slated for bullet-resistant shields for school police and $17.1 million was for districts to purchase panic-alert technology.
Other Republican governors who made money available for security upgrades include Ohio Gov. Mike DeWine, who announced $100 million for school security three days after the Uvalde shooting, and Georgia Gov. Brian Kemp, whose state is giving $2.6 million to increase training capacity and classes for school resource officers.
“While these are the latest measures we’re taking to ensure our children’s safety, I can assure you they will not be the last. I will work with anyone, even in the midst of a heated election cycle, to protect our students,” Kemp, who is running for reelection, said in June.
Some of the Republican governors who have moved aggressively to bolster school security have ruled out any kind of gun control measures.
Hutchinson had said there should be a conversation about raising the age to purchase an AR-15-style rifle — the type of weapon used in Uvalde — but didn’t pursue such a measure during the session. Abbott also has pushed back on calls for more gun control by families of the Uvalde shooting victims. Oklahoma Republican Gov. Kevin Stitt vowed to fight any firearms restrictions when he signed an executive order on training for law enforcement and risk assessment at schools.
In California, which already had some of the nation’s toughest gun laws, Democratic Gov. Gavin Newsom has signed a dozen more this legislative session and even took out ads in Texas newspapers criticizing the state’s stances on guns.
“We’re sick and tired of being on the defense in this movement,” Newsom said in July.
In New Jersey, Democratic Gov. Phil Murphy signed legislation last month requiring the state’s nearly 600 school districts to set up assessment teams aimed at stemming violence in schools. One of the bill’s sponsors recounted hearing of an Uvalde victim who pretended to have been killed in the attack to escape the shooter.
“Does anybody want to teach this — how to play dead?” Assemblywoman Pamela Lampitt, a Democrat, said during a hearing in June.
Despite the partisan divisions on gun violence, a group of governors says it will attempt to find common ground. A task force created by the National Governor Association following the Uvalde shooting will develop recommendations to stop mass shootings, with an emphasis on school safety. Hutchinson, a former chairman of the association, has said the task force will focus in part on how states might use money coming to them through the bipartisan gun control bill President Joe Biden signed in June.
Teachers, political opponents and others have raised questions about the scope and effectiveness of state leaders’ plans.
In Arkansas, Democratic lawmakers questioned whether districts taking the new grant program’s money would be required to have an armed presence on campus, one of the initial recommendations from the state’s school safety commission.
“It’s one thing to say ‘school safety,’ but that runs the gamut of so much,” said Democratic Sen. Linda Chesterfield, a retired educator and the only legislator to vote against the grant program. “What specifically do you have in mind, and what price is it going to cost? I guess I’m just tired of having to fly by the seat of my pants and not know a thing about what’s going to go into that (commission’s) report.”
In Ohio, teachers unions say one-time funding that’s for equipment like door locks and radio systems — but not ongoing needs like personnel — is helpful but not enough.
Schools need money for staffing, too, including for safety and mental health personnel, said Scott DiMauro, president of the Ohio Education Association.
“Ideally, you’re gonna use funding to ensure that every school that wants to hire well-trained school resource officers, as part of their school safety plan, can do that,” DiMauro said. “And from that perspective, you know, the $100 million isn’t going to solve the problem in the long run.”
___
Associated Press writers Samantha Hendrickson in Columbus, Ohio; Jeff Amy in Atlanta; Paul Weber in Austin, Texas; Don Thompson in Sacramento, California; Sean Murphy in Oklahoma City; and Mike Catalini in Trenton, New Jersey, contributed to this report.
___
For more back-to-school coverage, visit: https://apnews.com/hub/back-to-school
Copyright 2022 The Associated Press. All rights reserved. | https://www.whsv.com/2022/09/06/states-plans-make-school-safer-reflect-political-divides/ | 2022-09-06T12:54:31Z |
A federal judge ruled in favor of former President Trump on Monday, ordering an independent review of materials seized by the FBI at Trump's Florida home. It's a temporary setback for investigators.
Copyright 2022 NPR
A federal judge ruled in favor of former President Trump on Monday, ordering an independent review of materials seized by the FBI at Trump's Florida home. It's a temporary setback for investigators.
Copyright 2022 NPR | https://www.wyomingpublicmedia.org/2022-09-06/a-judge-grants-trumps-special-master-request-to-review-mar-a-lago-materials | 2022-09-06T12:54:35Z |
Education sector is 11% more likely to face account compromise attacks as the other industries surveyed.
IRVINE, Calif., Sept. 6, 2022 /PRNewswire/ -- Netwrix, a cybersecurity vendor that makes data security easy, today announced additional findings for the education sector from its global 2022 Cloud Data Security Report.
The survey revealed that 47% of educational institutions suffered a cyberattack on their cloud infrastructure within the last 12 months. For 27% of them, incidents in the cloud were associated with unplanned expenses to fix security gaps.
"Educational institutions are keen to broaden their cloud adoption: The sector expects to have 56% of the workload to be in the cloud by the end of 2023, compared to this year's 44%," comments Dirk Schrader, VP of Security Research at Netwrix. "But without proper visibility into who has access to sensitive data and when and how that data is being used, IT teams will not be able to proactively mitigate data overexposure and spot suspicious behavior in the cloud."
83% of educational organizations confirmed they store sensitive data in the cloud. With educators and students constantly sharing that information, they are more concerned about insider threats than other industries. 48% of respondents in this sector consider cybersecurity risks associated with their own employees to be the biggest ones.
"The educational sector has a good reason to be concerned about insider threats since 42% of them experienced account compromise attacks in 2022 compared to the average of 31% from the other industries surveyed. Accordingly, their IT teams should pay closer attention to identity and access management by implementing a zero standing privilege approach and enforcing strong password policies," adds Schrader.
Netwrix makes data security easy, thereby simplifying how professionals can control sensitive, regulated and business-critical data, regardless of where it resides. More than 11,500 organizations worldwide rely on Netwrix solutions to secure sensitive data, realize the full business value of enterprise content, pass compliance audits with less effort and expense, and increase the productivity of IT teams and knowledge workers.
Founded in 2006, Netwrix has earned more than 150 industry awards and been named to both the Inc. 5000 and Deloitte Technology Fast 500 lists of the fastest growing companies in the U.S.
For more information, visit www.netwrix.com.
Erin Jones
Avista PR for Netwrix
P: 704.664.2170
E: pr@netwrix.com
View original content to download multimedia:
SOURCE Netwrix Corporation | https://www.whsv.com/prnewswire/2022/09/06/47-educational-institutions-experienced-cyberattack-their-cloud-infrastructure-2022/ | 2022-09-06T12:54:37Z |
NPR's A Martinez talks to Cardozo Law School professor of law Jessica Roth, who analyzes a federal judge's decision to grant former President Donald Trump's request for a special master.
Copyright 2022 NPR
NPR's A Martinez talks to Cardozo Law School professor of law Jessica Roth, who analyzes a federal judge's decision to grant former President Donald Trump's request for a special master.
Copyright 2022 NPR | https://www.wyomingpublicmedia.org/2022-09-06/the-probe-into-trumps-seized-documents-raises-executive-privilege-questions | 2022-09-06T12:54:41Z |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.